Clinical trial NCT00175916
Conditions: Epilepsy
Keywords: Brivaracetam Epilepsy long term
Sponsor: UCB Pharma
Start date: 2005-09-01; Completion date: 2019-05-01
Enrollment: 853 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).

Detailed description:

Arms: arm 1: Flexible dosing, can up and down titrate as needed.
Interventions: intervention 1: Brivaracetam (ucb 34714)
Intervention descriptions: intervention 1: 10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.

Protocol documents:
Prot_000.pdf: 
A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 1 of 77
1.
TITLE
An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of
brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 
200 mg/day in subjects aged 16 years or older suffering from epilepsy
Sponsor: UCB Pharma SA
Chemin du Foriest
B-1420 Braine l’Alleud
BELGIUM
With registered office:
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Brivaracetam - EudraCT Number: 2004 - 002140-10
IND Number: 75,898
General Substantial Amendment 1 approved 1st April 2005: limitation of the maximal dose to 150 mg/day.
General Non-Substantial Amendment 2 approved 20th May 2005: clarification of several sections of the 
protocol
Country Specific - Germany- Substantial Amendment 3 approved 30th May 2005: only subjects aged 18 years 
or more can be included
Country Specific - The Netherlands – Substantial Amendment 4 approved 2nd December 2005: only subjects 
aged 18 years or more can be included
General Substantial Amendment 5 approved 07th April 2006: compliance with Central EC and Sponsor 
requirements. Clarification of several sections of the protocol
Specific Substantial Amendment 6 approved 05th May 2006: specifications for subjects with ULD
General Substantial Amendment 7 approved 02nd February 2007: specifications for subjects with POS
General Substantial Amendment 8 approved 01st June 2007: specifications for subjects with POS
Specific Substantial Amendment 9 approved 01st June 2007: specifications for subjects with ULD
Specific Substantial Amendment 10 approved 26th October 2007: specifications for subjects with ULD
Country Specific – Austria – Amendment 11/C3 approved 20-Nov-2007: addition of a monthly urine pregnancy 
test in female subjects of childbearing potential
Country Specific – France – Amendment 12/C4 approved 11-Feb-2008: subjects are not allowed to convert to 
brivaracetam monotherapy in case of excellent efficacy and tolerability of the study drug
Country Specific – Norway – Amendment 13/C5 approved 13-Mar-08: subjects are not allowed to convert to 
brivaracetam monotherapy in case of excellent efficacy and tolerability of the study drug and only subjects aged 
18 years or more can be included
Country Specific – Spain – Amendment 14/C6 approved 04-Apr-08: subjects are not allowed to convert to 
brivaracetam monotherapy in case of excellent efficacy and tolerability of the study drug
Site Specific – Site # 
 – Amendment 15/S1 approved 04-Apr-08: subjects are not allowed to convert to 
brivaracetam monotherapy in case of excellent efficacy and tolerability of the study drug
Country Specific – Turkey – Amendment 16/C7 approved 04-Apr-08: subjects are not allowed to convert to 
brivaracetam monotherapy in case of excellent efficacy and tolerability of the study drug
REDACTED 
Num
Num
umber
umber
st Apr
st Apr
proved
proved
COPY 
M
mb
mb
This document
Count
oun
briv
briv
1
cannot
male 
ale 
ry Spec
y Spec
aracet
racet
tr
be 
an
cific
cific
used 
Am
Am
al Am
al Am
tial A
tial A
to 
mend
mend
mend
support 
t 5 ap
5 ap
severa
ever
dment 6
ment 
ndmen
dme
any 
Sub
Su
ed
ed
ppr
pp
marketing 
20th
0th
mendme
mendm
bstan
bsta
authorization 
ber: 20
er: 2
r: 75,
 75,
il 2005
l 2005
h M
h M
application and any extensions or variations 
m of 
m of 
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 2 of 77
Site Specific – Site # 
 – Amendment 17/S2 approved 04-Apr-08: subjects are not allowed to convert to 
brivaracetam monotherapy in case of excellent efficacy and tolerability of the study drug
This amendment applies to all sites (with Partial Onset Seizures subjects) participating in the study
Specific Substantial Amendment 18 approved 04-April-2008: clarification of several sections of the protocol 
and FDA warning for suicidality and suicidal thoughts for subjects with POS
Site Specific – Site #
 – Amendment 19/S3 approved 29-May-2008: subjects are not allowed to convert to 
brivaracetam monotherapy in case of excellent efficacy and tolerability of the study drug
Country Specific – France – Amendment 20/C8 approved 09-Jun-2008: subjects are not allowed to enter the 
study if they are sexually inactive with childbearing potential
Country Specific – Czech Republic – Amendment 21/C9 approved 21-Jan-09: study entry of the N01258 
subjects allowed
Country Specific – Germany – Amendment 22/C10 approved 21-Jan-09: study entry of the N01258 subjects
allowed
Country Specific – Poland – Amendment 23/C11 approved 21-Jan-09: study entry of the N01258 subjects
allowed
Specific Substantial Amendment 24 dated 03 Jan 2011: clarification of several sections of the Integrated 
Protocol Amendment 18
Specific Substantial Amendment 25 dated 03 Jan 2011: clarification of several sections of the Integrated 
Protocol Amendment 10
Integrated Substantial Amendment 25 dated 03 Jan 2011 includes the changes to the previous Integrated 
Amendment 10 and to the Integrated Amendment 18 and applies to all subjects enrolled in N01125.
Integrated Substantial Amendment 26 dated 25 Oct 2011: addition of the suicidality assessment and the 
requirements per the FDA Final Rule and update of the study variables
Integrated Substantial Amendment 27 dated 12 Mar 2015: updated contact information, addition of procedures 
for subjects enrolling from another study (N01315), deletion of outdated exposure numbers, addition of 
language allowing all subjects to enroll into a managed access program (or similar), updated protocol adherence 
language, added Sponsor declaration page
Confidential Material
“The information contained in this document is strictly confidential. It is disclosed to you as a 
(potential) Investigator or (potential) consultant. Acceptance of this document constitutes 
your agreement that the information contained herein will not be disclosed or in anyway 
communicated to any third party without prior written approval of the Sponsor (or it’s 
representative(s) of the clinical study described therein except – to the extent necessary – to 
your staff, to members of appropriate review committee(s) and/or to persons to whom the 
investigational product may be administered or to their legal representative(s) to obtain their 
informed consent.”
REDACTED
: a
e stud
e stud
r 2015
2015
15), de
5), de
manag
mana
COPY
des 
des thth
plies t
plies 
addit
addit
This document
pote
ote
yo
your
u
c
cannot 
e info
info
tent
ent
be used to support any marketing 
g
authorization 
o ala
ion of 
on of 
y varia
y varia
updat
updat
letion 
etion 
ed acc
ed ac
application 
eral sec
ral se
e change
chang
all sub
ll su
and 
ctions
tions
any 
e N01
e N01
extensions 
r 
N01258
0125
N0125
N0125
or 
the
he
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 3 of 77
Principal Investigator
“By my signature below, I acknowledge that I have read the protocol RPCE03D0801 
Integrated Amendment 27 and agree that it contains all necessary details for carrying out the 
clinical study described therein.  Furthermore, I agree to conduct this clinical study in 
compliance with said Protocol, the ICH Good Clinical Practice guideline, as well as with any 
and all applicable federal, state and/or local laws and regulations and with my contractual 
obligations towards the Sponsor of the clinical study or its representatives(s).”
Signature:
Date:
Printed Name:
Address:
Phone:
Site Number:
REDACTED 
ED
CT
DA
RE
COPY 
or r
C
This document cannot be used to support any marketing 
g authorization 
io
za
ho
u
application
uidel
ide
ns and
ns an
represe
eprese
and
ls s
s clini
clin
elin
lin
any
E03
E0
for c
for c
extensions 
3D
3D
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 4 of 77
2.
CONTACT INFORMATION
Sponsor
Global address:
UCB Pharma SA 
Chemin du Foriest
B-1420 Braine l’Alleud Belgium
With registered office:
Allée de la Recherche 60
B-1070 Brussels, Belgium
Study Physician
Name:
, MD
Phone:
Fax:
Clinical Trial Manager
Name:
 PhD
Phone:
Fax:
Contract Research Organization (CRO)
PPD Development
Kleine Kloosterstraat 23
1932 St-Stevens-Woluwe
Belgium
During working hours:
Phone:
+32 2 723 26 26
Fax:
+32 2 723 26 00
REDACTED 
RO)
RO)
PPD
PPD
COPY 
This document cannot be used to support any marketing 
D Deve
Deve
Kleine K
leine
1932
193
Be
B
authorization application 
ne:e:
ax:x:
and
and any 
a
extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 5 of 77
SAE Reporting (24h/24), Safety Related Issues and Emergency Unblinding (GCSP)
Email:
Global
DSICT@ucb.com
Fax:
Europe and Rest of the World 
+32 2 386 24 21
USA:
+1 800 880 6949
Canada:
+1 877 582 8842
Central Laboratories:
Eurofins Medinet BV
Bergschot 71 
P.O. Box 5510
4801 DM Breda
The Netherlands
During working hours:
Phone:
+31(0)76 573 73 73
Fax:
+31(0)76 573 77 78
Quintiles Laboratories North America
1600 Terrell Mill Road
Marietta, GA 30067
USA
Phone:
+1 770 373 3900
Fax:
+1 770 373 3598
Investigator(s)
The complete and updated list of Investigators is maintained in the Trial Master File (TMF) 
at UCB.
REDACTED 
rlan
lan
worki
worki
Quin
Quin
COPY 
da
da
nds
nds
This document cannot 
.
be
lete 
ete
used 
(s)s)
an
an
to support any marketing
ntiles L
ntiles 
600 Te
600 T
Marie
Mar
US
U
authorization 
s
ing ho
ng ho
application and any extensions 
94
2 8842
884
or 
49
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 6 of 77
3.
TABLE OF CONTENTS
1.
TITLE..............................................................................................................................1
2.
CONTACT INFORMATION .......................................................................................4
3.
TABLE OF CONTENTS...............................................................................................6
3.1
List of Abbreviations........................................................................................10
4.
PROTOCOL SUMMARY...........................................................................................13
4.1
Schedule of Assessments .................................................................................18
4.2
Schematic Diagram ..........................................................................................22
5.
BACKGROUND INFORMATION............................................................................25
5.1
Background and epidemiology of targeted disease..........................................25
5.2
Background information regarding product.....................................................26
5.3
Efficacy with brivaracetam in fixed-dose Phase II/III studies in POS.............27
5.4
Safety with brivaracetam..................................................................................27
5.5
Efficacy and safety in subjects with Unverricht-Lundborg disease.................27
5.6
Study Rationale ................................................................................................28
5.6.1
Dose Selection....................................................................................28
5.6.2
Subjects Population............................................................................29
5.6.2.1
Minimal Age...............................................................29
5.6.3
Duration of Treatment........................................................................29
6.
STUDY OBJECTIVES AND PURPOSE...................................................................30
6.1
Primary Objective ............................................................................................30
6.2
Secondary Objective ........................................................................................30
6.3
Exploratory Objectives.....................................................................................30
7.
STUDY DESIGN ..........................................................................................................31
7.1
Type/Design .....................................................................................................31
7.2
Subjects/Sites Numbers....................................................................................32
7.3
Measures to Minimize/Avoid Bias...................................................................32
7.3.1
Randomization ...................................................................................32
7.3.2
Blinding..............................................................................................32
7.4
Study Duration .................................................................................................32
7.5
End of Study.....................................................................................................32
8.
SELECTION AND WITHDRAWAL OF SUBJECTS.............................................32
8.1
Subject Inclusion Criteria.................................................................................32
8.2
Subject Exclusion Criteria................................................................................34
8.3
Subject Withdrawal Criteria.............................................................................34
8.3.1
Withdrawal Criteria............................................................................35
8.3.2
Subject Replacement Policy...............................................................35
9.
TREATMENT OF SUBJECT (INVESTIGATIONAL PRODUCTS AND
CONCOMITANT MEDICATIONS) .........................................................................35
REDACTED 
......
......
imal
mal A
CT
atmen
atmen
DA
D PU
PU
R
COPY 
ve
v
Y
......
....
......
....
This document cannot 
5
o
SEL
SE
ca
8
be used 
3.1.1
ed
7.3.2
7.3.2
us
S
to
sur
ur
to support 
.....
ign
gn ....
po
ts/Sites
/Site
up
res
es t
any 
ctit
y
....
..
marketing 
RPO
RPO
ing
.......
...
e ......
....
tives
ives
authorization 
......
......
......
....
Age
Age
ho
nt....
....
u
O
application 
IIIII sts
ion
.......
...
chtht-Lu
L
pl
......
.....
and 
....
......
....
t
any 
......
.....
.....
extensions 
......
.....
......
....
......
.....
or 
....
...
variations 
.....6
va
10
1
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 7 of 77
9.1
Study Investigational Products.........................................................................35
9.1.1
Description of Investigational Products.............................................35
9.1.1.1
Dosing Schedule.........................................................36
9.1.2
Packaging...........................................................................................36
9.1.3
Labeling..............................................................................................37
9.1.4
Storage Requirements ........................................................................37
9.1.5
Monitoring of Subject Compliance....................................................37
9.1.6
Investigational Products Accountability ............................................38
9.1.7
Maintenance of Study Treatment Randomization Codes and
Procedures for Blind Breaking...........................................................38
9.2
Concomitant Treatments ..................................................................................38
9.2.1
Permitted Concomitant Treatments (Medications and Therapies) ....39
9.2.2
Not Permitted Concomitant Treatments (Medications and
Therapies)...........................................................................................39
10.
STUDY PROCEDURES..............................................................................................39
10.1
Subject Identifier..............................................................................................39
10.2
Description of Procedures ................................................................................39
10.2.1
Informed Consent...............................................................................39
10.2.2
Demography.......................................................................................40
10.2.3
Childbearing Potential and Birth Control ..........................................40
10.2.4
General Medical and Procedures History ..........................................40
10.2.5
Epilepsy History/Disease History ......................................................40
10.2.6
Antiepileptic/Antimyoclonic Medication History .............................40
10.2.7
Vital Signs..........................................................................................40
10.2.8
Body Weight and Height....................................................................41
10.2.9
Physical Examination.........................................................................41
10.2.10 Neurological Examination .................................................................41
10.2.11 ECG....................................................................................................41
10.2.12 Daily Record Card (DRC)..................................................................42
10.2.13 Patient Reported Outcomes................................................................43
10.2.14 Health Related Quality of Life Questionnaire (QOLIE-31-P)...........43
10.2.15 Hospital Anxiety and Depression Scale (HADS) ..............................44
10.2.16 Laboratory Assessments.....................................................................44
10.2.17 Adverse Events...................................................................................45
10.2.18 Assessment of Suicidality ..................................................................45
10.2.19 Medical Procedures............................................................................45
10.2.20 Health Care Provider Consultations not Foreseen by the
Protocol ..............................................................................................46
10.2.21 Hospital Stay......................................................................................46
10.2.22 Non-Antiepileptic and Antiepileptic Concomitant
Medications/Non-Antimyoclonic and Antimyoclonic
Concomitant Medications ..................................................................46
10.2.23 EQ-5D Questionnaire.........................................................................47
REDACTED 
..
........
........
ntial
ntial
AC
alal and
and
ED
story
story/D
/D
y
R
/A
/A
COPY 
.....
...
......
......
.......
......
This document cannot be used
0.2.1
0.2.
se
10.
10
u
to
.13
.13
to suppor
urolo
urol
ort
ECG
CG
pp
2 Da
Dai
s
P
any
alal Ex
Ex
an
log
log
marketing
Dise
ise
ng
Antimy
ntimy
ket
........
....
ght
ght an
m
authorization 
...
........
........
.........
.......
and
nd B
ho
d Proc
Proc
au
ea
ea
application 
......
....
........
.....
.......
...
....
..
and
ns
ns
d
dicati
dicati
an
any 
......
and
and
a
extensions 
.......
......
...
and
nd
en
......
....
or 
....
variations 
37
ar
37
37
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 8 of 77
10.2.24 Socio-professional Data .....................................................................47
10.2.25 End of Study.......................................................................................47
10.3
Study Conduct..................................................................................................48
10.3.1
Entry Visit..........................................................................................48
10.3.2
Full Evaluation Visit ..........................................................................49
10.3.3
Minimal Evaluation Visit...................................................................50
10.3.4
Yearly Evaluation Visit (replaces the FEV of each year)..................50
10.3.5
Early Discontinuation Visit................................................................51
10.3.6
Down-Titration Phone Call................................................................52
10.3.7
Final Visit (FV following a Study Drug-free Period after an
EDV or FV initiated upon Sponsor request at the End of the
program).............................................................................................52
10.3.8
Additional Visit..................................................................................53
10.4
Handling of Biological Samples ......................................................................53
10.5
Other Supplies..................................................................................................53
11.
ASSESSMENT OF EFFICACY .................................................................................53
11.1
Specifications of Efficacy Variables................................................................54
11.2
Methods and Timing for Assessing, Recording, and Analyzing the
Efficacy Variables............................................................................................54
12.
ASSESSMENT OF SAFETY ......................................................................................54
12.1
Specifications of Safety Variables ...................................................................54
12.2
Methods and Timing for Assessing, Recording, and Analyzing the
Safety Variables ...............................................................................................54
12.3
Adverse Events.................................................................................................54
12.3.1
Definition of Adverse Event (AE) .....................................................54
12.3.2
Procedures for Reporting and Recording Adverse Events.................55
12.3.2.1
Recording/Collection of AEs .....................................55
12.3.2.2
Description of AEs .....................................................55
12.3.3
Follow-up of Adverse Events.............................................................58
12.3.4
Rule for Repetition of an AE .............................................................58
12.3.5
Pregnancy...........................................................................................59
12.3.6
Overdose of Investigational Product..................................................59
12.4
Serious Adverse Events....................................................................................59
12.4.1
Definition of Serious Adverse Event (SAE)......................................59
12.4.2
Procedures for Reporting Serious Adverse Events (SAE).................60
12.4.3
Anticipated Serious Adverse Events..................................................61
13.
STATISTICS.................................................................................................................61
13.1
Statistical and Analytical Plans........................................................................61
13.1.1
Study Population(s)............................................................................61
13.1.2
Study variables...................................................................................62
13.1.2.1
Safety Variables..........................................................62
13.1.2.2
Efficacy Variables ......................................................62
REDACTED 
ing
D
......
......
......
.....
y Var
Var
RED
for
for A
R
COPY 
......
....
s........
O
g,g, R
C
This document 
1
cannot 
.4
ot be used 
.3.3.
d
12.3.
2.3.
us
12
12
to 
3
o
.4
support
e
t
2.3.2.1
.3.2.
po
12.3.2
12.3
up
Fo
F
any 
n
ny
dures
dures
a
marketing
i
Asses
Asses
tin
.......
......
........
.....
of
of A
authorization 
...
Record
ecord
tio
......
......
.......
......
ables
able
a
application 
........
.......
....
........
...
....
..
and 
...
......
....
any 
nd
nd
ny
.....
...
extensions 
.......
......
.....
......
....
fterer a
ex
of
of
or 
....
variations 
49
49
ar
50
50
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 9 of 77
13.1.2.3
Pharmacoeconomic Variables ....................................63
13.1.3
Statistical Evaluation..........................................................................64
13.2
Determination of the Sample Size....................................................................65
13.3
Statistical and Analytical Issues.......................................................................65
13.3.1
Handling of Dropouts or Missing Data..............................................65
13.3.2
Interim Analysis and Data Monitoring ..............................................66
13.3.3
Use of an Efficacy Subset of Subjects ...............................................66
13.3.4
Examination of Subgroups.................................................................66
13.4
Criteria for Starting the Analysis .....................................................................66
13.5
Dictionaries ......................................................................................................66
14.
ETHICS.........................................................................................................................67
14.1
Approval...........................................................................................................67
14.2
Subject Information and Consent.....................................................................67
14.2.1
Information.........................................................................................68
14.2.2
Informed Consent...............................................................................68
14.3
Subject Confidentiality.....................................................................................69
14.4
Informing the General Practitioner ..................................................................69
15.
STUDY MANAGEMENT AND ADMINISTRATION ............................................69
15.1
Monitoring........................................................................................................69
15.2
Direct Access to Source Data/Documents .......................................................70
15.3
Audit and Inspection ........................................................................................70
15.4
Case Report Forms (CRF)................................................................................71
15.5
Adherence to Protocol......................................................................................71
15.6
Termination of the Study..................................................................................72
15.7
Investigator Site File ........................................................................................72
15.8
Data Handling and Record Keeping.................................................................73
15.9
Clinical Study Report.......................................................................................73
15.10
Subject Insurance .............................................................................................73
15.11
Archiving and Data Retention..........................................................................73
15.12
Allocation of Responsibilities..........................................................................74
15.13
Curriculum Vitae..............................................................................................74
15.14
Financial Disclosure.........................................................................................74
16.
REFERENCES .............................................................................................................75
17.
SPONSOR DECLARATION ......................................................................................77
List of Tables
Table 4:1
Study Flowchart...........................................................................................18
Table 4:2
Schematic Diagram......................................................................................23
REDACTED
INI
IN
ED
....
... ....
Data/D
ata/D
DA
.......
.....
CRF
CRF
R
COPY 
.....
...
......
......
IS
IS
This document t cannot
REFE
EFE
no
SP
SP
c
be 
b
used 
loc
oc
d
Curri
Curri
us
Fi
Fi
to 
ivi
o
cati
cati
support
g
t
udy
udy R
po
Insura
sur
up
ing
ing
any 
Fil
Fi
ny
and
and R
a
marketing 
.
F)
F)......
......
ti
.......
......
Study
Study
ma
lele
authorization 
...
TRA
TRA
at
......
....
Docum
ocum
uth
....
....
application 
.
........
....
.......
....
.......
...
....
..
and 
......
...
....
....
any 
.... ....
...
.
extensions 
.......
......
.....
......
....
......
....
or 
....
variations 
65
65
ar
66
66
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 10 of 77
3.1
List of Abbreviations
AE
Adverse Event
AED(s)
Antiepileptic Drug(s)
ALAT/SGPT
Alanine Aminotransferase/Serum Glutamic Pyruvic Transaminase
ALP
Alkaline Phosphatase
ASAT/SGOT
Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase
AMD(s)
Antimyoclonic Drug(s)
AUC
Area Under the Curve
AUC(o-t)
Area Under the Curve from time 0 to infinity
b.i.d.
Twice Daily
BRV
Brivaracetam
CBZ
Carbamazepine
CBZE
Carbamazepine-10,11-epoxide
CDMS
Clinical Data Management System
cDNA
Copy-deoxyribonucleic Acid
CLB
Clobazam
Cmax
Highest Drug Concentration Observed in Plasma following Administration 
of an Extravascular Dose (= peak plasma level)
CNS
Central Nervous System
CPMP
Committee for Proprietary Medicinal Product
Cr Cl
Creatinine Clearance
CRF
Case Report Form
CRO
Clinical Research Organization
C-SSRS
Columbia-Suicide Severity Rating Scale
CTA
Clinical Trial Application
CTM
Clinical Trial Manager
CV
Curriculum Vitae
CZP
Clonazepam
dl
Deciliter
DRC
Daily Record Card
DTP
Down-titration Phone Call
ECG
Electrocardiogram
ED50
Effective Dose
EDV
Early Discontinuation Visit
EEG
Electroencephalogram
EQ-5D
EuroQol 5 Dimensions Questionnaire
ESM
Ethosuximide
EV
Entry Visit
FBM
Felbamate
FEV
Full Evaluation Visit
FSH
Follicle-stimulating Hormone
GAERS
Genetic Absence Epilepsy Rats from Strasbourg
GBP
Gabapentin
REDACTED 
ea
ry Me
y Me
rg
COPY 
erved 
erve
ak pl
k pl
This document 
EQ
EQ
ES
ES
cannot 
G
-5
be used
Dow
Dow
E
to
aily
aily
support
m V
m V
epam
epam
liter
iter
R
any
p
Man
Man
Vita
Vit
marketing 
ganizat
anizat
Severi
Sever
pplica
plica
authorization 
in
lasma 
asma
edicin
edicin
application 
n Pla
n Pla
and any extensions or 
e
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 11 of 77
GCP
Good Clinical Practice
GCSP
Global Clinical Safety and Pharmacovigilance
GGT
gamma-glutamyltranspeptidase
GMP
Good Manufacturing Practices
GP
General Practitioner
HADS
Hospital Anxiety and Depression Scale
HIPAA
Health Insurance Portability and Accountability Act Authorization
HRQOL
Health-related Quality of Life
β-hCG
Human Chorionic Gonadotropin
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
ILAE
International League Against Epilepsy
IND
Investigational New Drug
IRB
Institutional Review Board
ITT
Intention-to-treat
ITT PGS
Intention-to-treat Population for Primary Generalized Epilepsy
ITT POS
Intention-to-treat Population for Localization Related Epilepsy
kg
Kilogram
L
Liter
LBS
Levetiracetam Binding Site
LEV
Levetiracetam
LH
Luteinizing Hormone
LTFU
Long-term Follow-up
LTG
Lamotrigine
M
Month
MAD
Minimum Active Dose
MCH
Mean Corpuscular Haemoglobin
MCHC
Mean Corpuscular Haemoglobin Concentration
MCV
Mean Corpuscular Volume
MedDRA®
Medical Dictionary for Regulatory Activities
MEV
Minimal Evaluation Visit
μg
Microgram
mg
Milligram
min
Minute
mL
Milliliter
μM
Micromole
ms
Millisecond
Na
Natrium
NOAEL
No-observed-adverse-effect Level
NOEL
No-observed-effect Level
OC
Oral Contraceptive
OXC
Oxcarbazepine
PB
Phenobarbital
REDACTED 
tete
ne
ne
up
up
COPY
a
ocaliz
ocali
This document 
μM
ms
ms
N
cannot 
M
be used
Min
Min
M
to
edic
edi
nini
support 
pus
us
orpusc
orpus
n Corpu
Corp
ical 
ca
any
ve D
ve 
scula
scu
marketing 
Do
D
authorization application 
General
enera
ation R
ation
and any extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 12 of 77
PBO
Placebo
PGB
Pregabalin
PGS
Primary Generalized Seizures
PHT
Phenytoin
PK
Pharmacokinetics
POS
Partial Onset Seizures
PP
Per Protocol
PRO
Patient Reported Outcomes
QOLIE-31-P
Patient Weighted Quality of Life in Epilepsy Questionnaire
QTc
QT Interval Corrected
RBC
Red Blood Cell
SAE
Serious Adverse Event
SAP
Statistical Analysis Plan
SD
Source Documents or Standard Deviation
SDR
Safety Data Review
SOC
System Organ Class
SUSAR
Suspected Unexpected Serious Adverse Reaction
SV2A
Synaptic Vesicle Protein 2A
t ½
Half-life
TEAE
Treatment-emergent adverse event
TGB
Tiagabine
TMF
Trial Master File
TPM
Topiramate
UDP-GT
Uridine 5’-diphosphate Glucuronyl Transferase
ULD
Unverricht-Lundborg Disease
V
Visit
VGB
Vigabatrin
VPA
Valproate
W
Week
WBC
White Blood Cell
WHO
World Health Organization
YEV
Yearly Evaluation Visit
ZNS
Zonisamide
REDACTED 
rse ev
rse ev
COPY
verse
verse
This document cannot be used
Wo
Wo
Ye
Y
to 
hite
ite
orl
orl
support 
te
te Bl
e B
any marketing 
hate Gl
ate G
borg D
borg 
authorization 
vent
ent
application 
React
Reac
and any extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 13 of 77
4.
PROTOCOL SUMMARY
Study Number: N01125
Title of the study: An open-label, multi-center, follow-up trial to evaluate long-term safety 
and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to 
a maximum of 200 mg/day in subjects aged 16 years or older suffering from epilepsy.
Study Objectives
For all subjects:
•
To evaluate the long-term safety and tolerability of brivaracetam (BRV) at individualized 
doses with a maximum of 200 mg/day in subjects suffering from epilepsy
For subjects with partial onset seizures (POS)/primary generalized seizures (PGS):
•
To evaluate the maintenance of efficacy over time of brivaracetam
•
To explore direct medical resource use and indirect cost parameters for the first 2 years
•
To obtain a description of the subject’s self-reported health status for the first 2 years
•
To explore the effects of BRV on the subject’s Health-related Quality of Life, anxiety, 
and depression for the first 2 years
•
To explore any change in the subject’s socio-professional status for the first 2 years
This open-label long-term follow-up (LTFU) study will give subjects suffering from epilepsy, 
for whom the Investigator believes a reasonable benefit from the long-term administration 
may be expected, the opportunity to access adjunctive brivaracetam treatment. Conversion to 
monotherapy is not permitted anymore, however, subjects already on monotherapy are 
allowed to continue BRV monotherapy. The access to the study will be limited to the subjects
having completed a previous brivaracetam study as listed in Section 5.6. 
Methodology:
Multi-center, open-label, single arm study.
The individual starting dose of each subject will be the one recommended at the end of the 
previous study. Dose adjustment of study drug and/or concomitant antiepileptic drugs 
(AEDs) or antimyoclonic drug (AMDs) is allowed at any time during the study if seizure 
control is insufficient, or in case of safety or tolerability issue.
Study Type/Phase:
Therapeutic study/long-term follow-up.
REDACTED 
s soci
soci
p (LT
(LT
COPY
orted 
rted
s He
s He
This document 
Stu
Stu
cannot 
stu
stu
s) or 
or 
trol is
rol i
be 
ual 
ual
udy
udy
used 
n-
l sta
l sta
to
labe
lab
support
ous br
us b
l
any 
ym
ym
nother
nothe
riv
marketing 
TFU)
TFU)
reasona
reason
to acce
o acce
more
mor
authorization 
ealth
ealth
o-pro
pro
application
cetam
cetam
parame
param
health 
health
and 
pilil
eizur
eizur
any 
V)
V) ata
epsy
epsy
extensions 
at i
at i
or 
up
up
variations 
p toto
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 14 of 77
Diagnosis and Main Criteria for Inclusion:
•
Male/female subjects from 16 years (where legally permitted and ethically accepted) or 
18 years onwards suffering from epilepsy and having completed a previous study with 
brivaracetam as adjunctive treatment, which allowed access to this study.
•
Subjects for whom the Investigator believes a reasonable benefit from long-term 
administration of brivaracetam may be expected.
Study Period (years):
This study will run throughout the duration of the clinical development period of 
brivaracetam, and will continue until a marketing authorization is granted by any Health 
Authority in an indication for the adjunctive treatment in adults with refractory POS, whether 
or not secondarily generalized, until the Sponsor decides to close the study, until a managed 
access program, named patient program, compassionate use program, or similar type of 
access program is established as allowed per country-specific requirements in addition to 
legal and regulatory guidelines, or until brivaracetam development is stopped by the Sponsor.
Number of Subjects (planned):
500-1000 subjects, based upon the assumption that 90% of subjects having completed a 
previous study with brivaracetam as adjunctive treatment in epilepsy will roll over into the 
present study.
Number of Sites (planned):
As many sites as required and estimated between 150-200 sites.
Countries (planned):
This will be a worldwide protocol.
Investigational Product (dose, mode of administration):
brivaracetam - oral tablets containing 10 mg or 25 mg of brivaracetam.
Reference Product: Not applicable
Study Duration per Subject:
For each subject, the study will last from study entry until either regulatory approval of 
brivaracetam has been granted by any Health Authority in an indication of adjunctive 
treatment of partial onset seizures; or until the Sponsor decides to close the study; until a 
managed access program, named patient program, compassionate use program, or similar 
type of access program is established as allowed per country-specific requirements in 
addition to legal and regulatory guidelines, or until the investigational product development is 
stopped by the Sponsor.
REDACTED 
tha
th
ive tre
ive tr
COPY 
hat 9
at
This document
treatm
eatm
man
ma
cannot 
urara
ch sub
ch sub
varace
arace
m
be 
ation
ation
used
duct:
uct: N
to support 
(dose,
(dose
blets c
blets 
any 
ocol.
ocol.
marketing 
ed betw
ed be
authorization 
90% o
0% o
eatme
atme
application 
am
equirem
quire
pment 
pment
and
study
tud
m, or
, or
any
y
actory
actor
dy
extensions 
of 
of 
an
any
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 15 of 77
Safety Variables
Note: Assessments specified as performed within the first 2 years of the Evaluation Period 
are not applicable to subjects coming from N01315.
•
Primary safety variables
o
Occurrence of a treatment-emergent adverse event (TEAE)
o
Withdrawal due to adverse event (AE)
o
Occurrence of a serious adverse event (SAE)
•
Other safety variables
o
Laboratory tests (blood chemistry, hematology, urinalysis)
o
Vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) and body 
weight
o
Electrocardiogram (ECG)
o
Physical and neurological examinations
o
Change in Hospital Anxiety and Depression Scale (HADS) scores from the Baseline 
of the previous study to each assessment for the first 2 years and to the last Evaluation 
Period assessment during the first 2 years
Efficacy variables
Note: Assessments specified as performed within the first 2 years of the Evaluation Period 
are not applicable to subjects coming from N01315.
•
Secondary efficacy variables
For subjects with focal-onset epilepsy:
o
Partial onset seizure (type I) frequency per 28 days during the Evaluation Period.
o
Percent reduction in POS (type I) frequency per 28 days from Baseline of the previous 
study to the Evaluation Period.
o
Responder rate for POS (type I) frequency over the Evaluation Period. A responder is 
defined as a subject with a ≥50% reduction in seizure frequency from the Baseline 
Period of the previous study.
No secondary efficacy variables are defined for subjects with generalized epilepsy,
subjects with Unverricht-Lundborg Disease (ULD), or subjects coming from N01315.
•
Other efficacy variables
For subjects with focal-onset epilepsy:
REDACTED
ssio
ssio
ment f
ment f
t 2 ye
y
COPY 
on
on
This document cannot
Resp
Resp
def
de
be
dy
dy toto
y
used 
setet
nt redu
redu
o t
o t
to
h
t se
t se
support 
riable
iabl
focal
focal
any 
mi
m
es
marketing 
rformed
orme
ming f
ing 
authorization 
Scale
Scale
for the
or the
ars
ars
application
urere, p
, p
and 
pu
any extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 16 of 77
o
Percentage of subjects continuously seizure free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period.
For subjects with generalized epilepsy:
o
Generalized (type II) seizure days per 28 days during the Evaluation Period.
o
Percent reduction in generalized (type II) seizure days per 28 days from Baseline of 
the previous study to the Evaluation Period.
o
Responder rate for generalized (type II) seizure days over the Evaluation Period. 
A responder is defined as a subject with a ≥50% reduction in seizure days from the 
Baseline Period of the previous study.
o
Percentage of subjects continuously seizure free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period.
The following will be evaluated separately for subjects with focal-onset epilepsy and 
subjects with generalized epilepsy:
o
Change in Patient Weighted Quality of Life in Epilepsy Questionnaire (QOLIE-31-P) 
scores from Baseline of the previous study to each assessment for the first 2 years and 
to the last Evaluation Period assessment during the first 2 years.
o
EuroQol 5 Dimensions (EQ-5D) Questionnaire response for each assessment for the 
first 2 years for the Evaluation Period and for the last assessment during the first 
2 years of the Evaluation Period.
No other efficacy variables are defined for subjects with ULD or coming from N01315.
Pharmacoeconomic variables
The following will be evaluated separately for subjects with focal-onset epilepsy and subjects 
with generalized epilepsy:
•
Direct costs (healthcare provider consultations not foreseen by the protocol, concurrent 
medical procedures, concomitant medications, hospitalizations, and emergency room 
visits) during the first 2 years of the Evaluation Period
•
Indirect costs (work days or school days lost by the subject and days subject received help 
from a caregiver) during the first 2 years of the Evaluation Period
•
Socio-professional data for each assessment for the first 2 years and for the last 
assessment during the first 2 years of the Evaluation Period
No pharmacoeconomic variables are defined for subjects with ULD or for subjects coming 
from N01315.
REDACTED 
udy
udy
ment du
ment d
Quest
Quest
n Perio
n Peri
riod.
riod.
COPY 
fe in E
e in 
dy toto
y
This document
a
N
cannot
ectc
om a c
m a c
Soci
Soci
be 
t cos
t co
used
cedu
edu
ing th
ing th
to
ealth
alth
support 
aluated
aluat
eps
psy:y:
hca
hc
any marketing 
ned for
ed fo
authorization 
Epip
each
each
uring 
uring 
tionna
ionna
d and
d and
application 
with
with foc
fo
ileps
lep
and 
typ
y
Period
Period
any 
pes (
pes (
extensions 
n
Perio
Perio
day
ays f
s f
or
e of 
of
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 17 of 77
The periods considered are:
•
Evaluation Period (V1 until the last Evaluation Visit).
•
Down-Titration Period.
•
Post-treatment Period.
Statistical Methods:
All safety and efficacy variables will be analyzed using descriptive statistical methods.
COPY 
This document cannot be used to support any marketing authorization application and any extensions 
ethods
thods
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 18 of 77
4.1
Schedule of Assessments
Table 4:1
Study Flowchart
Entry 
Visit 
(EV)
Full 
Evaluation 
Visit (FEV)
Minimal 
Evaluation 
Visit (MEV)
Yearly 
Evaluation 
Visit (YEV)
Additional 
Visit 
(AV)
Early 
Discontinuation 
Visit (EDV)
Down-Titration 
Phone Call 
(DTP)(j)
Drug-free
Period Final 
Visit (FV)
Reference 
to Section
Assessments
Written Informed Consent
X
10.2.1
Clinical Trial Subject Card 
dispensing
X
10.5
Verification incl./excl. criteria
X
8.1/8.2
Demographic data
X
10.2.2
Childbearing potential
X
10.2.3
Medical and procedures history
(X)(a)
10.2.4
Epilepsy history/disease history(h)
(X)(a)
10.2.5
AED/AMD history(h)
(X)(a)
10.2.6
Vital signs
(X)(a)
X
X
X
X
X
10.2.7
Body weight and height(c)
X
X
X
X
X
10.2.8
Physical examination
(X)(a)
X
X
X
X
10.2.9
Neurological examination
(X)(a)
X
X
X
X
10.2.10
ECG(d)
(X)(a)
X
X
X
10.2.11
Daily record card dispense
X
X
X
X
X
10.2.12
Daily record card retrieval
X
X
X
X
X
10.2.12
Recording of seizures
(X)(a)
X
X
X
X
X
10.2.12
QOLIE-31-P(f) (k)
X(i)
M3(e)
X
X
10.2.14
HADS(f) (i) (k)
X
X
X
10.2.15
REDACTED 
ED
TE
CT
DA
RE
COPY 
Y
PY 
Y
C
This document cannot 
no
ca
be 
b
used
X
ed
us
u
to 
X)(a)
X
to support 
X
X
pp
su
su
su
su
any 
ny
an marketing 
g
eti
X
ark
m
authorization 
on
io
za
hor
ut
a
application
s
Visi
Vis
titititio
ati
ica
pp
and
Early
Early
contin
ontin
d any 
a
extensions or variations 
C
2 Mar
Ma
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 19 of 77
Table 4:1
Study Flowchart
Entry 
Visit 
(EV)
Full 
Evaluation 
Visit (FEV)
Minimal 
Evaluation 
Visit (MEV)
Yearly 
Evaluation 
Visit (YEV)
Additional 
Visit 
(AV)
Early 
Discontinuation 
Visit (EDV)
Down-Titration 
Phone Call 
(DTP)(j)
Drug-free
Period Final 
Visit (FV)
Reference 
to Section
Assessments
Laboratory assessments(g)
(X)(a)
X
X
X
X
10.2.16
Recording of Adverse Events
X(b)
X
X
X
X
X
X
X
10.2.17
C-SSRS(l)
X
X
X
X(m)
X
X
10.2.18
Medical procedures
X(b)
X
X
X
X
X
X
10.2.19
Healthcare provider consultation 
not foreseen by protocol(f)
X
X
X
X
X
10.2.20
Workdays and schooldays lost due 
to inability to perform an usual 
activity and days with caregiver’s 
help (excluding paid work)(f)
X
X
X
X
X
10.2.12
Hospital stay(f)
X
X
X
X
X
10.2.21
EQ-5D Questionnaire(f) (n)
X
X
X
10.2.23
Socio-professional Data(f) (o)
X
X
10.2.24
Concomitant AED/AMD(h)
X(b)
X
X
X
X
X
X
9.2
Concomitant non AED/AMD(h)
X(b)
X
X
X
X
X
X
9.2
Drug dispensing
X
X
X
X
(X)
X
9.1.1
Drug return/accountability
X
X
X
X
X
9.1.6
Down-titration
X
9.1.1.1
End of study status
X(p)
10.2.25
Clinical Trial Patient Card return
X
10.5
REDACTED 
TE
X
DA
RE
COPY 
Y
X
CO
This document cannot be used 
d
us
us
us
us
to 
o support 
X
X
or
upp
su
s
any
ny
an marketing 
ng
ket
X
ar
m
authorization 
on
on
on
on
a
on
au
a
application 
on
ati
X
ca
p
and 
X
d
X
an
any 
V)
V)
ny 
a
extensions 
n
Down
own
Ph
Ph
ns
e
or variations 
C
2 Mar
Ma
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 20 of 77
Table 4:1
Study Flowchart
Entry 
Visit 
(EV)
Full 
Evaluation 
Visit (FEV)
Minimal 
Evaluation 
Visit (MEV)
Yearly 
Evaluation 
Visit (YEV)
Additional 
Visit 
(AV)
Early 
Discontinuation 
Visit (EDV)
Down-Titration 
Phone Call 
(DTP)(j)
Drug-free
Period Final 
Visit (FV)
Reference 
to Section
Assessments
AED=antiepileptic drug; AMD=antimyoclonic drug; AV=Additional Visit; CRF=Case Report Form; C-SSRS=Columbia-Suicide Severity Rating 
Scale; DTP=Down-Titration Phone Call; ECG=electrocardiogram; EDV=Early Discontinuation Visit; EV=Entry Visit; FEV=Full Evaluation Visit; 
FV=Final Visit; HADS=Hospital Anxiety and Depression Scale; IEC=Independent Ethics Committee; IRB=Institutional Review Board; 
MEV=Minimal Evaluation Visit; QOLIE=Patient Weighted Quality of Life in Epilepsy Questionnaire; ULD=Unverricht-Lundborg disease; 
YEV=Yearly Evaluation Visit
(a)
The following data (in parentheses) will be transferred electronically from the previous study and should not be recorded in the CRF:
From the First Visit: General Medical and Procedure history, epilepsy history, disease history (for ULD subjects only), AED history and 
AMD history (for ULD subjects only).
From the last Evaluation Visit: vital signs, physical and neurological examinations, ECG, recording of seizures, laboratory assessment.
(b)
Ongoing AE, procedures and medications at the end of previous study have to be recopied into the N01125 CRF appropriate sections (except 
subjects from N01315).
(c)
Height will only be recorded at Visit 1 (EV). Height will also be measured at each YEV and FV for subject still in growing period.
(d)
If an ECG has not been performed within the year, an ECG has to be scheduled once a year at the YEV. As well, an ECG shall be performed at 
the EDV and at the FV (if applicable). An ECG is mandatory at FV except if FV follows an EDV where ECG results were normal.
(e)
For subjects coming from study N01114 and for ULD subjects.
(f)
Procedures only performed during the first 2 years of subject participation in the study (eg. till last scheduled visit (YEV-Y3) or EDV/FV in 
case the subject discontinues participation within the first 2 years). 
(g)
Laboratory assessment includes blood chemistry, hematology and urine analysis; where applicable (women with childbearing potential), a urine 
pregnancy test will be done. 
(h)
Disease history, AMD history, concomitant AMD and concomitant nonAMD are collected only for ULD subjects.
(i)
Procedure not to be performed for ULD or N01315 subjects.
(j)
Down-Titration Phone call at the end of the Down-Titration Period is mandatory for all subjects in case the subjects discontinue from more than 
20 mg/day brivaracetam. This phone call will also replace the previous Down-Titration Visit for ULD subjects.
(k)
QOLIE-31-P and HADS (not for ULD and N01315 subjects) are to be completed at the beginning of the visit by all subjects who are not 
mentally impaired. 
(l)
The C-SSRS assessment will be implemented by site per IRB/IEC approval and upon completion of required training. As of the time of Protocol 
Amendment 26, all subjects had completed their EV. Thus, the C-SSRS was not assessed for any subjects at their EV.
(m)
The C-SSRS will be done at the AV in case the AV is conducted for safety and efficacy reasons.
REDACTED 
gical ex
gical ex
ous stud
us stud
l also b
 also b
ECG 
ECG 
COPY
m the p
m the 
history
histor
This document cannot
ent 
nt
subjec
subjec
ll be do
be d
be 
t wil
t wil
used
phon
phon
ot for 
for U
to
end o
nd o
ne
support 
str
s
itant AM
ant A
LD 
D or N
or 
of t
f
any 
n the 
the
ry, hem
y, hem
marketing
be
has to
has to
atory at 
atory a
subjec
subje
of subje
f sub
fir
f
authorization
y, dis
di
xamina
amin
dy hav
y hav
e mea
mea
application 
Vi
mmitte
mmitt
uestionn
estion
revious
eviou
sea
se
and
m; C-
C-S
isit; 
sit; 
d a
S
any 
V)
V)
ny 
a
extensions 
n
Down
own
Ph
Ph
ns
e
or variations 
C
2 Mar
Ma
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 21 of 77
Table 4:1
Study Flowchart
Entry 
Visit 
(EV)
Full 
Evaluation 
Visit (FEV)
Minimal 
Evaluation 
Visit (MEV)
Yearly 
Evaluation 
Visit (YEV)
Additional 
Visit 
(AV)
Early 
Discontinuation 
Visit (EDV)
Down-Titration 
Phone Call 
(DTP)(j)
Drug-free
Period Final 
Visit (FV)
Reference 
to Section
Assessments
(n)
EQ-5D questionnaire is to be completed only by subjects coming from N01252 and N01254, and if not mentally impaired.
(o)
Socio-professional status is to be completed only by subjects coming from N01252 and N01254.
(p)
End of study status will be completed at the FV for subjects having performed an EDV (discontinued subjects) and for subjects leaving the study 
at the end of the program (completed subjects).
REDACTED COPY 
This document cannot be used to support any marketing authorization application 
N01254
0125
V (discon
(disc
and
and if 
nd if 
4
d any 
V)
V)
ny 
a
extensions 
n
Down
own
Ph
Ph
ns
e
or variations 
C
2 Mar
Ma
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 22 of 77
4.2
Schematic Diagram
For subjects coming from the therapeutic exploratory study (N01114): 
•
First year:
First 6 months: 1 visit/month: 1 Full Evaluation Visit (FEV) alternating with 1 Minimal 
Evaluation Visit (MEV).
Next 6 months: 1 visit/3months: 2 Full Evaluation Visits (at V7 and V8).
•
Second and subsequent years:
1 visit/3months: 1 Full Evaluation Visit alternating with 1 Minimal Evaluation Visit.
Yearly Evaluation Visit (YEV) will be performed in replacement of the first Full 
Evaluation Visit of each year.
For subjects coming from confirmatory studies (N01252 and N01254):
•
First year:
First 3 months: 1 visit/month: Full Evaluation Visit alternating with Minimal
Evaluation Visit
Next 9 months: 1 visit/3 months: Full Evaluation Visit alternating with Minimal 
Evaluation Visit.
•
Second and subsequent years:
1 visit/3 months: Full Evaluation Visit alternating with Minimal Evaluation Visit.
Yearly Evaluation Visit will be performed in replacement of the first Full Evaluation 
Visit of each year.
For subjects coming from ULD confirmatory studies (N01187 and N01236):
•
First year:
First 3 months: 1 visit/month: 1 Full Evaluation Visit alternating with 1 Minimal 
Evaluation Visit.
Next 9 months: 1 visit/3months: Full Evaluation Visit alternately with Minimal 
Evaluation Visit.
•
Second and subsequent years:
1 visit/3months: 1 Full Evaluation Visit alternating with 1 Minimal Evaluation Visit.
Yearly Evaluation Visit will be performed in replacement of the first Full Evaluation 
Visit of each year.
For subjects coming from long-term follow up study N01315:
•
Subjects will perform their Last Visit in N01315 and perform at the same time their First 
Visit in N01125. They will follow the schedule of 1 visit/3 months: 1 Full Evaluation 
Visit alternating with 1 Minimal Evaluation Visit. Yearly Evaluation Visit will be 
performed in replacement of the first Full Evaluation Visit of each year.
REDACTED 
a u
 Visit 
Visit
e perf
e perf
COPY
Visit
Vis
uatio
uatio
This document
For 
or 
•
cannot
ar
Visit o
sit o
su
be 
/3m
ly E
y E
used
V
d subs
subs
mon
mon
to
isit.
isit
suppor
it/mo
t/m
1 visi
1 vis
any 
mont
mon
marketing
form
form
confi
conf
authorization
on Vis
on Vi
t altern
altern
me
me
application
N012
N01
alternat
lterna
and 
2
any 
the 
the
extensions 
aluati
aluat
f
or
nim
nim
variations 
mal
ma
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 23 of 77
Table 4:2
Schematic Diagram
Subjects coming from Exploratory Studies
(N01114)
Subjects coming from Confirmatory Studies
(N01252, N01254)
Month
Visit
Type of Visit
Month
Visit
Type of Visit
1st year Follow-up
1st year Follow-up
MO
V1
Entry Visit
MO
V1
Entry Visit
M1
V2
MEV
M1
V2
MEV
M2
V3
FEV
M2
V3
FEV
M3
V4
MEV
M3
V4
MEV
M4
V5
FEV
M4
M5
V6
MEV
M5
M6
V7
FEV
M6
V5
FEV
M7
M7
M8
M8
M9
V8
FEV
M9
V6
MEV
M10
M10
M11
M11
2nd and subsequent years Follow-up
2nd and subsequent years Follow-up
M12
V9
YEV
M12
V7
YEV
M15
V10
MEV
M15
V8
MEV
M18
V11
FEV
M18
V9
FEV
M21
V12
MEV
M21
V10
MEV
FEV=Full Evaluation Visit; MEV=Minimal Evaluation Visit; M=month; V=Visit; YEV=Yearly Evaluation 
Visit
REDACTED 
D
TE
CT
AC
EV
EV
DA
EV
EV
RE
COPY 
M8
M8
M9
M
PY
M
O
C
This document cannot be used to support any mark
nimal E
imal 
rketi
EV
EV
eting 
g
eti
rk
authorization 
M10
10
n
M11
M11
tio
2
iza
ho
u
a
application 
V5
V
n
tio
ic
lic
lic
lic
plic
pp
a
and 
nd any y
ny
a
extensions 
f Vi
Vi
s
Entry V
ntry V
io
M
en
xt
or 
isit
isit
or variations 
ar
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 24 of 77
Subjects coming from ULD Confirmatory Studies
(N01187, N01236)
Month
Visit
Type of Visit
1st year Follow-up
M0
V1
Entry Visit
M1
V2
MEV
M2
V3
FEV
M3
V4
MEV
M4
M5
M6
V5
FEV
M7
M8
M9
V6
MEV
M10
M11
2nd and subsequent years Follow-up
M12
V7
YEV
M15
V8
MEV
M18
V9
FEV
M21
V10
MEV
...
...
...
FEV=Full Evaluation Visit; MEV=Minimal Evaluation Visit; 
M=month; ULD=Unverricht-Lundborg disease; V=Visit; 
YEV=Yearly Evaluation Visit
In case the subject will not continue with the study drug, the Investigator will first plan an 
Early Discontinuation Visit followed by the progressive down-titration of the study drug. 
During the down-titration, dose decrease can be made by steps of a maximum of 50 mg/day 
on a weekly basis. A last down-titration step at 20 mg/day for one week will be included prior 
to the study drug-free period. At the end of the Down-Titration Period, a phone call will be 
given to subjects having down-titrated from doses higher than 20 mg/day. The Down-titration 
Period will be followed by a study drug-free period and subsequently the Final Visit will 
occur.
At the time of study termination by the Sponsor (as defined in Section 7.4), subjects will 
discontinue the study drug following the above described down titration process or will be 
converted without titration to commercial BRV where available, alternatively subjects may 
be initiated without down-titration in a managed access program, named patient program, 
compassionate use program, or similar type of access program as allowed per country-
specific requirements in addition to legal and regulatory guidelines.
V8
V8
D
V9
V9
TE
V
CT
DA
on V
on V
RE
COPY 
ears F
ars 
PY
O
C
This document
disco
isco
con
con
b
cannot 
he t
he tim
im
on
be 
be 
be 
used
frfr
cts hav
ts hav
 fol
fol
to
ree
ee p
support
it fol
t fol
on, dos
n, do
last d
ast d
any 
ntinue
ntinu
llo
ll
marketing 
Visit; M
isit; M
verricht
verrich
luation 
atio
g authorization 
Fol
n
tio
iza
V10
10
ho
....
u
application 
MEV
MEV
n
tio
ic
llow
low
pp
a
and 
nd
a
any 
an
a
extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 25 of 77
5.
BACKGROUND INFORMATION
5.1
Background and epidemiology of targeted disease
Epilepsy is one of the most common and challenging neurological disorders. It has been 
estimated that over 50 million people are affected worldwide(1, 2, 3, 4). The prevalence of 
epilepsy is around 1%. The annual incidence in developed countries is approximately 
50 to 70 cases per 100,000. In developing countries, the figure is higher due to more limited 
obstetric services and the greater likelihood of cerebral infection and trauma. The incidence 
varies greatly with age, with high rates occurring in childhood, falling to low levels in early 
adult life, but with a second peak in those aged over 65 years. In many people, particularly 
children, the condition may remit, although a significant proportion will have epilepsy 
lifelong. The disease duration is often determined by the underlying cause. Sudden 
unexpected death, a complication of great concern, occurs in 1 to 5 per 1000 patient years, 
particularly if the seizure disorder remains uncontrolled. The treatment for epilepsy remains 
difficult, and there is an ongoing medical need for new antiepileptic drugs (AEDs). For a 
considerable proportion of patients, seizure freedom can still not be reached with currently 
available AEDs(5, 6).
Diagnosis of epilepsy is based on the recurrence of seizures. Seizures may be caused by an 
underlying brain disorder or lesion or due to genetic conditions. Characterization of the 
epileptic syndrome has profound implications for treatment and prognosis. The major 
dichotomy for the diagnosis of epilepsy is the differentiation between focal epilepsies (ie, 
related to a focal brain dysfunction), which are the most frequent and account for 
approximately 60 to 70% of all cases, and generalized epilepsy syndromes, which represent 
approximately 25 to 30% of all epilepsy syndromes. In about 10% of cases, other specific 
syndromes are classified or the classification remains uncertain.
The classification of epileptic syndromes and seizure types is - and always was - a matter of 
ongoing debate. First published in 1960 and last updated officially in 1981 for seizures and 
1989 for epilepsies (Commission on Classification and Terminology of the International 
League Against Epilepsy ([ILAE], 1981 and 1989), these ILAE classifications were based on 
concepts that, for the most part, predate modern technologies and concepts(7) ILAE
[http://www.ilae-epilepsy.org]). The availability of these modern techniques, like long-term 
video electroencephalograms (EEG) and high-resolution magnetic resonance imaging (MRI), 
providing much more precise knowledge in regard to seizure type classifications and epileptic 
syndromes, led some epilepsy groups and scientists towards introducing competing 
classification systems (like the Cleveland Clinic Epilepsy Classification) and even debating 
how useful the currently used ILAE classification system is at all(8). 
This ongoing debate regarding the classification systems for epilepsies and seizures is also 
reflected within the latest Report of the Commission on Classification and Terminology 
REDACTED 
rrence
rrence
ue to g
ue to g
plica
plicatiti
psy
psy
COPY 
w 
w a
m can 
m can
This document 
rov
ov
sy
synd
nd
y
clcl
cannot
www
www
o elec
elec
vidi
vidi
be
hat, f
hat, 
i
used
sies (
es (
nst Ep
st Ep
f
to
rst p
st p
(C
(C
support 
th
epilepti
pilept
pub
pu
any
epil
epi
e cla
e c
marketing 
ion
on
y isis the
the
which
whic
ase
ses, an
s, a
lep
l
authorization 
e of se
of se
genet
genet
ns fo
ns fo
application
o 5 pe
o 5 pe
treatme
reatm
epilept
epilep
still n
till n
and 
ll h
l h
cause
cause
any
ople,
ople
have
hav
extensions 
y
ore lim
re lim
he inc
he inc
w level
level
e
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 26 of 77
(Classification Task Force) which proposes a thoroughly revised terminology and concept for 
the diagnosis of epilepsy syndromes and also to some extent seizure types(9).
Despite this ongoing debate, for the purpose of this study the seizure type classification will 
follow the 1981 ILAE classification of epileptic seizures, which speaks of partial seizures, 
classified as simple partial seizures (no alteration of consciousness), complex partial seizures 
(with alteration of consciousness), and secondarily generalized seizures, and on the other 
hand defines generalized seizure types, referred to as absence seizures (typical and atypical), 
myoclonic seizures, clonic seizures, tonic seizures, tonic-clonic seizures, and atonic seizures. 
Apart from myoclonic seizures, consciousness is almost invariably impaired from the onset 
of the seizure(10) (Commission on Classification and Terminology of the ILAE, 1981).
Likewise, the classification of epilepsy syndromes will be used according to the 1989 
ILAE-publication(11) (Commission on Classification and Terminology of the ILAE, 1989).
5.2
Background information regarding product
Brivaracetam is a chemical relative of the AED levetiracetam (LEV) (Keppra®). Like LEV, 
brivaracetam displays a high and selective interaction with a novel brain-specific binding site 
SV2A (synaptic vesicle protein 2A). However, the binding affinity of brivaracetam for SV2A 
is approximately 10-fold higher. This binding site appears to be the major target for its 
pharmacological activity. Unlike LEV, brivaracetam also reduces voltage-dependent sodium 
currents. Brivaracetam also reverses the inhibitory effects of negative allosteric modulators 
on gamma-aminobutyric acid - and glycine-induced currents. Brivaracetam is extensively 
metabolized, but seizure protection appears to be associated with the parent compound.
Brivaracetam is rapidly and completely absorbed throughout the gastrointestinal tract. The 
extent of brivaracetam absorption is not affected by food. The pharmacokinetics (PK) is 
dose-proportional (at least from 10 mg to 600 mg). Brivaracetam is weakly bound to plasma 
proteins (≤20%). The volume of distribution is 0.5 L/kg, a value that is close to that of total 
body water. The plasma half-life of brivaracetam is approximately 8 hours in young healthy 
male adults. The main metabolic pathway of brivaracetam is by hydrolysis of the acetamide 
group to the corresponding carboxylic acid, while a second pathway is the ω1-hydroxylation 
mediated by CYP2C19 (with contributions of several other isoenzymes). The combination of 
these 2 pathways results in the hydroxyacid terminal metabolite. These metabolites are not 
pharmacologically active. There is no evidence of chiral inversion of brivaracetam. 
Brivaracetam is eliminated primarily by metabolism and by excretion in the urine. More than 
95% of the dose, with less than 9% as unchanged brivaracetam, is excreted in urine within 
72 hours after dosing. 
Pharmacokinetic studies in elderly subjects and in subjects with renal impairment showed a 
similar PK profile of brivaracetam compared to that in healthy subjects, while the elimination 
of the metabolites was markedly slowed down. A PK study in subjects with hepatic 
teract
terac
ever, t
ever, t
inding
inding
V, 
V, bri
bri
the
the
COPY 
pro
r
evetir
eveti
ti
This document 
riviv
95%
95%
72
72
cannot
pat
path
macol
maco
vara
vara
be
by CY
y C
used
ma
ma
orres
orres
Y
to
asm
asm
aini
support 
rpt
rpt
st from
t fro
volum
volum
ma h
ma
any
mple
mpl
tion 
tion
marketing 
va
va
e inhib
inhib
glycine
ycin
n appe
n app
ete
authorization
iracet
racet
ion w
on w
the bin
he bin
g site 
site 
arac
rac
application
ology
ology
uctct
and 
rding
rding
any
LAE
LAE
extensions
ther
her
atatypi
yp
onic s
onic s
from 
from 
E
or
zure
zur
variations 
res
res
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 27 of 77
impairment showed a 50% increase in exposure to brivaracetam associated with decreased 
hydroxylation.
Brivaracetam does not impair the efficacy of oral contraceptives containing 
ethinylestradiol 30 μg and levonorgestrel 150 μg. Brivaracetam does not induce CYP3A4 
using midazolam as a marker probe. Brivaracetam has no interaction on lamotrigine and 
topiramate. Brivaracetam plasma concentration is not increased by gemfibrozil, a selective 
CYP2C8/9 inhibitor but is increased in a nonclinically relevant manner in Japanese subjects 
possessing defective CYP2C19 mutations. Brivaracetam clearance is doubled by rifampicin, 
a potent CYP inducer.
Trough levels of concomitant AEDs were monitored in all efficacy studies. No significant 
change from Baseline nor dose-related trend was observed for the plasma concentrations of: 
carbamazepine, lamotrigine, LEV, oxcarbazepine metabolite, phenobarbital, phenytoin, 
topiramate, valproate, zonisamide. Carbamazepine epoxide was significantly increased from 
Baseline at all brivaracetam doses greater than 20 mg/day, nearly reaching the upper limit of 
normal (3.0 μg/mL) at brivaracetam doses of 100 and 150 mg/day.
5.3
Efficacy with brivaracetam in fixed-dose Phase II/III studies in POS
Following completion of the Phase II studies (N01114(12) and N01193(13)), clinical results 
supported further development of brivaracetam for the adjunctive treatment of POS. Two 
adequate and well-controlled fixed-dose studies (N01252(14) and N01253(15)) were conducted 
to assess brivaracetam across a dose range of 5 to 100 mg/day. 
N01253 assessed brivaracetam doses of 5, 20, and 50 mg/day and provided statistically 
significant and clinically relevant evidence of the efficacy of brivaracetam 50 mg/day. 
N01252 assessed brivaracetam doses of 20, 50, and 100 mg/day. Although N01252 was not 
positive, it provided supporting evidence for the efficacy of brivaracetam 100 mg/day in 
subjects with epilepsy.
5.4
Safety with brivaracetam
In Phase II/III studies, a favorable safety and tolerability profile has been demonstrated for 
brivaracetam. The discontinuation rate and the discontinuation rate due to TEAEs were low 
and similar to placebo (PBO) for all studies. The most frequently reported TEAEs were 
headache, somnolence, dizziness, and fatigue. The overall incidence of SAEs was low and 
similar to PBO. There were no clinically relevant changes in laboratory values, vital signs, or 
ECG abnormalities.
5.5
Efficacy and safety in subjects with Unverricht-Lundborg disease
REDACTED
n fix
n fix
tudies 
udies 
varac
varac
dose
dose
COPY 
/da
d
nd 15
nd 15
This document 
nd d
head
head
sisi
cannot
e IIII/I
racet
racet
sim
sim
be 
IIII
used 
Safe
Saf
to 
psy
psy.
support 
lev
ev
cetam
etam
upport
uppor
any
dose
dos
vant 
an
marketing 
etat
e studi
 stud
range 
rang
es
authorization 
ed-do
do
(N01
(N01
tam
am
application
enoba
enob
as sign
s sign
nearl
nearly
0 mg/
mg/d
and 
die
di
asma
asma
any 
es. N
extensions
ectiv
ctiv
e subj
e subj
by rifa
by rifa
or 
ve
ve
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 28 of 77
Two Phase III studies (N01187(16) and N01236(17)) were conducted to evaluate the efficacy 
and safety of brivaracetam (5, 50, and 150 mg/day) used as adjunctive treatment in adult 
subjects with genetically ascertained ULD. In both studies, primary efficacy endpoints failed 
to reach statistical significance. In N01187, the most frequently reported TEAEs were 
headache, somnolence, and dizziness. In N01236, the most frequently reported TEAEs were 
headache, myoclonus, and somnolence. There were no deaths or clinically relevant changes 
from Baseline observed for any vital sign parameters. Results indicate that in this population 
of ULD subjects, brivaracetam administered for 16 weeks was well tolerated. 
For additional details on safety and efficacy of BRV, please refer to the Investigator’s 
Brochure(18).
5.6
Study Rationale
The Sponsor wishes to develop brivaracetam as an antiepileptic treatment in subjects 16 years 
and older suffering from epilepsy. This N01125 study will give subjects who have 
participated in a previous brivaracetam adjunctive treatment study in epilepsy, the 
opportunity to access adjunctive brivaracetam treatment under the present protocol.
Conversion to monotherapy is not permitted anymore, however, subjects already on 
monotherapy are allowed to continue BRV monotherapy.
The subjects allowed to enter the study will mainly suffer from partial onset seizure (subjects 
coming from N01114, N01252, N01254(19), and N01315), while a minority will present with 
generalized epilepsy (subjects coming from N01254 and N01315). The study will explore the 
long-term safety and efficacy of brivaracetam in such a population.
It is to be noted that subjects suffering from Unverricht-Lundborg disease (ULD) and having 
participated in a previous UCB brivaracetam study (N01187 or N01236) are also allowed to 
participate in N01125. 
5.6.1
Dose Selection
In this study individualized doses up to a maximum of 200 mg/day will be used. Twice daily 
dosing is deemed necessary to ensure more regular exposure over the 24-hour interval. A 
maximum dose of 200 mg/day was chosen following consultation with regulatory authorities 
and is evaluated in more recent brivaracetam studies (eg, N01358 and N01379). According to 
available data, 200 mg/day doses have been well tolerated.
REDACTED
any
anym
y
V mon
V mon
dy
dy wi
wi
y
254
254
COPY 
w
treatm
treatm
eatme
atme
This document 
nd d
avail
avail
cannot
is de
s de
mum
mum
is e
is e
be
dy
dy inin
used
elect
lec
d
to 
titi
support 
s su
s s
s UCB
UCB
any 
suffe
uff
marketing 
ill m
l m
4(19), a
ng from
g fro
rivara
rivar
authorization
ent un
ent un
ore, h
ore, h
nother
other
mai
mai
application 
ic treat
c trea
give su
give s
ent stu
ent st
d
and any extensions
pula
ula
stigat
tigat
or
ges
ge
atio
ati
variations 
e
es
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 29 of 77
5.6.2
Subjects Population
5.6.2.1 Minimal Age
Subjects are allowed to participate in this study from the age of 16 where legally permitted 
and ethically accepted. Indeed epilepsy features in the range of 16 to 18 years do not differ 
from the ones of older subjects, and efficacy of AEDs seems to be comparable(20).
Depending on country-specific regulations, those subjects may be considered as adolescents 
or adults(21). In case they are considered as adolescents, parent(s) or legal representative will 
sign the Informed Consent Form. The consent form or a specific assent form, where required, 
will be signed and dated by the minor.
5.6.3
Duration of Treatment
For each subject, the study will run throughout the duration of the clinical development 
period of brivaracetam, and will continue until a marketing authorization is granted by any 
Health Authority in an indication for the adjunctive treatment in adults with refractory POS, 
whether or not secondarily generalized, until the Sponsor decides to close the study, until a 
managed access program, named patient program, compassionate use program, or similar 
type of access program established as allowed per country-specific requirements in addition 
to legal and regulatory guidelines, or until brivaracetam development is stopped by the 
Sponsor.
Statement
The present study will be conducted in accordance with:
•
This protocol.
•
International Conference on Harmonization (ICH): ICH E6 Note for Guidance on Good 
Clinical Practice [CPMP/ICH/135/95](22).
•
The principles that have their origin in the Declaration of Helsinki.
•
Code of Federal Regulations on Good Clinical Practice Title 21 Parts 50, 54, 56, 312, 
and 314.
•
All applicable local laws and regulations.
It is planned that approximately 30 sites enrolling ULD subjects will be involved in the US, 
Canada, Finland, France, Italy, The Netherlands, Sweden, Tunisia, and India. For the sites 
having participated in the previous ULD study N01236, this study will be conducted under 
the Investigational New Drug (IND) regulation in the US, in Finland, Tunisia, and in France.
For the sites having participated in the previous ULD study N01187, this study will not be 
conducted under IND/CTA. This study will not be conducted under the IND for all sites that
enrolled only POS/PGS subjects. For the sites having participated in the study N01315 
conducted under IND regulation, this study will not be conducted under IND/CTA as N01315 
enrolled only POS subjects.  
REDACTED
the S
the S
rogram
rogram
llowed
llowe
until 
until
COPY 
urara
arketi
arket
ive tr
ve tr
S
This document
Cana
ana
hav
hav
t
cannot 
pp
 plann
plann
ad
ad
be
plicab
plica
used
deral 
eral 
to
that 
hat
support 
ence on
nce o
CPMP
PMP
ha
h
any
ucted
ucte
marketing 
l br
br
d
authorization
reatm
eatm
ponso
ponso
m, co
m, co
d per 
d per 
riva
riva
application 
n of the
of th
ng aut
g au
and any
rm, w
rm, 
extensions 
s adol
adol
resen
resen
w
or 
er 
er
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 30 of 77
6.
STUDY OBJECTIVES AND PURPOSE
This open long-term follow-up study will give subjects suffering from epilepsy, for whom the 
Investigator believes a reasonable benefit from the long-term administration may be 
expected, the opportunity to access adjunctive brivaracetam treatment. Conversion to 
monotherapy is not permitted anymore, however, subjects already on monotherapy are 
allowed to continue BRV monotherapy. The maximum dose was increased to align with more 
recent LTFU studies. The access to the study will be limited to the subjects having completed 
a previous brivaracetam study as listed in Section 5.6.
6.1
Primary Objective
•
To evaluate the long-term safety and tolerability of brivaracetam at individualized doses 
with a maximum of 200 mg/day in subjects suffering from epilepsy
6.2
Secondary Objective
•
To evaluate the maintenance of efficacy over time of brivaracetam (for POS/PGS 
subjects)
No efficacy objectives are defined for ULD subjects or subjects coming from N01315.
6.3
Exploratory Objectives
Exploratory objectives for POS/PGS subjects:
•
To explore direct medical resource use and indirect cost parameters for the first 2 years
•
To obtain a description of the subject’s self-reported health status for the first 2 years
•
To explore the effects of BRV on the subject’s Health-related Quality of Life, anxiety, 
and depression for the first 2 years
•
To explore any change in the subject’s socio-professional status for the first 2 years
No exploratory objectives are defined for ULD or N01315 subjects.
over t
over 
or UL
or UL
COPY 
This document cannot 
rara
be 
atory
atory
used
any
any c
y
to
for 
for 
support
cal r
al r
ion of 
on of
fects o
ects o
th
any
/PG
/PG
any
reso
res
marketing
LD s
D s
S
authorization 
ime o
me o
sub
sub
application
tam a
tam 
m epilep
epile
and any extensions 
re
n with
n with
ing co
ing co
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 31 of 77
7.
STUDY DESIGN
7.1
Type/Design
This is a therapeutic long-term follow-up, multinational, multi-center, noncomparative, 
open-label and single arm study.
This long-term follow-up study will run throughout the duration of the clinical development 
period of brivaracetam, and will thus include therapeutic exploratory studies in the early stage 
of development as well as therapeutic confirmatory studies, in the later stage of the 
development. For this reason, the study design and in particular the frequency of study visits 
is adapted to the 3 types of study, as described below:
For subjects coming from the therapeutic exploratory study (N01114):
•
First year:
First 6 months: 1 visit/month: 1 FEV alternately with 1 MEV.
Next 6 months: 1 visit/3months: 2 FEV (at V7 and V8).
•
Second and subsequent years: 
1 visit/3months: 1 FEV alternately with 1 MEV.
Yearly Evaluation Visit will be performed in replacement of the first FEV of each year.
For subjects coming from confirmatory studies (N01252 and N01254):
•
First year:
First 3 months: 1 visit/month: FEV alternating with MEV.
Next 9 months: 1 visit/3 months: FEV alternating with MEV.
•
Second and subsequent years:
1 visit/3months: FEV alternating with MEV.
Yearly Evaluation Visit will be performed in replacement of the first FEV of each year.
For subjects coming from ULD confirmatory studies (N01187 and N01236):
•
First year:
First 3 months: 1 visit/month: 1 FEV alternating with 1 MEV.
Next 9 months: 1 visit/3months: FEV alternately with MEV.
•
Second and subsequent years:
1 visit/3months: 1 FEV alternating with 1 MEV.
YEV will be performed in replacement of the first FEV of each year.
For subjects coming from long-term follow up study (N01315):
•
Subjects will perform their Last Visit in N01315 and perform at the same time their First 
Visit in N01125. They will follow the schedule of 1 visit/3 months: 1 Full Evaluation 
Visit alternating with 1 Minimal Evaluation Visit. Yearly Evaluation Visit will be 
performed in replacement of the first Full Evaluation Visit of each year.
REDACTED
h 1 M
h 1 M
formed
ormed
matory
matory
COPY 
y w
V7 and
V7 and
This document 
F
cannot
xt
cond 
ond 
1 v
1 v
Y
be
m
9 m
9 m
used 
mont
mon
to
ng f
ng f
support
V alte
alt
n Visit w
Visit
fro
f
any 
ars:
ars:
tern
ter
marketing 
y stst
FEV a
FEV 
nths: 
nths
authorization 
EV.
EV.
d in re
d in re
tud
ud
application
(N01
(N01
1 ME
1 ME
V8).
V8).
and 
1
any
ncy
ncy
extensions 
velopm
elopm
the ea
he ea
of th
of th
o
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 32 of 77
7.2
Subjects/Sites Numbers
A 90% switch over rate is estimated as compared to the number of subjects completing the 
previous brivaracetam studies.
Approximately 500-1000 subjects may enter the study.
7.3
Measures to Minimize/Avoid Bias
7.3.1
Randomization
Not applicable.
7.3.2
Blinding
Open-label.
7.4
Study Duration
This study will run throughout the duration of the clinical development period of 
brivaracetam, and will continue until a marketing authorization is granted by any Health 
Authority in an indication for the adjunctive treatment in adults with refractory POS, whether 
or not secondarily generalized, until the Sponsor decides to close the study, until a managed 
access program, named patient program, compassionate use program, or similar type of 
access program is established as allowed per country-specific requirement in addition to legal 
and regulatory guidelines, or until brivaracetam development is stopped by the Sponsor.
7.5
End of Study
The end of the study is defined as the date of the last visit of the last subject in the study.
8.
SELECTION AND WITHDRAWAL OF SUBJECTS
Before any study procedures are initiated for any subject in this study, an Independent Ethics 
Committee (IEC)/Independent Review Board (IRB) approved written Informed Consent 
Form will be properly executed and documented.
8.1
Subject Inclusion Criteria
•
An IEC/IRB approved written informed consent signed and dated by the subject or 
legally acceptable representative(s). The consent form or a specific assent form will be 
signed and dated by minors, according to country-specific regulations.
•
Male/female subjects from 16 years or older. Subjects under 18 years may only be 
included where legally permitted and ethically accepted.
REDACTED
f the 
f the
rketin
rketin
ctive t
ctive t
the Sp
the Sp
ram
ram
COPY 
This document 
8.1
8.1
cannot
ttee 
tee 
m will 
will
be
y stud
y stu
(I(I
used
CTI
TIO
d
to 
O
support 
s defin
s defin
any marketing 
pon
on
m, com
, com
owed p
wed 
l briva
briv
authorization 
clinica
linic
ng auth
g auth
treatm
reatm
onso
nso
application and any extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 33 of 77
•
Subjects with POS/PGS: inpatients or outpatients with epilepsy who participated in 
previous brivaracetam studies / programs which allow access to the present study.
Subjects with ULD: inpatients or outpatients with epilepsy who were treated with 
brivaracetam in previous studies / programs which allow access to the present study.
•
Subjects for whom the Investigator believes a reasonable benefit from the long-term 
administration of brivaracetam may be expected.
•
Female subjects with childbearing potential:
o
POS/PGS subjects: Female subjects without childbearing potential (premenarcheal; 
2 years postmenopausal; bilateral oophorectomy or ovariectomy; bilateral 
salpingectomy, complete hysterectomy; congenital sterility) are eligible. Female 
subjects with childbearing potential are eligible if they use a medically accepted 
contraceptive method for the duration of the study participation (Intra Uterine Device;
diaphragm with spermicide; male or female condom with spermicide; oral hormonal 
contraceptive; non-oral hormonal contraceptive medication; bilateral tubal ligation;
monogamous relationship with vasectomized partner). In particular, oral or depot 
contraceptive treatment with at least 30 μg [or 50 μg if associated with carbamazepine 
(CBZ) or other strong enzyme inducing drugs] ethinylestradiol per intake must be 
used in conjunction with a barrier method. The subject must understand the 
consequences and potential risks of inadequately protected sexual activity, be 
educated about and understand the proper use of contraceptive methods, and 
undertake to inform the Investigator of any potential change in status. Sexual 
inactivity might be accepted on a case-by-case basis according to the judgment of the 
Investigator.
o
ULD subjects: Female ULD subjects without childbearing potential (premenarcheal, 
postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, 
complete hysterectomy) are eligible. Female subjects with childbearing potential are 
eligible if they use a medically accepted contraceptive method. Oral or depot 
contraceptive treatment with at least 30 μg [or 50 μg ethinylestradiol per intake if 
associated with carbamazepine (or other strong enzyme inducers e.g. phenobarbital, 
primidone, oxcarbazepine)] must be used in conjunction with a barrier method. 
Monogamous relationship with vasectomized partner or double-barrier contraception 
are acceptable methods. The subject must understand the consequences and potential 
risks of inadequately protected sexual activity, be educated about and understand the 
proper use of contraceptive methods, and undertake to inform the Investigator of any 
potential change in status. Sexual inactivity might be accepted on a case-by-case 
basis.
•
Subject/legally acceptable representative considered as reliable and capable of adhering to 
the protocol (eg, able to understand and complete diaries and questionnaires), visit 
schedule or medication intake according to the judgment of the Investigator.
REDACTED
od
nadeq
nadeq
e prope
prop
gator o
gator o
on a c
on a c
COPY
r 50
r 5
ugs] et
ugs] et
d. Th
d. Th
This document 
•
cannot
prop
prop
po
po
be
cc
ks of
ks of
used
amou
mou
cepta
cepta
to
oxc
oxc
support
a me
me
atment
atmen
h carb
h carb
arb
any
y) are
) are
medi
ed
marketing
case
ase
 subjec
subje
st 2 ye
t 2 y
authorization
eth
he sub
e sub
quately
uately
per use
per use
of an
of an
e-b
application
p
on
on; bi
; b
. In par
. In pa
μg if as
g if a
hiny
inylel
and
n (In
(In
ermic
rmic
any
cally
cally
Intra
ntr
extensions 
enarch
narch
ral
ral
ble. F
le. F
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 34 of 77
8.2
Subject Exclusion Criteria
•
Severe medical, neurological and psychiatric disorders, or laboratory values which may 
have an impact on the safety of the subject.
•
Poor compliance with visit schedule or medication intake in previous brivaracetam study.
•
Participation in any clinical study of another investigational drug or device during the 
study.
•
Pregnant or lactating woman.
If the Investigator has any medically valid reason to doubt the eligibility of a subject, the 
subject should not be included into the study. If however, the Investigator has any other kind 
of doubts concerning the eligibility, he/she should consult the Sponsor’s Clinical Study
Physician or representative for clarification.
8.3
Subject Withdrawal Criteria
Investigators should attempt to obtain information on subjects, in case of withdrawal or 
discontinuation. The Investigator should make every effort, and document his/her effort, to 
complete the Early Discontinuation Visit and preferably also the Down-Titration Phone Call 
and Final Visits. All results of these evaluations and observations, together with a narrative 
description of the reason(s) for removing the subject, must be recorded in the source 
documents. The Case Report Form (CRF) must document the primary reason for withdrawal 
or discontinuation.
The study medication will be progressively down-titrated until a study drug-free state is 
reached. After a period of free of study medication, the subject will attend the Final Visit.
After decision of subject’s discontinuation, the Investigator will provide the subject with 
information about alternative treatments.
The Sponsor could decide to discontinue or prematurely terminate the study for reasons 
related to safety and/or efficacy of the Investigational Product or, decide to stop the 
development of brivaracetam.
REDACTED
io
ke eve
ke ev
and pr
nd pr
valuati
valuati
oving 
oving 
CR
COPY 
n on
n on
This document cannot
pmen
pmen
be
c
afet
afet
used 
could
oul
to
alter
alter
support
ree 
ee 
ect’s d
ect’s d
rna
any
progr
progr
e of
of
marketing
the 
the 
RF) mu
RF) mu
authorization
n subj
subj
ery
ery eff
ef
y
prefe
referara
ions a
ons a
e su
su
application 
ns
and
ator
tor
or’s
or’s
any
of a s
of a 
r ha
r h
extensions
g the
g the
o
tud
tud
variations 
dy
dy
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 35 of 77
8.3.1
Withdrawal Criteria
•
Withdrawal for safety reasons by the Investigator.
•
Subject and/or Investigator does not think that the investigational drug is effective.
•
Lost to follow-up.
•
Withdrawal of consent by the subject for any reason, at any time.
•
Other reason that has to be specified in the CRF.
Withdrawal criteria for already enrolled subjects who did not complete a Columbia-Suicide 
Severity Rating Scale (C-SSRS) assessment at the Entry Visit:
•
Subject has a lifetime history (prior to study entry or since study start) of suicide attempt 
(including an active attempt, interrupted attempt, or aborted attempt) of the “Already 
Enrolled Subjects” version of the C-SSRS. The Investigator must withdraw the subject 
from the study and immediately refer the subject to a Mental Healthcare Professional.
•
Subject had active suicidal ideation prior to study entry or since study start as indicated 
by a positive response (“Yes”) to either Question 4 or Question 5 of the “Already 
Enrolled Subjects” version of the C-SSRS. The Investigator must immediately refer the 
subject to a Mental Healthcare Professional and use clinical judgment as to whether to 
withdraw the subject from the study.
•
Subject has active suicidal ideation as indicated by a positive response (“Yes”) to either 
Question 4 or Question 5 of the “Since Last Visit” version of the C-SSRS. The subject 
should be referred immediately to a Mental Healthcare Professional and must be 
withdrawn from the study.
8.3.2
Subject Replacement Policy
Not applicable.
9.
TREATMENT OF SUBJECT (INVESTIGATIONAL PRODUCTS AND 
CONCOMITANT MEDICATIONS)
9.1
Study Investigational Products
9.1.1
Description of Investigational Products
The investigational product (tablets containing 10 mg or 25 mg of brivaracetam) will be 
supplied under the responsibility of the Sponsor Clinical Trial Supply Department for all 
subjects.
REDACTED 
est
est
RS. Th
S. Th
ssional
siona
dy
dy.
ion a
ion a
COPY
to a
to a
udy
udy en
e
y
tion
io
This document
9.1.1
1.1
cannot 
Stu
St
1
be 
ON
used 
ATME
TME
NCO
CO
to support
ment 
ent 
any 
P
marketing
as ind
as ind
Since L
nce 
y to a M
to a M
authorization 
ntry
ntr
n 4 or 
4 or
he I
e Inv
nv
al and 
l and
didi
application
dy
attem
attem
tor mu
tor mu
Mental 
Menta
ry o
y
nd 
star
star
any extensions 
lumb
umb
e
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 36 of 77
The frequency at which investigational product will be supplied to each individual center will 
be adapted to the recruitment capacity of that center and to the expiry date of the 
investigational product.
9.1.1.1 Dosing Schedule
Subjects coming from brivaracetam studies have the opportunity to access brivaracetam 
treatment at a flexible dose up to a maximum of 200 mg/day in b.i.d administration. It is 
recommended that the daily dose will be divided into two equal intakes, taken with or without 
food and that the first intake will be in the evening of the day of the dispensation of the 
medication.
The individual starting dose of each subject will be the one recommended at the end of the 
previous study.
At each subject visit, if necessary, the dosage can be adapted:
•
Up-titration can be made by increments of 50 mg/day on a weekly basis and this to a 
maximum of 200 mg/day.
•
Dose decreases can be made by steps of 50 mg/day on a weekly basis. A last 
down-titration step at 20 mg/day for one week will be included prior to the study drug-
free period.
At each visit, the Investigator will evaluate, as closely as possible, the supplies needed by the 
subject in terms of number of containers (200 tablets per container) of each dosage (10 mg or 
25 mg tablets) according to the dose prescribed and the possibility to down-titrate/up-titrate 
by a maximum of 50 mg/day steps. 
In case the subject will not continue with the study drug, the Investigator will plan the 
progressive down-titration of the study drug. The Down-Titration Period will be followed by 
a period free of study drug of minimum two weeks and a maximum of four weeks and 
subsequently the Final Visit will occur.
9.1.2
Packaging
Tablets of brivaracetam (10 mg or 25 mg) will be packaged in containers of 200 tablets. 
Containers of 80 tablets have been removed. On request, the Investigator will be supplied 
with a sufficient number of containers. Each container will have a unique, pre-printed 
identification number.
The Investigator will inform each subject included on how to take the drug and that an excess 
of drug is present in the investigational product container.
REDACTED
50 mg
50 m
ne we
ne we
valu
va
COPY 
ada
d
mg/day
mg/da
This document 
on
on
with
with
idi
cannot 
lets of
ets of
ntain
tain
be
acka
acka
used
e Fin
Fin
to
dy
dy d
support 
ot con
ot co
ation o
tion o
dru
d
any
teps.
eps
marketing 
luate, a
uate, a
iners 
ners (2
ose pre
se pr
authorization 
y
g/day o
g/day 
eek wi
eek wi
application 
ed:d:
y on a 
on a
y
and 
ended
nded
any extensions 
am
n. ItIt isis
with o
with o
tion o
ion o
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 37 of 77
9.1.3
Labeling
Each type of container will be distinguished, per dosage, by colored labels.
The label consists of two parts. The first is a tear-off sticker which must be attached to the 
Case Report Form at the time of visit and the second remains fixed to the investigational 
product package.
Clinical Drug Supplies will be labeled in accordance with the current ICH Guidelines on 
Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) and will include any 
locally required statements.
The label will be adapted to local regulatory requirements and to the size of the 
investigational product package, and translated as appropriate.
Subject number, subject initials, dispensation date and name of Investigator will be added 
manually by the Investigator before dispensing. Dosage instructions will be specified in the 
dispensing card.
9.1.4
Storage Requirements
Investigational product packages should be stored in a secured limited access area and 
maintained at controlled temperature (as specified on the label of the investigational product 
packages). A recording of the controlled temperature should be done on site. If the storage 
conditions are not controlled (with recording), a temperature log should be completed at least 
once a week with the minimal and the maximal temperatures reached in the week preceding 
the record.
Storage should be in a pharmacy or in a locked facility. Supplies for this study will be stored 
in such a way that they may not be mixed up with supplies being used for another study. A 
standard storage statement will appear on each package label of study medication.
The Investigator or the hospital pharmacist is responsible for the appropriate storage of 
investigational product packages at the research site.
The Investigator will instruct the subject/legally acceptable representative to store the 
medication at controlled temperature (as specified on the label) in a secure place out of the 
reach of children.
9.1.5
Monitoring of Subject Compliance
Containers of study drug will be supplied to each subject at each Visit. Subjects will be 
instructed to ingest the study drug in the morning and in the evening (approximately 12 hours 
between doses).
REDACTED 
e store
e store
s spec
s spec
lled te
lled te
eco
eco
COPY 
This document 
ac
ac
9
cannot
vestig
estig
cation
catio
ch o
h o
be used
r or t
or t
al pro
l pro
to 
thth
support 
ma
ma
may
ay no
 n
y
ment w
ment w
any 
acy
acy o
y
marketing 
emp
m
ording)
rding)
he max
e ma
authorization 
ed in 
d in 
cified 
ified 
mper
mper
application
nvest
nves
ctions 
ctions
and 
titi
any
of th
of th
extensions 
nes on
nes on
ill incl
ill inc
he
h
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 38 of 77
The Investigator will instruct the subject to bring back at each visit, the original containers 
(even empty) dispensed at the previous visit and containing all the remaining tablets of the 
study medication. Drug reconciliation must be done in the subject’s presence in order to 
obtain explanations regarding discrepancies in compliance with the dosing regime. This 
information will be documented on the drug accountability form (see also Section 9.1.6).
The number of tablets returned must be recorded in the CRF. Compliance with study
medication is defined as investigational product consumption by the subject within 80% -
120% of the prescribed dosage.
9.1.6
Investigational Products Accountability
The Sponsor or its representative will supply a drug accountability form, to be kept 
up-to-date. Study medication disposition records, such as shipping, dispensing and returned 
drug records, inventory logs, must be kept at the site.
Drug accountability form should include at least:
•
Number of tablets dispensed to and returned by each subject, with the subject’s number 
and container number.
•
Initials of the person who actually dispensed and/or received returned study medication.
•
Dates of the above.
•
Explanations for non-compliance.
After completion of the study, all used (including empty bottles) and unused investigational 
product containers must be reconciled and returned (preferably in their original package) to 
the Sponsor, according to a procedure to be defined at the time.
9.1.7
Maintenance of Study Treatment Randomization Codes and Procedures for Blind 
Breaking
Not applicable.
9.2
Concomitant Treatments 
For any treatment other than the investigational product, an accurate record must be kept in 
the clinic chart (source documentation) and the Case Report Form. 
This record should include the brand name of the drug, the dose, the date(s) of administration, 
and the indication for use.
REDACTED 
pensed
ensed
e.e.
COPY 
by ea
y ea
This document
he c
he c
T
cannot 
C
any tr
y t
clin
cli
be
onco
onc
used to support 
of f Stud
Stu
any
ocedu
oced
marketing 
sed (in
ed (in
ciled a
iled 
authorization
ach su
ach s
d and/
d and/
application
ng, di
ng, di
b
and 
orm, 
orm, 
i
any extensions 
n 80%
80%
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 39 of 77
9.2.1
Permitted Concomitant Treatments (Medications and Therapies)
The Investigator may adapt the AED/AMD drug/dosage for safety or efficacy reasons. 
Benzodiazepines taken more than once a week will be considered as AED/AMD.
9.2.2
Not Permitted Concomitant Treatments (Medications and Therapies)
Felbamate and vigabatrin are not permitted for all subjects. Phenytoin is not permitted for
ULD subjects.
10.
STUDY PROCEDURES
Note: Entry Visit procedures for N01315 subjects were already conducted and will not be 
repeated in N01125. Assessments specified as performed within the first 2 years of the 
Evaluation Period are not applicable to subjects coming from N01315.
10.1
Subject Identifier
Each subject will be identified by initials (only letters preferably 4, without spaces or any 
punctuation signs like coma, slash, hyphen, etc.) and subject number. The subject number 
will be different from the previous study in which the subject was participating and it 
includes a newly assigned site number and a sequential enrollment number per site.
At the level of the database, the Master CRF number (from CRFs Yearly Book one) will be 
used as additional identifier to the subject numbers. Subjects coming from N01315 will retain 
their current subject numbers.
10.2
Description of Procedures
For N01315 subjects, ongoing procedures will be transferred electronically from the previous 
study and should not be recorded again in N01125 CRF.
10.2.1
Informed Consent
Before any study-related procedures are performed, an IEC/IRB approved informed consent 
will be properly executed and documented.
For subjects already ongoing in the study, an IEC approved addendum will also be signed 
covering the increased risk of suicidality or suicidal thoughts to comply with the warning 
issued by FDA subsequent to an analysis performed on marketed antiepileptic drugs. 
Although data from brivaracetam studies were not included in FDA's analysis, this risk 
cannot be ruled out because brivaracetam belongs to this class of medications.
REDACTED 
only
only lel
y
hen, et
hen, e
udy
udy inin
ber a
ber a
COPY 
ng
This document 
illll
Fo
F
cannot 
re an
e an
l be p
be 
be
nform
nform
used
d not
no
to
ts, o
ts, o
ot b
ot b
support 
Pr
Proced
oce
ong
ong
any marketing 
n w
and a s
nd a 
ter CR
er CR
e subjec
subj
authorization 
letters
etters
tc.) an
c.) an
whic
whic
application 
ondu
ndu
in the f
n the
m N01
m N0
and 
uc
uc
any extensions 
rmitte
rmitte
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 40 of 77
Where legally acceptable, a Partner Pregnancy Consent Form will be issued in case the 
partner of a male subject becomes pregnant (Section 12.3.5). 
10.2.2
Demography
At the first visit, date of birth, gender and racial group will be recorded.
10.2.3
Childbearing Potential and Birth Control
At the first visit, information on childbearing potential and contraceptive method used by 
female subjects will be collected. During the course of the study, the Investigator should 
make sure that birth control remains optimal should a subject’s status change. A pregnancy 
test will be performed as specified in the flow chart (Section 4.1).
10.2.4
General Medical and Procedures History
The General Medical and Procedure History will be transferred electronically from the 
previous study in which the subject was participating.
10.2.5
Epilepsy History/Disease History
The history of epilepsy reported at the first visit of the previous study the subject was 
participating, will be considered as history of epilepsy in this study and will be directly 
electronically transferred from this study.
Similarly, a disease history will be recorded for ULD subjects only.
10.2.6
Antiepileptic/Antimyoclonic Medication History
The AED medication history and the AMD medication history (for ULD subjects) will be 
transferred electronically from first visit of the previous study in which the subject was 
participating. The AED and AMD being used concurrently at the current dose will be 
recorded on the concomitant AED/AMD medication page of the CRF.
10.2.7
Vital Signs
At every visit, after five minutes supine or sitting, pulse rate and blood pressure will be 
obtained, followed by standing pulse rate and blood pressure. At the Entry Visit, vital signs 
will be obtained electronically from the last Evaluation Visit of the previous study and should 
not be recorded in the CRF.
REDACTED
cipat
cipat
tory
tory
he f
he f
COPY 
be tr
be t
i
This document 
0.2.2
A
cannot
d on
on
2.7.7
be
ng. T
ng. T
t
used
cation
atio
ectron
ctron
Th
to 
n
support 
wil
wi
/Antim
/Antim
any 
ill be
ll b
marketing 
first vi
irst vi
history
istor
s s study
stud
authorization
ransf
ransf
ng.
ng.
application and 
nve
ve
s cha
s cha
any
meth
meth
estig
esti
extensions 
ho
h
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 41 of 77
10.2.8
Body Weight and Height
At Entry Visit, at each Full Evaluation Visit, at each Yearly Evaluation Visit, and at the Final 
Visit, body weight (subject wearing light clothing without shoes and rounded to the nearest 
kilogram) will be obtained. Height will be obtained only at the Entry Visit. For a subject still 
potentially growing, height will also be measured at each Yearly Evaluation visit and Final 
Visit.
10.2.9
Physical Examination
Physical examination will be performed at every Full Evaluation Visit, Yearly Evaluation 
Visit, Early Discontinuation Visit and Final Visit. At the Entry Visit, the physical 
examination will be obtained electronically from the last Evaluation Visit of the previous 
study and should not be recorded in the CRF. The standard physical examination will include 
investigation of skin, eyes, ear, nose, throat, cardiovascular system, respiratory system, 
gastro-intestinal system, musculoskeletal system, endocrine, metabolic and nutritional 
system, blood and blood-forming organs and immune system and optionally genitourinary 
system.
10.2.10 Neurological Examination
At every Full Evaluation Visit, Yearly Evaluation Visit, Early Discontinuation Visit and Final 
Visit a standard neurological examination will be performed, consisting of a brief review of 
cortical functions, cranial nerves, motor function, reflex function, sensory function, gait and 
stance. At the Entry Visit, the neurological examination will be obtained electronically from 
the last Evaluation Visit of the previous study and should not be recorded in the CRF. 
Psychiatric and mental status will be reported by recording the presence or absence of 
psychiatric symptoms, mental impairments and behavioral symptoms.
10.2.11 ECG
Once the subject has signed the updated Informed Consent, the number of standard 12-lead 
ECGs will be reduced to once per year at the following visits: at the Yearly Evaluation Visit, 
Early Discontinuation Visit and at the Final Visit (in case the FV follows an EDV and the 
EDV ECG is normal, no additional ECG has to be performed at FV). At the Entry Visit, the 
ECG will be obtained electronically from the last Evaluation Visit of the previous study and 
should not be recorded in the CRF. The Investigator will determine whether the results of the 
ECG are normal or abnormal and assess the clinical significance of any abnormalities. The 
original ECG tracing will be signed or initialed and dated by the Investigator and retained as 
part of the source data. 
REDACTED 
y Eva
y Ev
nati
nati
COPY 
ocrc
une sy
une sy
This document 
CG
CG
shou
shou
E
cannot
Disco
isco
V ECG
ECG
G w
G w
be
j
be
be r
used 
ect ha
ect h
to support 
us w
s w
mental i
ental
any
prev
prev
will 
wil
marketing 
alulu
ion wil
on wi
otor fu
tor f
urologi
rolog
vioi
authorization 
y
uatio
uatio
application 
cal ex
al e
stem, r
tem, 
e, meta
, met
stem a
tem a
and 
he p
e 
Visit
Visit
any
arly
arly
phys
phy
extensions 
y E
or 
alal
variations 
illll
l
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 42 of 77
10.2.12 Daily Record Card (DRC)
At the Entry Visit, every Full Evaluation Visit, every Minimal Evaluation Visit, Yearly 
Evaluation Visit, and the Early Discontinuation Visit, the subject will receive a Daily Record 
Card (DRC) and will be asked to come back at the next visit with the completed DRC. 
The following information will be recorded on the DRC:
•
Date and the number (where possible) of epileptic seizures 
•
Type of seizure (according to individual description of epileptic seizures) 
•
Occurrence of seizure clusters 
•
All unusual events concerning the subject’s health
•
Changes in concomitant medication (dosage and/or product) 
•
Changes in investigational product (dosage)
A new DRC designed according to these protocol amendment requirements, to reflect the 
update of the assessments and to enhance the subjects’ compliance will be used by all 
subjects from the visit following the IEC/IRB approval and after the subject has signed the 
N01125 Informed Consent.
Due to the nature of their disease, some ULD subjects may be unable or have physical 
difficulty in writing down their answers. These subjects may be helped by asking the 
subject’s legally acceptable representative/care giver/study nurse/study physician to write 
down their answers; the helping person should preferably be the same during the course of 
the study.
The written information will be discussed with the subject at each visit in order to ensure 
completeness and accuracy. As a result of the discussion, the Investigator will assess the 
epileptic seizures according to the ILAE codes and record the seizure types and frequency on 
the CRF (except for ULD subjects); he/she will also confirm the presence of adverse events 
(if applicable). The concomitant medication changes and adverse events will be reported by 
the Investigator on the specific pages of the CRF.
The DRC will be considered part of the CRF as well as source documentation. The subject 
should be educated to complete the DRC on a regular basis (each time that a seizure, an 
undesirable event, a modification of medication or investigational product, or a medical visit 
occurs).
REDACTED 
ULD s
ULD s
rs. The
rs. Th
ntativ
ntativ
COPY
s’ co
s’ c
roval
ova
This document
occu
ccu
cannot
C w
d be ed
be ed
desirab
esirab
urs
be 
will 
will 
used
he
r on th
on t
to
con
con
support 
y. As
. As
ding to
ding t
ULD s
LD 
any
be dis
e dis
s a
marketing 
ve/car
e/ca
n s
n shou
hou
authorization 
an
a
ubjec
ubjec
ese su
ese su
are
application 
t t requi
requ
mplian
mplia
nd af
nd a
and any extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 43 of 77
10.2.13 Patient Reported Outcomes
A Patient Reported Outcomes (PRO) booklet per visit will be created for the FEV, YEV as 
well as for EDV. The assessment of the Patient Reported Outcomes will be limited to the first 
2 years after study entry which includes the YEV of year 3. Subjects coming from the 
N01114 will not have to complete the EQ-5D questionnaire and ULD and N01315 subjects 
will not have to complete the EQ-5D questionnaire and the HADS.
These booklets will include, in order of appearance: the Patient Weighted Quality of Life in 
Epilepsy Inventory - 31 item form (QOLIE-31-P, Version 2), the Hospital Anxiety and 
Depression Scale (HADS), and the EQ-5D self report questionnaire. The PRO booklet is to 
be provided to subjects that are not mentally impaired, at the very beginning of the study 
visit. The subject will be asked to complete the questionnaires on his/her own. Once 
completed, the subject will hand back the booklet to the Investigator who will check that all 
questions have been answered.
The PRO booklets will be considered as part of the CRF as well as source documentation.
10.2.14 Health Related Quality of Life Questionnaire (QOLIE-31-P)
The QOLIE-31-P(23) will be only completed by subjects coming from studies during which 
Health-related Quality of Life (HRQOL) was a part of the assessment.
The subjects will complete the QOLIE-31-P (Version 2) at Month 3 (for subjects coming 
from N01114 and ULD subjects only), at every Full Evaluation Visit (for POS and PGS
subjects only), at every Yearly Discontinuation Visit for the first 2 years, and at the Early 
Discontinuation Visit if the Early Discontinuation Visit occurs within the first 2 years.
Subjects coming from N01315 will not complete the QOLIE-31-P (Version 2) in this study.
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument(24) that includes seven 
subscales (seizure worry, overall quality of life, emotional well-being, energy-fatigue, 
cognitive functioning, medication effects, and social function) and the health status item. In 
addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains seven items asking the 
subjects to grade his or her overall "distress" related to the topic of each subscale. The 
QOLIE-31-P also contains an item asking about the relative importance of each subscale 
topic. The questionnaire will be completed by the subject, provided he/she is not mentally 
impaired.
It will be considered as part of the CRF as well as source documentation.
REDACTED
stion
stion
eted b
eted b
OL
OL) w
COPY 
 CRF 
 CRF
This document 
opic
pi
impa
impa
cannot
s to g
to g
LIE-31
E-3
ic. T
c. T
be
the 
the 
used
re w
e w
ctioni
tioni
3
to
s an
s an
wo
support 
Ea
Ea
01315 
131
n ad
n a
any
Disc
Dis
arl
arly y
marketing 
was
was
LIE-31
-31
only
nly), a
)
co
authorization 
naire 
naire 
by sub
y sub
as a 
s a
application
ator w
ator w
as we
as we
and 
nn
nn
s/her 
/her 
any
RO
RO
ning o
ing
extensions 
ity
ity of 
of 
y
nxiety
nxiety
O b
O b
or 
cts
cts
variations 
s
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 44 of 77
10.2.15 Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) will be used to evaluate anxiety and 
depression/depressed feelings. The HADS will not be assessed in subjects with ULD or from 
N01315. The HADS was developed as a self administered scale to assess the presence and 
severity of both anxiety and depression simultaneously. It consists of 14 items that are scored 
on a 4-point severity scale ranging from 0 to 3. A score per dimension (anxiety, depression) 
will be calculated as recommended by the authors with each score ranging from 0 to 21 and 
higher scores indicating higher depression/anxiety. The subjects will complete the HADS at 
every Full Evaluation Visit and Yearly Evaluation Visit for the first 2 years, and at the Early 
Discontinuation Visit if the Early Discontinuation Visit occurs within the first 2 years.
10.2.16 Laboratory Assessments 
At the following visits: Full Evaluation Visit, Yearly Evaluation Visit, Early Discontinuation 
Visit, and Final Visit, laboratory assessments will be conducted using standard methods at a 
central laboratory. At the Entry Visit, data will be transferred electronically from the last 
Evaluation Visit of the previous study and should not be recorded on the CRF. The central 
laboratory will provide the Investigator with dedicated, standardized sampling equipment 
(labels, needles, tubes), and a study-specific laboratory manual, which will explain how to 
use the equipment and how to ship the samples back to the central laboratory. Results for 
hematology, chemistry, urinalysis and serum pregnancy tests (if the local urine pregnancy test 
was positive) will be provided by fax to the Investigator within 72 hours after sample receipt.
Total blood volume drawn for clinical laboratory assessments will be maximum 
11 mL/sampling. Subject should preferably be fasting. Study medication intake must not be 
delayed.
The following laboratory assessments will be conducted:
•
Blood chemistry: glucose, urea, creatinine, sodium, potassium, calcium, phosphorus 
(inorganic), total protein, albumin, total bilirubin, alkaline phosphatase, aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (ASAT/SGOT), alanine 
aminotransferase/serum glutamic pyruvic transaminase (ALAT/SGPT), 
gamma-glutamyltranspeptidase (GGT), and uric acid.
•
The creatinine clearance (Cr Cl) will be calculated by the Cockroft’s formula (only at 
Entry Visit):
o
male: Cr Cl mL/min= [(140-age) x body weight] / (72 x serum creatinine (mg/dl)),
o
female: Cr Cl mL/min= [(140-age) x body weight] / (72 x serum creatinine (mg/dl))] 
x 0.85.
•
Hematology: white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), platelet count, lymphocytes 
REDACTED
ould 
ould
th ded
th ded
cific l
cific l
he sam
he sam
nd
nd
COPY 
Ev
Ev
be con
be con
e tran
tran
This document
T
E
cannot
notra
otra
gamm
amm
The
The
be
rans
rans
used
mistry
stry
), tot
), tot
f
to
rato
rato
support 
hou
ou
ory
ory
any
clini
clin
uld p
uld
marketing 
mpl
mpl
serum
erum
x to the
to t
ica
i
authorization
nsferr
nsfer
not be
ot be
dicate
icate
labora
abora
ples 
les
application 
ation V
ation
ducted
ducte
and 
he
he
any 
s, , an
a
e firs
fir
extensions
re sc
e sc
epress
press
m 0 to 
m 0 to 
te the
e the
an
or 
nd 
nd 
cor
cor
variations 
m
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 45 of 77
(number, %), monocytes (number, %), neutrophils (number, %), eosinophils (number, %), 
basophils (number, %), other cells (number, %).
•
Urinalysis: specific gravity, pH, glucose, bilirubin, ketones, occult blood, protein, nitrites, 
leukocytes. If the test for protein, blood or leukocytes shows a trace or is positive, 
sediment and microscopic analyses (erythrocyte cast, leukocyte casts, haemoglobin casts, 
uric acid crystals, bihydrate calcium oxalate crystals, monohydrate calcium oxalate 
crystals, triple phosphate crystals and bacteria) will be conducted.
•
Where applicable (women with childbearing potential), a local urine pregnancy test 
(human chorionic gonadotropin [β-hCG] levels) will be conducted. In case of a positive 
outcome, a serum pregnancy test will be performed by the central laboratory. If 
pregnancy is suspected at any time during the study, an interim test should be performed.
Plasma samples to analyze brivaracetam and concomitant AED/AMD plasma concentrations 
have been collected up to Protocol Amendment 25, dated 03 Jan 2011, but will no longer be 
obtained.
10.2.17 Adverse Events
At Entry Visit, the Investigator will record all the adverse events that were still ongoing at the 
end of the previous study. From Entry Visit onwards, adverse events will be assessed at each 
visit and recorded in the CRF and in the source documents. The study participant will be 
given the opportunity to report AEs spontaneously. A general prompt will also be given to 
detect adverse events, e.g., “Did you notice anything unusual about your health (since your 
last visit)?” In addition, the Investigator should review any self-assessment procedures (e.g. 
daily record cards) used in the study.
10.2.18 Assessment of Suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS. This scale will be 
used to assess suicidal ideation and behavior that may occur during the study. The C-SSRS 
will be completed according to the tabular schedule of assessments (Section 4.1).
10.2.19 Medical Procedures
At Entry Visit, the Investigator will record all the medical procedures that were still ongoing 
at the end of the previous study. From Entry Visit onwards, collection of data on medical 
procedures (surgery, therapeutic and/or diagnostic, hospitalizations) undertaken during the 
study will be obtained. ECGs required by protocol will not be recorded on the Medical 
Procedures page of the CRF, but on the ECG module.
ll the 
ll the
sit onw
it onw
e sour
e sour
spont
spont
no
n
COPY 
This document
t the
the
proc
proc
s
cannot 
Entry
ntry V
y
he e
he e
be
Medic
Medic
used
ted ac
d ac
to
dal 
dal
support
icida
cid
sessed 
essed 
idid
any 
dalit
dal
marketing
taneo
ne
otice a
otice a
gator sh
ator s
dy
dy.
authorization 
adver
adver
wards
wards
rce do
ce do
eou
eou
application
2011
2011
and 
D pla
D pla
any
ould
ould
extensions 
cy test
test
y
of a p
of a p
tory
ory
or variations 
sts, 
s, 
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 46 of 77
10.2.20 Health Care Provider Consultations not Foreseen by the Protocol
From Entry Visit onwards, health care provider consultations not foreseen by the protocol 
will be assessed in the CRF. It includes the type of provider [General practitioner (GP), 
specialist physicians, nurses...], the site of care (office-private, office-hospital, home, 
emergency room) and the reason. Healthcare provider consultations not foreseen by the 
protocol will be assessed at every Full Evaluation Visit, Minimal Evaluation Visit, and 
Yearly Evaluation Visit for the first 2 years, and at the Early Discontinuation Visit and the 
Final Visit if these visits occur within the first 2 years. Health care provider consultations not 
foreseen by the protocol will not be assessed for N01315 subjects.
10.2.21 Hospital Stay
From Entry Visit onwards, the collection of data on hospital stay will be assessed in the CRF.  
It includes the reason of hospitalization, the admission wards, transfers and length of stay.
Hospital stays will be assessed at every Full Evaluation Visit, Minimal Evaluation Visit, and 
Yearly Evaluation Visit for the first 2 years, and at the Early Discontinuation Visit and the 
Final Visit if these visits occur within the first 2 years. Hospital stay will not be assessed for 
N01315 subjects.
10.2.22 Non-Antiepileptic and Antiepileptic Concomitant Medications/Non-Antimyoclonic 
and Antimyoclonic Concomitant Medications
At Entry Visit, the Investigator will record all the non-antiepileptic/non-antimyoclonic and 
antiepileptic/antimyoclonic concomitant medications that were still ongoing at the end of the 
previous study. All medications (including over-the-counter preparations) taken during the 
course of the study must be documented in the CRF (brand name, indication, dosage, and the 
dates of start and discontinuation).
At each visit, a complete listing of all medications currently being taken will be obtained. 
Any changes, additions or deletions in the administration of non-antiepileptic/
non-antimyoclonic concomitant medications must be recorded on the Non-Antiepileptic/
Non-Antimyoclonic Concomitant Medications page of the CRF. In case of intake of 
forbidden concomitant medication (Section 9.2.2) during the study period, the Investigator 
will contact the monitor immediately.
Changes, additions or deletions in the administration of antiepileptic/antimyoclonic
concomitant medications must be recorded on the Antiepileptic/Antimyoclonic Concomitant 
Medications page of the CRF.
Antimyoclonic and non-antimyoclonic medication will only be recorded for ULD subjects.
REDACTED 
ileptic
ileptic
mitant
mitant
COPY 
n n
the E
the E
years
years
This document 
Chan
Chan
co
co
cannot
en co
en co
contac
conta
be
my
myoc
oc
used
dditio
ditio
lonic
onic
l
to
mple
mple
on
support 
do
do
tinuatio
nuat
ete
ete
any
s (in
s (in
ocum
ocu
marketing 
t M
record 
ecor
mitant
mitan
ncl
authorization
. Ho
Ho
c Con
Con
Med
Med
application 
will 
will
transfe
transf
it, M
, Min
arlrly D
y D
and 
b
any extensions 
d d
and t
and t
nsultat
nsulta
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 47 of 77
10.2.23 EQ-5D Questionnaire
The EQ-5D(25) is a self-administered questionnaire designed to measure health status. EQ-5D 
defines health in terms of 5 dimensions (mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression). Each dimension is divided into 3 levels:
•
no problem = 1
•
some or moderate problems = 2
•
extreme problems = 3
EQ-5D also captures a self-rating of health status on a 20 cm vertical visual analogue scale, 
anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) 
at the bottom. The EQ-5D questionnaire will not be completed by subjects with ULD and by 
subjects coming from N01114 or N01315. The EQ-5D questionnaire will be assessed at every 
Full Evaluation Visit and Yearly Evaluation Visit for the first 2 years, or at the Early 
Discontinuation Visit if the Early Discontinuation Visit occurs within the first 2 years.
10.2.24 Socio-professional Data
Socio-professional data will be collected at the Yearly Evaluation Visit for the first 2 years 
and/or at the Early Discontinuation Visit if the Early Discontinuation Visit occurs within the 
first 2 years in the CRF for subjects coming from N01252 and N01254 only. It collects 
information such as education level, housing status, employment status, need for caregiver 
and driving license.
10.2.25 End of Study
In case the subject will not continue with the study drug, the Investigator will first plan an 
Early Discontinuation Visit followed by the progressive down-titration of the study drug 
dose. Dose decreases can be made by steps of 50 mg/day on a weekly basis. A last 
down-titration step at 20 mg/day for one week will be included prior to the study drug-free
period. At the end of the Down-Titration Period, a Down-Titration Phone Call will occur for
subjects having down-titrated from doses higher than 20 mg/day. The Down-titration Period 
will be followed by a study drug-free period and subsequently the Final Visit will occur.
The end of the subject’s participation in the study will be confirmed on the subject’s status 
evaluation section of the CRF. All data about the subject’s final status (study completion or 
reason for early study termination) will be recorded. It will be specified:
•
Whether the subject completed (participated until the study is stopped) or prematurely 
discontinued the study.
A subject will be considered lost to follow-up following two documented unsuccessful 
attempts to contact the subject by telephone.
REDACTED
he E
he Eara
ng from
g from
ousing
using
COPY 
Yearl
earl
This document
easo
aso
•
cannot
d of t
d of t
uation
atio
son
on
be 
w
used
dow
dow
wed b
ed b
to
of th
of th
support
t fol
fol
n be m
n be m
20
20 mg
mg
he
h
any
ntinue
ntinu
ollow
llo
marketing authorization
y Eva
y Eva
rly
rly Di
Di
y
om N0
om N0
g statu
statu
application
within 
within
and
will 
ill 
s, or
, or
any
s wit
s wi
l be 
be
extensions 
alogue
alogue
able h
able 
h
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 48 of 77
10.3
Study Conduct
Conduct of the visits is described in Flow chart (Section 4.1). Detailed description of 
assessments done during different type of visits is described in this section and in Procedures 
(Section 10.2).
The Entry Visit will be performed on the same day as the last visit of the previous study in 
which the subject was enrolled.
Should an interval become necessary between the last visit of the previous study and the 
entry visit in the present study, the Sponsor’s Clinical study physician or representative 
should be contacted for agreement. The Adverse Events, medical procedures, non-
antiepileptic/non-antimyoclonic and antiepileptic/antimyoclonic concomitant medication 
belonging to the interim period will be reported in the CRF, on specific pages.
Each visit will be planned within a “window” of ±7 days from the previous visit. When 
possible, out-of-window visits should be rescheduled with respect to the Entry Visit.
At any time, the subject may have an additional study visit/phone call if the Investigator or 
the subject deems it necessary. All information, including reason for visit/phone call, any 
information on adverse events, etc., should be collected in the source documents and recorded 
in the appropriate section of the CRF.
For subjects coming from therapeutic exploratory studies during the early stage of 
development, visits will be organized on a monthly basis during the first 6 months, afterwards 
subjects’ visits will be scheduled once every three months.
Coming from confirmatory studies at a later stage of the drug development, subjects will 
have monthly clinic visits during the first 3 months, afterwards subjects’ visits will be 
scheduled on a-three-monthly basis (Section 4.2). Subjects coming from N01315 will be 
scheduled on a three-monthly basis.
Note: Procedures performed within the first 2 years are not applicable to subjects coming 
from N01315.
10.3.1
Entry Visit
•
Signing and dating of written informed consent.
•
Dispensation of “clinical trial subject card” (participation in the study).
•
Verification inclusion/exclusion criteria.
•
Demography data: date of birth, gender and racial group.
•
Childbearing potential.
•
Body weight and height.
•
Dispensation of “daily record card”.
REDACTED
nal
nal sts
ation, 
ation, 
uld be
uld be
F.
F.
COPY 
ay
ed wit
ed wi
This document 
•
S
•
cannot 
1
E
be 
15.
15.
used 
ures p
res p
to
e-m
support 
stutu
s durin
dur
monthl
month
mon
mo
any
ed on
ed o
udies
udi
marketing 
ic explo
c exp
ized on
zed o
nc
authorization 
udy
dy viv
inclu
nclu
e coll
e coll
application
pecifi
pecif
om the
m th
h resp
h resp
and 
edu
du
ncomi
comi
fifi
any
epre
epre
ures,
ure
extensions
udy i
dy 
udy
udy a
y
es
or 
inin
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 49 of 77
•
Recording of Adverse Events.
•
Medical procedures.
•
Concomitant medications (AED and nonAED) documentation.
•
Concomitant medications (AMD and nonAMD) documentation (for ULD subjects).
•
Dispensation of study medication: subject will receive study medication at Entry Visit 
once all inclusion/exclusion criteria have been met.
•
Appointment for the next visit according to schedule described in Section 4.2.
The following data will be transferred electronically from the first visit of the previous study
and should not be recorded in the CRF:
•
General medical and procedures history.
•
Epilepsy history.
•
Disease history (for ULD subjects).
•
AED history.
•
AMD history (for ULD subjects).
The following data will be transferred electronically from the last Evaluation Visit of the 
previous study and should not be recorded in the CRF:
•
Vital signs including blood pressure, pulse rate.
•
Physical and neurological examinations.
•
ECG.
•
Recording of epileptic seizures.
•
Laboratory assessment includes safety: blood chemistry, hematology and urinalysis. 
Urine pregnancy test (β-hCG levels) for women with childbearing potential.
10.3.2
Full Evaluation Visit
•
Vital signs including blood pressure, pulse rate.
•
Body weight.
•
Physical and neurological examinations.
•
Retrieval of previous and dispensation of new daily record card.
•
Recording of epileptic seizures.
•
Laboratory assessment includes safety: blood chemistry, hematology and urinalysis. 
Urine pregnancy test (β-hCG levels) for women with childbearing potential.
•
Recording of Adverse Events.
•
Assessment of suicidality (C-SSRS).
•
Medical procedures.
•
Concomitant medications (AED and nonAED) documentation.
•
Concomitant medications (AMD and nonAMD) documentation (for ULD subjects only).
•
Drug return/accountability include study medication intake and compliance check.
•
Dispensation of study medication.
REDACTED 
he C
he 
ulse ra
ulse ra
ons.
ons.
COPY 
ally
ally fro
fr
y
CR
CR
This document
R
•
cannot
rd
borato
orato
Urine
Urine
Re
R
be
l o
ding 
ding 
used
d neu
neu
of pr
of p
to support 
isisi
ing blo
ng blo
any 
t
marketing 
safet
afety
levels)
evels
authorization
om 
m 
RF:
F:
atete.
application 
the
the
and any extensions 
previo
revio
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 50 of 77
•
Appointment for the next visit according to schedule described in Section 4.2.
The following assessments will be performed during the first 2 years which includes the YEV
in year 3
•
QOLIE-31-P assessment: the questionnaire should be filled in at the beginning of the 
Visit (not for ULD subjects).
•
HADS: the questionnaire should be filled in at the beginning of the Visit, after the 
QOLIE-31-P (not for ULD subjects).
•
Health care provider consultation not foreseen by protocol.
•
Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home.
•
Hospital stay.
•
EQ-5D questionnaire for subjects coming from N01252 and N01254.
10.3.3
Minimal Evaluation Visit
•
Vital signs including blood pressure, pulse rate.
•
Retrieval of previous and dispensation of new daily record card.
•
Recording of epileptic seizures.
•
QOLIE-31-P assessment: the questionnaire should be filled in at the beginning of the 
Visit at the MEV in Month 3 (for ULD subjects and subjects coming from N01114).
•
Recording of Adverse Events.
•
Assessment of suicidality (C-SSRS).
•
Medical procedures.
•
Health care provider consultation not foreseen by protocol during the first 2 years.
•
Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home during the first 2 years.
•
Hospital stay during the first 2 years.
•
Concomitant medications (AED and nonAED) documentation.
•
Concomitant medications (AMD and nonAMD) documentation (for ULD subjects only).
•
Drug return/accountability include study medication intake and compliance check.
•
Dispensation of study medication.
•
Appointment for the next visit according to schedule described in Section 4.2.
10.3.4
Yearly Evaluation Visit (replaces the FEV of each year)
•
Vital signs including blood pressure, pulse rate.
•
Body weight.
•
Height for subject still in growing period.
•
Physical and neurological examination.
•
ECG.
REDACTED
new 
new
onnair
nnai
ULD
ULD
COPY 
te.
te.
w da
w d
This document
10.3.
0.3.
cannot
en
ppoint
point
4
be
ur
satio
satio
used
nt me
me
rn/ac
n/ac
to
edic
edi
d
support 
and
an
t) at ho
) at h
ng the 
ng the
cat
any
tatio
tati
nd sc
d s
marketing 
RS).
RS).
on
o
authorization 
aily
aily rere
y
re shou
e sho
subje
ubje
application 
01
and 
1254
254
any extensions 
he
lp fro
p fro
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 51 of 77
•
Retrieval of previous and dispensation of new daily record card.
•
Recording of epileptic seizures.
•
Laboratory assessment includes safety: blood chemistry, hematology and urinalysis. 
Urine pregnancy test (β-hCG levels) for women with childbearing potential.
•
Recording of Adverse Events.
•
Assessment of suicidality (C-SSRS).
•
Medical procedures.
•
Concomitant medications (AED and nonAED) documentation.
•
Concomitant medications (AMD and nonAMD) documentation (for ULD subjects only).
•
Drug return/accountability include study medication intake and compliance check.
•
Dispensation of study medication.
•
Appointment for the next visit according to schedule described in Section 4.2.
The following assessments will be performed during the first 2 years which includes the YEV
in year 3
•
QOLIE-31-P assessment. The questionnaire should be filled in at the beginning of the 
Visit.
•
HADS: the scale should be filled in at the beginning of the Visit (except for ULD 
subjects).
•
Health care provider consultation not foreseen by protocol.
•
Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home.
•
Hospital stay.
•
EQ-5D questionnaire for subjects coming from N01252 and N01254.
•
Socio-professional data for subjects coming from N01252 and N01254.
10.3.5
Early Discontinuation Visit
•
Vital signs including blood pressure, pulse rate.
•
Body weight.
•
Physical and neurological examination.
•
ECG.
•
Retrieval of previous and dispensation of new daily record card.
•
Recording of epileptic seizures.
•
Laboratory assessment includes safety: blood chemistry, hematology and urinalysis. 
Urine pregnancy test (β-hCG levels) for women with childbearing potential.
•
Recording of Adverse Events.
•
Assessment of suicidality (C-SSRS).
•
Medical procedures.
•
Concomitant medications (AED and nonAED) documentation.
•
Concomitant medications (AMD and nonAMD) documentation (for ULD subjects only).
REDACTED
be
begig
ot fore
ot fore
olday
olday
COPY
ould b
uld b
ini
This document
•
L
cannot 
triev
riev
Reco
Reco
L
be 
an
sed 
ht.t.
nd n
nd n
to
udin
udin
support 
nuation
uatio
ng
any
subj
sub
marketing 
ys lo
s l
ects co
ects c
j
authorization 
nning 
ning 
eseen 
een 
lost 
ost 
application 
ye
years
ar
e filled
e fille
and
n Sect
Sec
any 
anc
n
i
extensions 
subje
ubje
nce c
ce
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 52 of 77
•
Drug return/accountability include study medication intake and compliance check.
•
Dispensation of study medication with down-titration dosing schedule.
•
Appointment for the next visit according to schedule described in Section 4.2.
•
Down-titration.
The following assessments will be performed only if the EDV occurs within the first 2 years.
•
QOLIE-31-P assessment: the questionnaire should be filled in at the beginning of the 
Visit.
•
HADS: the scale should be filled in at the beginning of the Visit (except for 
ULD subjects). 
•
Health care provider consultation not foreseen by protocol.
•
Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home.
•
Hospital stay.
•
EQ-5D questionnaire for subjects coming from N01252 and N01254. 
•
Socio-professional data for subjects coming from N01252 and N01254.
10.3.6
Down-Titration Phone Call
•
Recording of Adverse Events.
•
Remind appointment for the next visit according to schedule described in Section 4.2.
10.3.7
Final Visit (FV following a Study Drug-free Period after an EDV or FV initiated 
upon Sponsor request at the End of the program)
•
Vital signs including blood pressure, pulse rate.
•
Body weight.
•
Height for subject still in growing period.
•
Physical examination.
•
Neurological examination.
•
ECG (except after an EDV when EDV ECG results were normal).
•
Retrieval of previous daily record card.
•
Recording of epileptic seizures.
•
Laboratory assessment has to be scheduled (except after an EDV when EDV laboratory 
results were normal). Laboratory assessment includes safety: blood chemistry, 
hematology and urinalysis. Urine pregnancy test (β-hCG levels) for women with 
childbearing potential.
•
Recording of Adverse Events.
•
Assessment of suicidality (C-SSRS).
•
Medical procedures.
•
Health care provider consultation not foreseen by protocol during the first 2 years.
REDACTED 
visit ac
isit ac
S
COPY 
N0
N
This document
h
cannot
ordin
rdin
Labora
abora
resu
resu
be
al o
l o
ing
ing
used 
ex
ex
ept aft
pt aft
of p
of p
to
a
xam
xam
support 
till in g
ill in 
tion.
ion.
any
d pres
d pre
marketing 
Study D
tudy D
he End
he En
authorization 
ccordi
cordi
application 
nd d N01
N0
252
52 and
an
and 
ved
ed
any 
d hel
d hel
extensions 
the
he
or 
e
variations 
ars.s.
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 53 of 77
•
Recording of workdays and schooldays lost and days subject received help from a 
caregiver (paid or not) at home during the first 2 years.
•
Hospital stay during the first 2 years.
•
Concomitant medications (AED and nonAED) documentation.
•
Concomitant medications (AMD and nonAMD) documentation (for ULD subjects only).
•
Drug return/accountability including study medication intake and compliance check.
•
End of study status
•
Return of “Clinical Trial Patient Card”.
10.3.8
Additional Visit
At any time, the subject may have an additional study visit/phone call if the Investigator or 
the subject deems it necessary. All information, including reason for visit/phone call, any 
information on AEs, medical procedures, concomitant AEDs and nonAEDs, concomitant 
AMDs and nonAMDs (for ULD subjects only), should be collected in the source documents 
and recorded in the appropriate section of the CRF. Study medication can be dispensed if 
required.
If an Additional Visit is conducted for safety or efficacy reasons, a C-SSRS assessment will 
be performed during this visit. If an Additional Visit is conducted for reasons other than 
safety or efficacy issues (eg, replacement of lost medication, repeated collection of a 
laboratory specimen due to collection or analysis issues), a C-SSRS will not be required at 
this visit.
10.4
Handling of Biological Samples
The safety samples (hematology, biochemistry, urinalysis, pregnancy test) will be routinely 
assayed and the results sent by fax to the Investigators as specified in Section 10.2.16.
Urine samples must be collected under hygienic conditions and transferred by study site staff 
in vacutainer tubes.
10.5
Other Supplies
At Entry Visit (or First Visit for subjects coming from N01315), each subject will receive a 
study card that will mention his/her participation in the study, indicating the name and phone 
number of the Investigator to be contacted in case of emergency and the name of the study
product concerned. Participation in the study will be mentioned in the subject’s clinical 
records.
11.
ASSESSMENT OF EFFICACY
REDACTED 
y or ef
y or e
tional
ona
ent of
ent of
on or 
n or 
COPY
Study
Stud
This document
study
udy
num
num
cannot 
Ot
O
Entry
Entry
y
be 
ther
ther
used 
usts
ubes.
bes.
to
t be
t be
support
tolog
olog
sent by
ent b
any 
S
gy
marketing 
anal
analy
Samp
Sam
authorization 
fficac
fficac
Visit
Visi
f lost m
lost m
application 
or 
nd nonA
d non
llected
llecte
medic
medi
and
l if th
if th
r visi
visi
any 
he
h
extensions or variations 
y).).
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 54 of 77
11.1
Specifications of Efficacy Variables 
The procedures for obtaining the data of the efficacy variables are found in Section 10.2.
The complete list of variables to be analyzed is found in Section 13.1.2.1.
11.2
Methods and Timing for Assessing, Recording, and Analyzing the Efficacy 
Variables
The methods and timing for assessing and recording the efficacy variables are found in 
Section 4.2 and in Section 10.3.
The analysis methods are found in Section 13.1.3.
12.
ASSESSMENT OF SAFETY
12.1
Specifications of Safety Variables
Safety assessments will be made using adverse events, laboratory tests (including blood and 
urine), electrocardiogram (ECG), physical and neurological examinations, vital signs, and 
body weight.
The procedures for obtaining the data of the safety variables are found in Section 10.2.
The complete list of variables to be analyzed is found in Section 13.1.2.1.
12.2
Methods and Timing for Assessing, Recording, and Analyzing the Safety 
Variables
The methods and timing for assessing and recording the safety variables are found in 
Section 4.2 and in Section 10.3. The analysis methods are found in Section 13.1.3.
12.3
Adverse Events
12.3.1
Definition of Adverse Event (AE)
An adverse event is any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.
In order to ensure complete safety data collection, all AEs or undesirable experiences 
occurring during the study (i.e. after signature of the Informed Consent), including any 
REDACTED
d neu
d ne
a of th
a of th
ana
ana
COPY 
vents
vents
This document 
ubjbj
relat
relat
un
un
cannot 
dvers
dvers
ject 
ect
be
efini
efin
used
e Ev
e Ev
i
to 
ve
support 
for ass
for a
tion
ion 1
any marketing 
he s
e 
alyz
yzed 
ed 
r Asse
r Ass
authorization
s, lab
s, lab
urolog
rolog
safaf
application and any extensions 
ound 
und 
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 55 of 77
pre- and post-treatment periods required by the protocol, must be reported even if no 
investigational product was taken but specific study procedures were conducted.  These 
include all AEs not present prior to the initial visit and all AEs which recurred or worsened 
after the initial visit.  In the event subjects terminate study participation after signing 
informed consent but prior to any study procedures being conducted, adverse events will not 
be recorded on the CRFs.
Signs or symptoms of epilepsy for which the investigational product is being studied should 
be recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history.
12.3.2
Procedures for Reporting and Recording Adverse Events
12.3.2.1 Recording/Collection of AEs
The study participant will be given the opportunity to report Adverse Events spontaneously.  
A general prompt will also be given to detect adverse events, e.g.,
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self-assessment procedures (e.g. diary cards) 
employed in the study.
12.3.2.2 Description of AEs
The following guidelines and definitions should be used by the Investigator for the 
description of an AE when reporting information:
Nature of the AE:
Preferably an overall diagnosis or syndrome, rather 
than individual symptoms or signs.  The Investigator 
must report adverse events using standard medical 
terminology.
Any discrepancies between the subject’s own words 
on his/her own records (e.g. diary card) and the 
corresponding medical terminology should be 
clarified in the source documentation.
Date of onset:
Date of AE started.
REDACTED 
our he
our he
eview
eview
COPY 
to rep
to re
verse 
verse
This document 
Da
D
cannot be used to support 
nd d
d 
en repo
n rep
any 
defin
def
marketing 
w an
an
authorization
p
even
even
ealth (
alth (
any y
application 
ort Ad
ort A
t
and any extensions 
ied sho
ed sh
or int
or in
e know
know
or variations 
ot 
ot 
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 56 of 77
Pattern:
Intermittent
The AE recurs with the same intensity at various 
intervals throughout the entire time period specified.  
There were intervals within the specified time period 
when the AE was not present.
Continuous:
The AE is present at the same intensity for the entire 
time period specified.  There was no time at which the 
event abated or was not present during the time period 
specified.
Intensity:
Mild
The subject is aware of the sign or symptom 
(syndrome), but it does not interfere with his/her usual 
activities and/or it is of no clinical consequence.
Moderate
The AE interferes with the usual activities of the 
subject or it is of some clinical consequence.
Severe
The subject is unable to work normally or to carry out 
his/her usual activities, or the AE is of definite clinical 
consequence.
Action taken with investigational product:
Not applicable
For AEs occurring during the study drug-free period.
No charge
Investigational product dosing remained the same in 
spite of AE being present. 
Dosage changed
Investigational product dose was increased or 
decreased because of this AE.
Temporarily discontinued
Investigational product was temporarily discontinued 
because of this AE, either because the subject chose to 
discontinue the study drug or the physician felt it was 
in the subject’s best interest to temporarily discontinue 
the investigational product.
Permanently discontinued
Investigational product was permanently discontinued 
because of this AE, either because the subject chose to 
discontinue the study drug or the physician felt it was 
in the subject’s best interest to discontinue the 
investigational product.
Other actions taken:
None
No other action was taken for this AE.
Concomitant medication
Drug treatment: the subject took a concomitant 
medication (either prescription or non-prescription) 
specifically for this AE 
OR existing concomitant medication dosage was 
modified as a result of this AE.
REDACTED 
AEs o
AEs o
nvesti
nvesti
spit
spit
I
COPY 
una
n
l activ
l activ
nce.
ce.
This document cannot 
er act
r act
N
be used 
nently
nently
to support 
inu
nu
any 
ued
ued
marketing 
te o
e o
Investi
nvesti
decr
de
In
authorization 
occur
ccur
igatio
gatio
of A
of A
application 
usua
usu
clinica
clinic
e to wo
to w
ities, o
ties, 
and 
rfer
fer
nical 
nical 
any 
ym
ymp
re w
re w
extensions
hich
hich
time p
me p
p
or 
ire
ire
h t
h t
variations 
e
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 57 of 77
Hospitalization or 
prolongation of 
hospitalization
The subject was hospitalized for this AE or subject’s 
stay in hospital was prolonged because of this AE.
Therapeutic or diagnostic 
procedure
Subject used other therapeutic measures (e.g. ice, 
heating pad, brace, cast, etc.) or subject underwent a 
diagnostic procedure (e.g., additional lab test, x-ray, 
etc.) for this AE.
Date of outcome:
Date (and time) the AE abated.  If the AE consists of 
several signs and symptoms (syndrome), the sign or 
symptom with the longest duration determines the 
duration of the AE.
If the AE is marked “ongoing”, the outcome date 
should be blank.
Resolved
The AE is no longer present at any intensity -
completely abated.
Resolved with sequelae
The AE is resolved but residual effects are still 
present.
Worsened
The AE is still present but at a heightened intensity.  
The rule of repetition of AE reporting should be 
applied.
Fatal
This AE caused or directly contributed to subject’s 
death.
Ongoing
The AE is still present at the last contact with the 
subject.
Relationship to investigational product:
None
only applicable when no investigational product was 
taken or when the subject is taking single-blind 
placebo, or when the AE can be ascribed with 
reasonable certainty to another cause.
Unlikely
there are good reasons to think that there is no 
relationship, e.g. the AE is a known adverse drug 
reaction of a concomitant medication.
Possible
equally valid arguments can be considered for or 
against an implication of the investigational product, 
e.g. the AE:
•
follows a reasonable temporal sequence from the 
administration of the investigational product;
•
follows a known or expected response pattern to 
the investigational product;
•
but could readily have been produced by a number 
of other factors.
REDACTED
le of 
le of
lied.
lied.
This A
This A
deat
dea
T
COPY 
v
still 
still 
This document cannot be
sible
sible
used to support any marketing 
th.h
The AE
he AE
subj
sub
roduct
roduc
authorization
prese
res
repeti
epeti
AE cau
E cau
application
nt at 
nt at
ut resi
ut re
and 
the
he
any 
e out
e ou
extensions 
onsist
onsist
 the si
the s
termin
ermin
or 
ay, 
ay,
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 58 of 77
Probable
the relationship is likely, e.g. the AE:
•
follows a reasonable temporal sequence from 
administration of the investigational product;
•
follows a known or expected response pattern to 
the investigational product;
•
is confirmed by improvement on stopping or 
reducing the dosage of the investigational product;
•
could not be reasonably explained by the known 
characteristics of the subject’s clinical
Highly probable
there is a strong relationship, e.g.  the AE:
•
follows a reasonable temporal sequence from 
administration of the investigational product or in 
which the investigational product level has been 
established in body fluids or tissues;
•
follows a known or expected response pattern to 
the investigational product;
•
is confirmed by improvement on stopping or 
reducing the dosage of the investigational product, 
and reappearance of the AE on repeated exposure 
(rechallenge).
12.3.3
Follow-up of Adverse Events
If an AE is still ongoing at the time the last CRF is being collected, a follow-up report should 
be provided at a later date.
If no follow-up report is being provided, the Investigator must provide a justification.
The Sponsor may request that the Investigator perform or arrange for the conduct of 
supplementary measurements and/or evaluations (e.g. rechallenge procedure).
A serious AE or an AE leading to premature discontinuation from the study must always be 
followed up until it has resolved/has a stable level of sequelae or the Investigator no longer 
feels it is clinically significant.
12.3.4
Rule for Repetition of an AE
An increase in the intensity of an AE should lead to the repetition of the AE reporting with:
•
the outcome date of the first AE being the same as the start date of the repeated AE,
•
the Investigator’s original description of the AE being the same for the first and repeated 
AE, so that they code to the same dictionary term.
REDACTED 
cin
cin
nd rea
nd rea
(rech
(rec
nts
nts
COPY
gatio
gati
rmed 
med
ng t
ng
This document
12.3.
2.3.
A
cannot 
up
up
t is cli
is cli
4
be 
E o
p un
p un
used 
ea
ea
or a
or a
to
q
asur
sur
support
eing p
ing 
uest th
uest t
any 
pr
marketing 
e the la
the l
authorization 
by
the do
he do
appear
ppear
hallen
hallen
application
l p
uids o
uids o
r expec
r expe
nal pro
al pr
y imp
y im
and
igat
gat
prod
prod
any
seque
sequ
tion
tio
extensions
prod
prod
he kno
e kno
calal
AE:
AE:
or 
d
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 59 of 77
12.3.5
Pregnancy
Should a subject become pregnant during the course of the study, the Clinical Study 
Physician of the Sponsor should be informed immediately and the pregnancy will be 
documented in the AE section of the CRF. The subject should be excluded from the study as 
soon as pregnancy is known (immediate start of down-titration of investigational product 
intake). The Investigator must inform the subject about the potential risk of malformations 
that may be caused by any AED/AMD, and about the available alternatives, e.g., voluntary 
termination with medical indication.
The progression of the pregnancy and eventual birth must be followed up using the Sponsor’s 
standard Pregnancy & Delivery form in which the Investigator reports on the health of the 
mother and of the offspring.
In cases where the partner of a male subject enrolled becomes pregnant, UCB will ask the 
Investigator or designee to contact the subject and his partner to request consent via the 
Partner Pregnancy Consent form where legally acceptable. If the partner agrees to provide 
additional information, the Pregnancy Report and Outcome form will be forwarded to the 
subject’s partner for completion.
12.3.6
Overdose of Investigational Product
For this protocol, any daily intake of more than 200 mg/day will be considered as an 
overdose.
Symptoms associated with an overdose must be recorded as AEs.
Overdose without signs or symptoms will be documented in the “Trial Medication Intake” 
section of the CRF.
12.4
Serious Adverse Events
12.4.1
Definition of Serious Adverse Event (SAE)
A Serious Adverse Event is any untoward medical occurrence that at any dose:
•
Results in death.
•
Is life threatening.
•
Requires in-patient hospitalization or prolongation of existing hospitalization.
•
Results in persistent or significant disability/incapacity, or.
•
Is a congenital anomaly/birth defect.
REDACTED 
roduc
roduc
f mo
f mo
COPY 
pa
p
eptabl
eptab
d Out
d Ou
This document 
R
•
I
•
cannot 
erious 
rious
Res
Res
be
efini
efin
used
s Ad
Ad
i
to 
dv
d
support 
or sy
r sym
y
any
overd
over
marketing 
ore tha
ore tha
do
d
authorization
tcom
tcom
ct
application 
pregna
pregn
ner to re
er to 
e. If th
. If t
and 
on
on
any
usin
usin
n the 
th
extensions
ation
tion
volunt
olunt
ng
or 
ns
ns
variations 
as 
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 60 of 77
In this context, the term life threatening refers to an event in which the subject was at 
immediate risk of death at the time of the event; it does NOT refer to an event which might 
have caused death if it would have been more severe.
Any important medical event that may not be immediately life threatening or result in death 
or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above 
should also be reported as a SAE. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that 
do not result in hospitalization; or development of drug dependency or drug abuse.
Any event reported by the Investigator to the local authorities will follow the same reporting 
procedure as a “Serious Adverse Event”.
Cases involving cancer as an Adverse Event could be reported as serious using the criterion 
“medically important”.
Hospitalization for diagnostic or therapeutic procedures in the absence of any associated 
Adverse Event will not be considered as a SAE, except when otherwise required by 
Regulatory Authorities. This also applies to situation of scheduled elective surgery where no 
AE is present.
12.4.2
Procedures for Reporting Serious Adverse Events (SAE)
If a SAE is reported, the Sponsor or its representative must be informed within 24 hours of 
receipt of this information by the site (see emergency contact information on front page). The 
Investigator must promptly forward to the Sponsor or its representative a duly filled in 
“Investigator SAE report form” provided by the Sponsor, even if the data are incomplete or if 
it is obvious that more data will be needed in order to draw any conclusions.
The SAE report form and the completion guide will be provided by the monitor to the 
Investigator. The SAE report form has to be completed in English.
Additional information (e.g. autopsy or lab reports…) should be provided to the Sponsor in a 
timely fashion to ensure accurate follow-up of each case. All documents in local language 
must be accompanied by a translation in English, or the relevant information included in the 
same document must be summarized in the SAE report form.
The Sponsor or its representatives will communicate safety information (Suspected 
Unexpected Serious Adverse Reaction – SUSARs) to the appropriate Regulatory Authorities
and all active Investigators, in accordance with applicable regulatory requirements. The 
appropriate IEC/IRB will also be informed by the Investigator or by the Sponsor, as specified 
REDACTED
AE, ex
AE, e
o situ
o situ
Ser
Ser
COPY 
cedur
edur
This document 
must
us
same
same
cannot
onal i
nal i
ly fash
 fas
y
st be
t be
be used
form
form
The S
The S
to 
m
support 
for
fo
t form”
form
data w
data 
any
he si
he s
rwar
rwa
marketing 
rious A
ous A
or its r
or its
ite
it
authorization
res in
es in
xcept w
cept 
uation 
tion 
application 
d as ser
as se
th
and 
ow
any 
w the 
th
extensions
on a
on a
t in an
in an
vulsio
vulsi
abuse
buse
or
jec
jec
abo
ab
variations 
h 
ctct
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 61 of 77
by the applicable regulatory requirements in each concerned country. Investigators are to 
provide the Sponsor or its representatives with evidence of such IEC/IRB notification.
A copy of the Investigator SAE report form and the completion guide will be provided by the 
monitor.
If known by the Investigator, Serious Adverse Events up to 30 days after withdrawal of study
medication must be reported to the Sponsor, even if the Investigator is certain that they are in 
no way associated with the study drug. Adverse Events that the Investigator thinks may be 
associated with the study medication must be reported to the Sponsor regardless of the time 
between the event and the end of the study.
The reference document for the assessment of the expectedness of the SAEs is the 
Investigator’s Brochure.
12.4.3
Anticipated Serious Adverse Events
The following list of Anticipated SAEs has been identified, as these events are anticipated to 
occur in the population studied in this protocol at some frequency that is independent of drug 
exposure: convulsion. This original list will remain in effect for the duration of the protocol. 
This list does not change the Investigator’s obligation to report all SAEs (including 
Anticipated SAEs) as detailed in Section 12.4.2.
13.
STATISTICS
A general description of statistical methods is presented below. Additional detail will be 
described in the Statistical Analysis Plan (SAP). Statistical analyses of data for subjects 
transferring from N01315 will be handled as described in the SAP.
13.1
Statistical and Analytical Plans
13.1.1
Study Population(s)
•
Subpopulations
There are 3 mutually exclusive subpopulations. They are defined based upon enrollment.
1. Partial onset seizure: Subjects enrolled from prior studies N01114, N01252, and subjects 
from N01254 with a diagnosis of POS at N01254 study entry
2. Primary generalized seizure: Subjects enrolled from prior study N01254 with a diagnosis 
of PGS at N01254 study entry
ol at 
ol at 
ll rem
ll rem
gator’s
gator’
ctio
ctio
COPY 
ident
iden
This document 
Ther
The
cannot 
Sub
ubpo
po
be 
tudy
udy
used
ical a
cal 
P
to 
an
support 
tist
is
al Ana
l An
315 w
315 w
any 
tical
tica
marketing 
s ob
o
on 12.4
12.4
authorization
tified
tified
some f
ome 
main in
ain in
obli
bli
application and 
he SA
e SA
any extensions
of f s
they
they
nks m
nks m
less o
ess o
or 
stu
stu
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 62 of 77
3. Unverricht-Lundborg disease: Subjects enrolled from prior studies N01187 and N01236
The Efficacy Population will consist of all subjects who took at least 1 dose of study 
medication and have at least 1 seizure diary during the Evaluation Period.
The Safety Population will consist of all subjects who took at least 1 dose of study 
medication.
13.1.2
Study variables
13.1.2.1 Safety Variables
•
Primary safety variables
o
Occurrence of a TEAE
o
Withdrawal due to AE
o
Occurrence of an SAE
•
Other safety variables
o
Laboratory tests (blood chemistry, hematology, urinalysis)
o
Vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) and body 
weight
o
ECG
o
Physical and neurological examinations
o
Change in HADS scores from the Baseline of the previous study to each assessment 
for the first 2 years and to the last Evaluation Period assessment during the first 
2 years
13.1.2.2 Efficacy Variables
•
Secondary efficacy variables
For subjects with focal-onset epilepsy:
o
Partial onset seizure (type I) frequency per 28 days during the Evaluation Period.
o
Percent reduction in POS (type I) frequency per 28 days from Baseline of the previous 
study to the Evaluation Period.
o
Responder rate for POS (type I) frequency over the Evaluation Period. A responder is 
defined as a subject with a ≥50% reduction in seizure frequency from the Baseline 
Period of the previous study.
REDACTED 
ry
ry, hem
, he
ressur
ressur
COPY 
This document
o
cannot 
For sub
or su
be 
dary
dary
used
y Va
Va
to 
ari
ari
support 
or
or
rs and 
s and
any
al e
al e
es fr
es fr
marketing 
re, , did
exam
exa
authorization 
matol
matol
dia
dia
application and any extensions or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 63 of 77
No secondary efficacy variables are defined for subjects with generalized epilepsy or 
subjects with ULD.
•
Other efficacy variables
For subjects with focal-onset epilepsy:
o
Percentage of subjects continuously seizure free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period.
For subjects with generalized epilepsy:
o
Generalized (type II) seizure days per 28 days during the Evaluation Period.
o
Percent reduction in generalized (type II) seizure days per 28 days from Baseline of 
the previous study to the Evaluation Period.
o
Responder rate for generalized (type II) seizure days over the Evaluation Period. 
A responder is defined as a subject with a ≥50% reduction in seizure days from the 
Baseline Period of the previous study.
o
Percentage of subjects continuously seizure free for all seizure types (I+II+III) for at 
least 6 months and at least 12 months during the Evaluation Period.
The following will be evaluated separately for subjects with focal-onset epilepsy and 
subjects with generalized epilepsy:
o
Change in QOLIE-31-P scores from Baseline of the previous study to each 
assessment for the first 2 years and to the last Evaluation Period assessment during the 
first 2 years.
o
EQ-5D Questionnaire response for each assessment for the first 2 years for the 
Evaluation Period and for the last assessment during the first 2 years of the Evaluation 
Period.
13.1.2.3 Pharmacoeconomic Variables
The following will be evaluated separately for subjects with focal-onset epilepsy and subjects 
with generalized epilepsy:
•
Direct costs (healthcare provider consultations not foreseen by the protocol, concurrent 
medical procedures, concomitant medications, hospitalizations, and emergency room 
visits) during the first 2 years of the Evaluation Period
•
Indirect costs (work days or school days lost by the subject and days subject received help 
from a caregiver) during the first 2 years of the Evaluation Period
REDACTED 
seizu
seizu
nths d
nths d
sep
sep
COPY
re d
re 
≥50% 
≥50% 
This document 
ithth
•
cannot 
follow
follow
h ge
h ge
be
harm
harm
used to 
e
support 
nnaire 
nnaire
riod 
iod
any 
2 ye
ye
marketing 
paratel
aratel
sy:
cores 
ores
authorization 
 re
re free
fre
during
during
application
r 28 d
r 28 
ys over
s ove
educt
educt
and
aluatio
luati
d
any extensions 
+III) fo
III) f
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 64 of 77
•
Socio-professional data for each assessment for the first 2 years and for the last 
assessment during the first 2 years of the Evaluation Period
No pharmacoeconomic variables are defined for subjects with ULD.
13.1.3
Statistical Evaluation
•
General considerations:
Summary statistics will consist of frequency tables for categorical variables and descriptive 
statistics (number of available observations, mean, median, standard deviation, minimum, 
maximum, 25th and 75th percentiles) for continuous variables.
The periods considered are:
•
Evaluation Period (V1 until the last Evaluation Visit).
•
Down-Titration Period.
•
Post-treatment Period.
Efficacy summaries will be created separately for the POS and PGS subpopulations within 
the efficacy population, and safety summaries will be created for the safety population and 
separately for the POS, PGS, and ULD subpopulations within the safety population. 
•
Baseline:
Baseline, whether efficacy or safety, will always refer to the original prior study pretreatment 
Baseline value. Baselines created and validated, as part of the prior study SAPs, will be 
copied and used by this study for all change from Baseline analyses.
•
Study entry/disposition:
Subjects will be sufficiently described to enable a clear understanding of the populations and 
subpopulations and relevant demographics, disease, medical history, current treatment(s), as 
well as disposition. Historical and Baseline data will be copied from the prior study as 
required by the SAP.
•
Seizure efficacy variables:
Analyses will be based upon the Efficacy Population. Summaries will be over the entire 
Evaluation Period and by 3-month periods over the Evaluation Period. The ULD
subpopulation seizure diary data will not be summarized.
REDACTED
ly for 
for
y
aries w
ries w
sub
subpo
po
COPY 
This document
S
A
cannot
sp
ed b
d by y
Se
S
be
on
posit
posi
sed
e suff
suff
ns an
s an
to support
udy
dy f
y
sition
ition
any
ted an
ted a
for
for
marketing 
ty, w
y, w
authorization 
the PO
he PO
will be
will be
opula
opula
application and any 
on
o
extensions 
nd des
d de
on, m
n, m
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 65 of 77
•
QOLIE-31-P and EQ-5D efficacy variables:
Analyses will be based upon the Efficacy Population and summarized by data collection 
scheduled visits and for the last Evaluation Period assessment during the first 2 years. Data 
collected after year 2 are not planned to be summarized. The ULD subpopulation 
QOLIE-31-P and EQ-5D data will not be summarized.
•
Pharmacoeconomic variables:
Analyses will be based upon the Efficacy Population and summarized by 3-month periods. 
Data collected after year 2 are not planned to be summarized. The ULD subpopulation 
pharmacoeconomic data will not be summarized.
•
Safety variables:
Analyses will be based upon the Safety Population. Summary tables will be presented over 
the Evaluation Period by time windows, by periods, and by categories of total duration of 
exposure.
Treatment-emergent adverse events will be summarized by categories of total duration of 
exposure, period, and Medical Dictionary for Regulatory Activities (MedDRA®) Primary 
System Organ Class and Preferred Term in incidence tables. Separate tables will be provided, 
by categories of total duration of exposure, for AEs leading to withdrawal from the study and 
SAEs. 
Laboratory values, vital signs, and weight will be summarized by period and visit. Possibly 
clinically significant treatment-emergent abnormalities for laboratory values, vital signs, and 
weight will be listed and summarized by period and visit. Electrocardiogram abnormalities, 
as well as physical and neurological abnormalities, will also be listed by period and visit.
Hospital anxiety and depression scales will be analyzed for the POS/PGS subpopulation only.
13.2
Determination of the Sample Size
No sample size calculation has been made. Sample size will depend upon recruitment into 
and completion of preceding studies; approximately 500-1000 subjects are expected.
13.3
Statistical and Analytical Issues
13.3.1
Handling of Dropouts or Missing Data
Safety and efficacy variables will be analyzed as they are available. Days with missing 
information will be ignored in the calculation of the seizure frequency and seizure days. 
REDACTED 
be sum
e sum
ary
ary for
for
y
Term i
Term i
os
o
COPY
um
um
s, and
s, and
This document
nd c
nd c
1
cannot 
sampl
amp
com
com
be
eter
eter
used
y and
and
y
to 
d
support
ment
ent
d summ
summ
d neur
d neur
any
and w
and 
t-em
e
marketing
in in
n in
sure, fo
ure, fo
authorization 
d b
mmariz
mmariz
r Reg
r Reg
nci
nc
application 
ary
ary tab
ta
y
by cat
ca
y
and any
ubpo
po
extensions 
month
month
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 66 of 77
Since subjects will drop out at different times from the study, results will be presented by 
categories of duration of exposure.
13.3.2
Interim Analysis and Data Monitoring
Due to the single-arm open-label nature of this study, no interim analysis as such will be 
performed. However, interim database snapshots may be performed to allow safety and 
efficacy analyses in support of submission activities or to allow optimization of the 
development program. In addition, an ongoing medical review (Safety Data Review) 
applying to the entire BRV program is organized.
13.3.3
Use of an Efficacy Subset of Subjects
The efficacy population will be a subset of the safety population. The efficacy population will 
be divided into two mutually exclusive groups, the POS and PGS subpopulations. 
Additionally, as needed, the POS and the PGS subjects may be subset into categories that 
group subjects and subject data according to similar BRV exposure times.
13.3.4
Examination of Subgroups
Subgroup analyses, if performed, will be specified in the SAP.
13.4
Criteria for Starting the Analysis
A pre-analysis data review will take place before starting any formal analysis. A pre-analysis 
data review will follow pertinent UCB Standard Operating Procedures.
13.5
Dictionaries
Adverse events and medical and surgical history will be coded according to the MedDRA 
dictionary. Coding of indications of concomitant medication has been stopped during the 
course of the study.
Medications will be coded according to the World Health Organization (WHO) Drug 
dictionary.
REDACTED 
ll be s
ll be s
COPY 
OS
ects
ects m
ilar B
lar B
This document 
icti
ct
cannot 
icatio
catio
tiona
ion
be
he st
he s
used 
and
nd
oding
ding
to 
m
support 
tine
ne
any
take
tak
ent U
ent
marketing 
spe
pe
Analys
naly
e p
authorization
BRV 
BRV 
ecif
cif
application 
on. T
on. The
h
d PGS 
PGS
may
ay be
be
y
and any extensions 
be
be
y and 
y and 
f the
f the
Revie
Revie
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 67 of 77
14.
ETHICS 
14.1
Approval
When finalized, the protocol must be signed by the Principal Investigator of the site, the 
Sponsor Clinical Study Physician, the Sponsor Clinical Program Director, the Sponsor 
Statistician, and the Sponsor Clinical Trial Manager (CTM). The final version must be 
submitted to and approved by:
•
a duly constituted IEC/IRB.
•
the relevant Authorities, according to local regulations.
If any alterations to the protocol are required by these bodies, they can be implemented only 
with the written agreement of the Investigator, the Clinical Study Physician, the Clinical 
Program Director, the Statistician, the CTM, and the Sponsor approval committee(s) and this 
before further submission to the requesting body.
A copy of the written IEC/IRB approval (with clear identification of the submitted 
document(s) and a list of members attending the meeting (listed by function and affiliation) 
should be forwarded by the Investigator to the CTM. In addition, for the sites under IND:
The usual composition of the IEC/IRB (or DHHS number) along with an IEC/IRB statement 
of compliance should also be forwarded to the CTM. 
The study is not allowed to start until the protocol and related documents (Subject 
Information Sheet/Informed Consent, advertisements if any, …) have received written 
approval/favorable opinion from the IEC and Regulatory Authorities, wherever required as 
well as until other GCP prerequisites are fulfilled.
If relevant new information becomes available, it should be communicated without delay to 
the subject, the Investigator, the IEC/IRB and the Regulatory authorities wherever required.
14.2
Subject Information and Consent
Adequate information will be provided to the subject and parent(s) or legal representative, if 
applicable, in both oral and written form and consent will be obtained in writing prior to the 
performance of any study specific procedure. The content and process of obtaining informed 
consent will be in accordance with all applicable regulatory requirements.
The Sponsor may provide a sample Informed Consent Form/subject information sheet.  The 
final form must be agreed by the IEC/IRB and must contain all ICH-GCP (4.8.10) elements 
in a language readily understood by the subject.
The original Informed Consent Form can be amended as appropriate. If the Informed Consent 
Form is amended during the study, the Investigator (or the Sponsor, if applicable) must 
REDACTED
he CT
he CT
r DHH
DHH
d to th
d to th
l t
l th
COPY 
ar iden
r iden
meet
meet
This document
ons
ons
T
cannot
able, i
ble, i
orman
rman
sen
sen
be
nfor
nfor
used
ct Inf
Inf
to 
f
support 
ion bec
on be
tigator,
igator
any
uisite
uisit
marketing 
he prot
he prot
nt, adve
t, adv
the IE
he IE
authorization
nt
ting (
ting (
M. 
M. In
In
HS num
HS num
he CT
e CT
application
prova
prova
tificat
ificat
i
and 
n be 
be
hysici
sici
l
any 
e im
e im
extensions 
be
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 68 of 77
follow all applicable regulatory requirements pertaining to the approval of the amended 
Informed Consent Form by the IRB/IEC and use of the amended form.
All studies conducted at centers in the United States must include the use of a Health 
Insurance Portability and Accountability Act Authorization form.
14.2.1
Information
The Investigator, or a person designated by the Investigator, should fully inform the subject 
or, if the subject is unable to provide informed consent, the parent(s) or legal representative, 
of all pertinent aspects of the study, including the fact that the protocol has been granted, the 
approval of the IEC/IRB and local regulatory authorities if required.
The subject will be informed of the nature of the study in an unambiguous, easily 
understandable language. The subject’s participation is voluntary. The subject can at any time 
withdraw consent without any influence on future care or treatment. The subject must be 
informed about the main procedures used to guarantee anonymity, especially during the 
analysis of personal data. The subject should be able to ask all the questions about the study
and to receive relevant answers. The subject will receive complete written information in the 
“Subject Information Sheet”.
14.2.2
Informed Consent
After having received extensive information about the nature, significance, implementation 
and risks of the study and having had enough time to consider, the subject must give his/her 
written consent by signing and dating the Informed Consent Form. For minors, the informed 
consent must be signed by the parent(s) or legal representative, in accordance with local 
regulations. The consent form or a specific assent form, where required, will be signed and 
dated by minors. For mentally retarded subjects, the Informed Consent Form must be signed 
by the legal representative.
If the signature of a witness is required, the witness should sign and personally date the 
consent form after the subject has signed. By signing the consent form, the witness attests 
that the information in the consent form and in any other written information was accurately 
explained to, and apparently understood by, the subject and that informed consent was freely 
given by the subject.
This form will also be dated and signed by the person who obtained the informed consent and 
then retained by the Investigator. Obtaining of consent will be confirmed in the subject’s 
medical chart and in the CRF.
Two copies of the Informed Consent Form will be signed. The subject will receive one and 
the other will be filed in the Investigator’s Site File.
REDACTED
will r
will 
COPY 
e o
ntee an
ntee a
able t
able 
This document 
ive
ve
T
cannot
info
info
ained 
ined 
en b
n b
be
rm a
rm a
used 
re of a
e of a
f
to
entat
nta
support 
the 
he
form o
form
mental
menta
ativ
ativ
any
datin
dat
par
pa
marketing 
ormatio
rmat
had en
had e
ing
i
authorization
to ask
to ask
eceive
ceiv
application
mbigu
mbig
ary
ary. Th
. T
reatmen
eatm
non
onym
ym
k
and any
s bee
s be
extensions 
m the s
m the 
repre
repre
en
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 69 of 77
The subject may withdraw his/her consent to his/her participation in the study at any time.
A subject is considered as enrolled in the study when he/she has signed the Informed Consent 
Form. A CRF must not be started, nor may any study specific procedure be performed for a 
given subject, without having obtained his/her written consent to participate in the study.
If any relevant new information that could influence the subject’s decision to stay in the study
becomes available, this will be transmitted without delay to the subject and the Investigator.
The Investigator will keep up to date a Subject Identification List, i.e. a log of all subjects 
having entered the study by signing an Informed Consent Form. This log is to be filed in the 
Investigator Site File.
14.3
Subject Confidentiality
Subject confidentiality will be maintained at all times.
Personnel from the Sponsor, from the CRO, from Regulatory Authorities, independent 
auditors and members of IEC/IRB are obliged to respect medical secrecy and to refrain from 
divulging the subject's identity or any other personal information they might fortuitously be 
aware of. Medical records will be handled by professional standards and existing local laws.
14.4
Informing the General Practitioner
If the subject agrees, the Investigator will inform the subject’s regular physician of his/her 
participation in the study.
15.
STUDY MANAGEMENT AND ADMINISTRATION
15.1
Monitoring
The monitoring of the study is the responsibility of the Sponsor. The monitor (the individual 
responsible for monitoring) will help the Investigator with the practical conduct of the study
and assist him/her in working according to the protocol, Good Clinical Practice (GCP), and 
the regulatory requirements.
The Investigator will allow the Sponsor or its representatives to periodically monitor at 
mutually convenient times during and after the study, all CRFs and the corresponding 
portions of source documents (e.g. office, hospital, and laboratory records for each study
participant). Therefore, the monitor will have direct access to these records. The monitoring 
visits provide the Sponsor or its representatives with the opportunity to evaluate the progress 
of the study, to verify the accuracy and completeness of CRFs, to ensure that all protocol 
REDACTED
d to r
d to 
er pers
r pers
led by
led by
act
act
COPY 
m Reg
m Reg
This document 
The 
The 
m
cannot
ist hi
st hi
egulat
egula
be
e for
e for
i
used 
ng of 
g of 
to 
ng
ng
support 
AGEM
GEM
any marketing 
titione
itione
ator wi
tor w
authorization
gulato
gulat
espect
spec
sonal 
onal 
y profe
profe
y
application and any
s to 
s to
extensions
the
he s
vestiga
estig
of all s
f all s
b
or 
stu
stu
variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 70 of 77
requirements, applicable local Authority regulations and Investigator's obligations are being 
fulfilled, and to resolve any inconsistencies in the study records.
15.2
Direct Access to Source Data/Documents
The Investigator(s)/Institution(s) will permit study-related monitoring, audits by or on behalf 
of the Sponsor, IEC/IRB review, and regulatory inspection(s), providing direct access to 
source data/documents.
Source documents (SD) are original records in which raw data are first recorded. These may 
be: hospital/clinic/general practitioner (GP) records, charts, diaries, x-rays, laboratory results, 
printouts, ECG tracing and reports and EEG tracing and reports, pharmacy records, care 
records, etc.
Original laboratory results, ECG tracing and reports, DRC, PRO booklets, etc. will be 
inserted in the CRF and are also to be considered as source data.
All source documents must be, accurate, clear, unambiguous, permanent and capable of being 
audited. They should be made using a permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correcting fluid or have temporary attachments 
(such as "post-it" notes).
Source documents that are computer generated and stored on magnetic support media must 
be printed. The Investigator will sign and date the print-out and the monitor will counter-sign 
these print outs after monitoring. The Investigator will authorize the monitor to compare the 
content of the print-out and the data stored in the computer to ensure all data are consistent.
The minimum requirements for source data in the medical records used in clinical studies are 
that they should contain: the identity of the subject and a study related identifiers (such as 
treatment number, CRF number or similar), a note of the subject's participation in the study
and identification of that study (protocol/study title or number), the date of obtaining signed 
informed consent, the subject's medical history, the treatments that the subject received, AEs 
and SAEs and the dates of the visits. The source documents should also provide evidence that 
inclusion/exclusion criteria were evaluated and met. Information recorded in the CRF must 
be consistent with entries in the source document. The monitor will verify 100% of the source 
documents against the CRFs.
15.3
Audit and Inspection
The Investigator will permit study-related audits by auditors mandated by the Sponsor, and 
inspections by domestic or foreign regulatory authorities, after reasonable notice. The main 
purposes of an audit or inspection are to confirm that the rights and well-being of the subjects 
enrolled have been protected, and that all data relevant for the evaluation of the 
REDACTED
nent f
nent 
d by
by co
co
y
r ge
r ge
COPY 
ou
namb
namb
f
This document 
ocu
cu
1
cannot
n/ex
n/ex
onsiste
nsist
ume
ume
be
and t
and 
used
n of
of
sent, 
ent, 
h
to
CRF
CR
f t
f t
support 
nts for
nts fo
ain: the
in: the
RF n
F
any
data
dat
marketing 
enerate
nerate
n and d
and
The In
The I
a s
authorization
biguo
biguo
form o
orm o
orrecti
rrect
application 
RO boo
O bo
data.
data.
and 
mac
ac
any
, lab
, lab
cy re
cy r
extensions 
s to 
to
ded. T
ded. T
bo
b
or 
ha
ha
variations 
alf
alf
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 71 of 77
investigational product have been processed and reported in compliance with the planned 
arrangements, GCP and applicable regulatory requirements. The Investigator will provide 
direct access to all study documents, source records and source data. If an inspection by 
Health Authorities is announced, the Investigator will immediately inform the Sponsor.
15.4
Case Report Forms (CRF)
Data reflecting participant experience with the drugs under investigation will be reported to 
the Sponsor. These data will be recorded on the CRF. The CRF is essentially a data entry 
form and may not routinely constitute the original (or source) medical record.
The CRF will be organized in Yearly Books and general section workbooks. CRFs will be 
signed and dated by the Principal Investigator as indicated.
The CRF will be adapted to reflect the changes in the study assessments. It will be used after 
the approval of the Ethics Committee and after the subjects have signed the new Informed 
Consent Form.
The Principal Investigator’s signature on the CRF attests to its accuracy and completeness. 
The CRFs will be completed in black ink, and must be legible.
Data reported in the CRF that are derived from source documents should be consistent with 
the source documents or the discrepancies should be explained in these source documents.
The Investigator must submit to the Sponsor or its representatives a completed CRF for each 
participant exposed to the investigational product.
All supportive documentation submitted to the Sponsor in addition to the CRF, such as 
laboratory or hospitalization records, must be clearly identified with the study number, study
participant number, and study participant initials; any personal information, including the 
study participant’s name, must be removed or rendered illegible to preserve individual 
confidentiality.
15.5
Adherence to Protocol
The Investigator/Institution should conduct the study in compliance with the protocol agreed 
to by the Sponsor and, if required, by the Regulatory Authority(ies) and for which an 
approval/favorable opinion by the IEC/IRB was given. The Investigator/Institution and the 
Sponsor should sign the protocol to confirm agreement.
The Investigator should not deviate from the protocol. However, the investigator should take 
any measure necessary in deviation from or not defined by the protocol in order to protect 
clinical study subjects from any immediate hazard to their health and safety. In this case, this 
CRF
CRF
and m
and m
rived f
ived 
anc
anc
COPY 
bjej
This document 
he 
he
to by
to by
ap
ap
cannot
Ad
Ad
e Inv
Inv
be 
h
used
t’s n
’s n
y.
to
, an
 an
nam
support 
tation s
ation
ization
zation
nd
nd s
any
stiga
stiga
marketing 
fro
ro
cies sho
es sh
he Spo
he Sp
atit
authorization 
attests
attest
must b
ust b
om 
om
application 
sessme
essm
 have s
have
and 
boo
oo
any 
oks
oks
extensions 
eporte
porte
data e
data e
d.
or variations thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 72 of 77
action should be taken immediately, without prior notification of the regulatory authority, 
IRB/IEC or sponsor. After implementation of such measure, the investigator must notify the 
CPM of the sponsor within 24 hours and follow any local regulatory requirements. 
Significant changes in or deviations from the protocol will ONLY be made as an amendment 
to the protocol and must be approved by the Sponsor and the IEC/IRB prior to being 
implemented. Unless the Sponsor has consented to any such deviations or changes in writing, 
they cannot be implemented and the Sponsor will not assume any resulting responsibility or 
liability for implementation of unapproved deviations or change.
Any significant protocol deviation will be documented and explained by the Investigator or 
the person designated by the Investigator and will be included in the final Study Report.
15.6
Termination of the Study
Upon completion of the study, the monitor will conduct the following activities in 
conjunction with the Investigator, as appropriate:
•
Return of all study data to the Sponsor or its representative.
•
Data clarification and/or resolution.
•
Accountability, reconciliation and arrangements for used and unused study drugs.
•
Review of site study records for completeness.
•
Discussion/reminder on archiving responsibilities.
In addition, the Sponsor reserves the right to temporarily suspend or prematurely discontinue 
this study either at a single site or at all sites at any time for reasons including, but not limited 
to, safety or ethical issues, severe non-compliance, recurrent non-compliance, with respect to 
quality or quantity.
If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators/Institutions, and the regulatory authority(s) of the termination or suspension and 
the reason(s) for the termination or suspension.  The IEC/IRB should also be informed 
promptly and provided with the reason(s) for the termination or suspension by the Sponsor or 
by the Investigator/institution, as specified by the applicable regulatory requirement(s).  In 
addition, arrangements will be made for all unused study drugs in accordance with the 
Sponsor procedures for the study.
15.7
Investigator Site File
The content of the Investigator file is structured in a manner that aids in the filing, retrieval, 
and/or auditing of study-related documents. All documents will be filed according to 
Standard File Categories that identify specific aspects of the study.
REDACTED
gemen
gemen
pletene
etene
respon
respon
i
COPY 
presen
presen
This document 
5.7
5.7
T
cannot
ar
or pro
r pro
be
tig
rrang
rran
sed
e
rovid
rovid
gato
gato
to
e ter
e te
support 
elyly term
ter
y
ons, an
ons, a
rm
any marketing 
ight to 
ght to 
t all sit
all si
non
non
authorization 
nts for 
ts for 
ess.
ess.
nsibili
nsibil
application 
llowin
lowin
tative
ative
and any
Stud
Stu
extensions
ility
lity
Inves
nves
dy
d
or
itin
itin
y o
y
variations 
ng
ng
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 73 of 77
15.8
Data Handling and Record Keeping
The Sponsor will be responsible for data processing.
CRF data will be entered in an electronic database using a clinical data management system 
(CDMS). Computerized data cleaning checks will be used in addition to manual review to 
check for discrepancies and to ensure consistency of the data. An electronic audit trail system 
will be used to track all data changes in the database subsequent to the reconciliation of the 
interactive double data entry. The SAS system will be used for the statistical analysis of the 
data. Regular back-ups of the electronic data will be carried out.
15.9
Clinical Study Report
A clinical study report, conforming to the relevant ICH guidelines, will be prepared by the 
Sponsor. The report will include a thorough description of the clinical and laboratory 
methods, a discussion of the results and a list of all measurements.
This report may be included in submissions to government Drug Regulatory Authorities 
world-wide, or used for whatever reason considered appropriate by the Sponsor. No use 
should be made of the report before approval by the Sponsor.
The coordinating Investigator (designated by the Sponsor) will sign the report and will have 
an opportunity to comment on the draft version. He/she must give his/her comments within 
seven (7) days of receiving the report. In addition, he/she will sign the report for approval 
within 7 days of receipt of the revised version or a satisfactory reply to these comments.
15.10
Subject Insurance
The Sponsor declares that it has taken out an insurance, for the total duration of the study, 
covering the subjects (and for US sites only: Investigators, employees or co-workers of 
Investigators assisting with the study), in respect of the risks involved in this study according 
to this protocol. In case of injury or disability deriving from participation in the study, the 
subject is requested to inform without delay the treating physician responsible for the study.
15.11
Archiving and Data Retention
The Investigator will maintain adequate records for the study including CRFs, medical 
records, laboratory reports, informed consent documents, drug disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
All records are to be retained by the Investigator until at least 2 years after the last approval 
of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents 
REDACTED
by
by tht
y
ed b
ed by
raft ve
aft ve
rt I
rt I
COPY 
eas
a
ernme
ernme
red a
red a
h
This document 
he 
he
reco
reco
rere
cannot
Ar
Ar
e Inv
Inv
be used
I
d
n c
n c
uested
uested
to
ing 
ing 
as
support 
at it ha
t it h
(and fo
and f
wi
w
any marketing 
ersi
rsi
In addi
n addi
ed vers
d ver
authorization
appro
ppro
he Spo
e Spo
y the S
the S
ion
on
application
es, wi
es, w
clinica
clinic
ements
ment
nt Dru
nt Dr
and 
ilil
any extensions
il sy
l sy
on of 
on of 
alys
ysisis
or 
toto
stst
variations 
m
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 74 of 77
should be retained for a longer period however if required by the applicable regulatory 
requirement(s) or by an agreement with the Sponsor (ICH-GCP Guideline-Section 4.9.5). The 
Investigator will contact the Sponsor for authorization prior to the destruction of any study
records or in the event of accidental loss or destruction of any study records.  The 
Investigator will also notify the Sponsor should he/she relocate or move the study related files 
to a location other than that specified in the Sponsor’s Trial Master File.
15.12
Allocation of Responsibilities
The Investigator is responsible for the implementation of the protocol but can delegate tasks 
to the research team. He/she remains responsible for coordinating and informing his/her staff 
about the protocol and the possible changes made to it.
The Investigator should maintain a list of appropriately qualified persons to whom he/she has 
delegated significant study-related duties ("authorized signatures" document with name, 
function, signature, initials, dates of participation in the study and type of delegated tasks). 
This list should be kept up to date.
15.13
Curriculum Vitae
The Investigators should supply their updated curriculum vitae (CV) (English translation),
dated and signed, together with a list of their collaborators responsible for the practical 
conduct of the study. These collaborators should also provide a recent English version of 
their CV, dated and signed.
In addition, for ULD sites under IND, a signed and dated FDA Form 1572 (Qualified 
Investigator Undertaking and Clinical Trial Site Information forms in Canada) and recent 
(updated every 2 years) CV (in English) are required from each Investigator showing a 
current affiliation with the research center.
15.14
Financial Disclosure
A financial disclosure statement must be obtained from each clinical site for every 
Investigator and co-Investigator participating in the study. This must be collected before 
subject enrollment. They must inform the Sponsor if information related to financial 
disclosure changes during the course of the study and/or after study completion/end of study.
REDACTED 
pdated
pdated
t of the
t of th
ato
ato
COPY 
he
This document 
iscl
sc
cannot
gator
ator
ect en
ct en
closu
losu
be
l disc
l dis
used
ial D
al D
to 
Di
Di
support 
nd C
d 
CV (in
V (i
h the re
the r
any
r IN
r IN
Clin
Cli
marketing 
heir 
eir
ors shou
rs sho
ND
ND
authorization 
d curr
curr
r co
co
application
perso
pers
res" do
es" d
dy
dy and
an
and any
ormin
rmi
extensions 
n dele
n dele
ini
or variations 
les
es 
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 75 of 77
16.
REFERENCES
1.
Engel J, Pedley TA. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-
Raven; 1998.
2.
Sander JW, Shorvon S. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry.
1996;61:433-43.
3.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures
in Rochester, Minnesota: 1935-1948. Epilepsia. 1993; 34:453-68.
4.
Loiseau J, Loiseau P, Guvot M, Duche B, Dartigues JF, Aublet B. Survey of seizures 
disorders in the French southwest. Incidence of Epileptic Syndromes. Epilepsia 
1990;31:391-6.
5.
Nasreddine W, Beydoun A, Atweh S, Abou-Khalil B. Emerging drugs for partial onset 
seizures. Expert Opin Emerg Drugs. 2010;15:415-31. 
6.
Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 
2001;42:1255-60.
7.
Engel J. Report of the ILAE classification core group. Epilepsia. 2006;47:1558-68.
8.
Lüders HO, Acharya J, Alexopoulos A, Baumgartner C, Bautista J, Burgess R, et al. 
Are epilepsy classifications based on epileptic syndromes and seizures types outdated? 
Epileptic Disord. 2006;8:81-5.
9.
Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. 
Revised terminology and concepts for organization of seizures and epilepsies: report of
the ILAE Commission on Classification and Terminology. 2005-2009. Epilepsia 2010; 
51:676-85.
10.
Commission on Classification and Terminology of the International League Against 
Epilepsy. Proposal for revised clinical and electroencephalographic classification of 
epileptic seizures. Epilepsia 1981;22:489-501.
11.
Commission on classification and terminology of the International League Against 
Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. 
Epilepsia 1989;30:389-99.
12.
A multicenter, double-blind, randomized, placebo-controlled, 3 parallel groups, 
dose-ranging trial evaluating the efficacy and safety of ucb 34714 used as adjunctive 
treatment at doses of 50 and 150 mg/day in b.i.d. administration (oral capsules of 25 
mg) for a maximum of 12 weeks in subjects from 16 to 65 years with refractory 
epilepsy suffering from partial onset seizures whether or not secondarily generalized. 
UCB study number N01114. UCB protocol reference code RPCE02K0301.
13.
A multicenter, double-blind, randomized, placebo-controlled, 4 parallel groups, 
dose-ranging trial evaluating the efficacy and safety of brivaracetam used as adjunctive 
treatment at doses of 5, 20 and 50 mg/day in b.i.d. administration (oral tablets of 2.5 or 
10 mg) for a maximum of 7 weeks in subjects from 16 to 65 years with refractory 
epilepsy suffering from partial onset seizures whether or not secondarily generalized. 
UCB study number N01193. UCB protocol reference code RPCE05C2201.
REDACTED 
Buchh
Buchh
s for o
s for o
ssifica
sifica
COPY 
gro
r
mgartn
mgart
ptic s
ptic s
This document 
3.
cannot
pilep
ilep
UCB
UCB
A
be
for a
for a
used
ing t
ng t
nt 
nt at d
at d
to
r, do
r, d
tri
support 
ific
fic
for rev
for r
30:389
0:389
doub
ou
any
sia 1
sia 
catio
cati
marketing 
atioio
and T
and T
ed clin
ed cli
19
1
authorization
yn
yndr
dr
halter 
alter 
organ
rgan
on a
n a
application
g. Ep
g. Ep
. Epile
Epil
er C, 
er C,
and 
dru
dr
i
any 
ugs 
ugs
extensions
seizu
eiz
y of se
of se
Epilep
pilep
or 
zur
zur
variations 
try.y.
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 76 of 77
14.
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: 
evaluation of the efficacy and safety of brivaracetam in subjects (≥ 16 to 70 years old) 
with Partial Onset Seizures. UCB study number N01252. UCB protocol reference code 
RPCE06G0704.
15.
An international, double-blind, parallel-group, placebo-controlled, randomized study: 
evaluation of the efficacy and safety of brivaracetam in subjects (≥ 16 to 70 years old) 
with Partial Onset Seizures UCB study number N01253. UCB protocol reference code 
RPCE06G0705.
16.
A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate 
the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in 
adolescent and adult patients (≥16 years) with genetically ascertained 
Unverricht-Lundborg disease. UCB study number N01187. UCB protocol reference 
code RPCE06C2321.
17.
A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate 
the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in 
adolescent and adult patients (≥16 years) with genetically ascertained 
Unverricht-Lundborg disease. UCB study number N01236. UCB protocol reference 
code RPCE06C2320.
18.
UCB Investigator’s brochure: brivaracetam. UCB reference code RXCE06E2216. 
2010.
19.
An international, randomized, double-blind, parallel-group, placebo-controlled, flexible 
dose study: evaluation of the safety and efficacy of brivaracetam in subjects (≥ 16 to 
70 years old) suffering from localization-related or generalized epilepsy. UCB study 
number N01254. UCB protocol reference code RPCE06G0706.
20.
EMEA. Note for guidance on clinical investigation of medicinal products in the 
treatment of epileptic disorders. CPMP/EWP/566/98 rev 1, 16-Nov-2000.
21.
EMEA. Note for guidance on clinical investigation of medicinal products in the 
paediatric population. CPMP/ICH/2711/99, 27-Jul-2000.
22.
CPMP/ICH/135/95 Note for guidance on good clinical practice (EMEA). Jul 2002.
23.
Cramer JA, Van Hammée G. Maintenance of improvement in health-related quality of 
life during long-term treatment with levetiracetam. Epilepsy Behav. 2003;4:118-23.
24.
Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. 
Development and cross-cultural translations of a 31-item quality of life in epilepsy 
inventory. Epilepsia. 1998;39:81-9.
25.
EuroQol Group. EQ-5D. A measure of health-related quality of life developed by the 
EuroQol group. User guide. 8th issue. April 2000.
REDACTED
etam.
etam
uble
uble-b
afet
afety a
y 
ocal
ocal
COPY 
en
mber N
mber 
U
This document cannot
nvent
vent
Euro
Euro
E
be
elopm
elopm
t
used
g lon
lon
JA,
JA, P
to
Van 
Van 
ng
support 
danc
an
on. CP
on. C
/95 No
/95 N
n Ha
H
any
orde
orde
ce o
ce
marketing 
and
and
lization
izatio
ol refer
l ref
on clin
n clin
ers
authorization 
UCB 
UCB
blind, 
lind, 
nd ef
d ef
application
ed, pa
ed, p
ve treat
e trea
cally
ally as
a
y
N0123
N012
and 
B pr
p
any 
d d 
rotoc
rot
extensions
ce c
e c
dy to e
dy to 
r 12 w
12 w
or
old)
old
cod
cod
variations 
d)
d)
thereof. 


A
Brivaracetam / N01125
CONFIDENTIAL
Protocol RPCE03D0801 Integrated Amendment 27
12 Mar 2015 / Page 77 of 77
17.
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


ELECTRONIC SIGNATURES
Signed by 
Meaning of Signature 
Server Approval Date 
(dd-mon-yyyy
(HH:mm))
13URWRFRO$PHQGPHQW,QWHJUDWHG
&OLQLFDO$SSURYDO
0DU*07
&OLQLFDO$SSURYDO
0DU*07
COPY 
DO
This document cannot be used to support any marketing authorization application and 
an
a
y
any 
erve
a y extensions or variations thereof. 

SAP_001.pdf: 
UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 1 of 50 
 
STATISTICAL ANALYSIS PLAN 
Study: N01125 
Product: Brivaracetam 
An open-label, multi-center, follow-up trial to evaluate the long-term safety and efficacy of 
brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 
200mg/day in subjects aged 16 years or older suffering from epilepsy 
 
SAP/Amendment Number 
Date 
Final SAP 
SAP Amendment 1 
27 January 2014 
11 February 2019 
Confidentiality Material 
Confidential 
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
 
 
REDACTED COPY 
nnot be used to support any marketing authorization application and any extensions or variations thereof. 
safety a
ny ex
safety a
dose up
d any
dose up
ng from
and 
ng from
Date
ng a
Date
2
e
2
se
ocume
not b
ocume
This document ca
roduce
cann
roduce


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 2 of 50 
 
 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS .............................................................................................. 6 
1 
INTRODUCTION ....................................................................................................... 8 
2 
PROTOCOL SUMMARY ........................................................................................... 8 
2.1 
Study objectives ................................................................................................. 8 
2.1.1 
Primary objective ..................................................................................... 8 
2.1.2 
Secondary objectives ............................................................................... 8 
2.1.3 
Exploratory objectives ............................................................................. 8 
2.2 
Study variables ................................................................................................... 8 
2.2.1 
Safety variables ........................................................................................ 8 
2.2.1.1 
Primary safety variables ................................................................. 8 
2.2.1.2 
Other safety variables..................................................................... 9 
2.2.2 
Efficacy variables .................................................................................... 9 
2.2.2.1 
Secondary efficacy variables ......................................................... 9 
2.2.2.2 
Other efficacy variables ................................................................. 9 
2.2.3 
Pharmacoeconomic variables ................................................................ 10 
2.3 
Study Design and Conduct............................................................................... 10 
2.4 
Determination of Sample Size ......................................................................... 14 
3 
DATA ANALYSIS CONSIDERATIONS ................................................................ 14 
3.1 
General presentation of summaries and analyses ............................................ 14 
3.2 
Analysis time points ......................................................................................... 14 
3.2.1 
First and last dose of BRV ..................................................................... 14 
3.2.2 
Relative day ........................................................................................... 14 
3.2.3 
Summaries at Study Entry ..................................................................... 15 
3.2.4 
Study periods ......................................................................................... 16 
3.2.5 
Monthly time intervals ........................................................................... 17 
3.2.6 
Last Value on BRV Treatment .............................................................. 17 
3.2.7 
Exposure duration and exposure duration cohorts ................................. 18 
3.2.8 
Study visit cohorts ................................................................................. 18 
3.3 
Definition of Baseline Values .......................................................................... 18 
3.4 
Protocol deviations........................................................................................... 18 
3.5 
Analysis Sets .................................................................................................... 19 
3.5.1 
Safety Analysis Set ................................................................................ 19 
3.5.2 
Efficacy Analysis Sets ........................................................................... 19 
3.6 
Treatment Assignment and Treatment Groups ................................................ 19 
REDACTED COPY 
......
OP
......
s
D
s ....
D C
....
......
TE
......
ize
DAC
ize .
AC
.
ERAT
RED
ERAT
su
R
su
support any marketing authorization application and any extensions or variations thereof. 
8
....
r v
....8
va
8
........
s 
........
..
s
.......
sio
.....
.......
xte
.......
...
y
........
y
.....
.......
d a
.......
........
a
.......
.......
tio
.......
.......
lic
.......
........
ap
........
.......
tio
.......
........
riz
........
.......
th
.......
TIONS
g au
TIONS
ummar
keting
ummar
.......
ar
.......
t dose 
y m
t dose 
day
rt an
day .
a
.
maries 
ppor
maries 
This document cannot be used to s
tudy 
o su
tudy pe
up
pe
Mon
ed to
Mon
L
e
L
2.7
t be
2.7
3.2.8
nnot
3.2.8
3.3
t can
3.3
3
t
3


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 3 of 50 
 
3.7 
Coding dictionaries .......................................................................................... 19 
3.8 
Definitions of study-specific derived variables ............................................... 20 
3.8.1 
Calculation of seizure frequency/days ................................................... 20 
3.8.1.1 
Initial seizure data processing ...................................................... 20 
3.8.1.2 
Calculation of adjusted seizure frequency ................................... 20 
3.8.1.3 
Calculation of adjusted seizure days ............................................ 20 
3.8.2 
QOLIE-31-P ........................................................................................... 21 
3.8.3 
HADS ..................................................................................................... 22 
3.9 
Subject site transfers ........................................................................................ 22 
4 
STATISTICAL/ANALYTICAL ISSUES ................................................................. 22 
4.1 
Adjustments for covariates .............................................................................. 22 
4.2 
Handling of dropouts or missing data .............................................................. 22 
4.3 
Interim analyses and data monitoring .............................................................. 23 
4.4 
Multicenter studies ........................................................................................... 23 
4.5 
Multiple comparisons/multiplicity ................................................................... 23 
4.6 
Use of an “Efficacy Subset” of subjects .......................................................... 23 
4.7 
Active-control studies intended to show equivalence ...................................... 23 
4.8 
Examination of subgroups ............................................................................... 23 
5 
STUDY POPULATION CHARACTERISTICS ....................................................... 24 
5.1 
Subject disposition ........................................................................................... 24 
5.2 
Protocol Deviations .......................................................................................... 25 
6 
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS .................. 26 
6.1 
Demographics .................................................................................................. 26 
6.2 
Medical and procedure history......................................................................... 27 
6.2.1 
Medical history diseases ........................................................................ 27 
6.2.2 
Procedure history and concomitant procedures ..................................... 27 
6.3 
History of epilepsy ........................................................................................... 27 
6.3.1 
Etiology of epilepsy ............................................................................... 27 
6.3.2 
Epileptic seizure profile ......................................................................... 27 
6.3.3 
Classification of epileptic syndrome ...................................................... 27 
6.3.4 
Focus localization .................................................................................. 27 
6.3.5 
History of epileptic seizures .................................................................. 28 
6.3.6 
Seizure types experienced during baseline of the previous study ......... 28 
6.4 
Medications ...................................................................................................... 28 
6.4.1 
Non-AEDs taken at study entry ............................................................. 29 
6.4.2 
Number of previous AEDs .................................................................... 29 
TED COPY
......
PY 
......
how e
COP
how e
......
ED
......
REDACT
TERI
CTE
TERI
......
EDA
......
...
R
...
rization application and any extensions or variations thereof. 
21
a
21
.....
or
.....22
r v
22
........
on
........
.......
en
.......
........
ex
........
.......
any
.......
...
nd
.......
nd
....
........
on 
........
.......
ca
.......
........
pp
........
equival
on ap
equival
.......
at
.......
t any marketing autho
ISTICS
horiz
ISTICS
.......
au
.......
........
ing
........
H
rk
HER B
rket
ER B
.......
m
.......
cedure
any 
cedure
ot be used to suppo
al histo
port a
al histo
cedure
supp
cedure
y of ep
to s
y of ep
Eti
ed 
Eti
This document cannot
.2
be
.2
6.3.3
ot b
6.3.3
6.3
nn
6.3


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 4 of 50 
 
6.4.3 
History of previous AED use ................................................................. 29 
6.4.4 
AEDs taken at study entry ..................................................................... 29 
7 
MEASUREMENTS OF TREATMENT COMPLIANCE ......................................... 29 
8 
EFFICACY ANALYSES .......................................................................................... 29 
8.1 
Statistical analyses of secondary efficacy variables ........................................ 29 
8.1.1 
Partial onset seizure frequency .............................................................. 30 
8.1.2 
Percent reduction in POS frequency ...................................................... 30 
8.1.3 
Responder outcome for POS frequency ................................................. 30 
8.2 
Analysis of other efficacy variables ................................................................. 30 
8.2.1 
Subjects with partial onset seizures ....................................................... 30 
8.2.1.1 
Specified Month seizure freedom ................................................ 31 
8.2.2 
Subjects with Primary Generalized Seizures ......................................... 31 
8.2.2.1 
All type seizure days .................................................................... 31 
8.2.2.2 
Percent reduction in all type seizure days .................................... 31 
8.2.2.3 
Responder outcome for all type seizure days............................... 31 
8.2.2.4 
Specified month seizure freedom ................................................. 31 
8.2.3 
QOLIE-31-P ........................................................................................... 32 
8.2.4 
EQ-5D .................................................................................................... 32 
8.2.5 
Direct cost parameters ........................................................................... 33 
8.2.6 
Indirect cost parameters ......................................................................... 33 
8.2.7 
The number of school or working days lost will not be summarized but 
will be provided in subject data listings. Socio-professional data ......... 33 
9 
PHARMACOKINETICS AND PHARMACODYNAMICS .................................... 33 
10 IMMUNOLOGICAL PROCEDURES ...................................................................... 34 
11 SAFETY ANALYSES ............................................................................................... 34 
11.1 
Extent of exposure ........................................................................................... 34 
11.2 
Adverse events ................................................................................................. 35 
11.2.1 
Definition of treatment-emergent AE .................................................... 35 
11.2.2 
General summaries of TEAEs ............................................................... 35 
11.3 
Clinical laboratory evaluations ........................................................................ 36 
11.3.1 
Hematology and blood chemistry parameters ....................................... 37 
11.3.2 
Macroscopic urinalysis .......................................................................... 37 
11.3.3 
Microscopic urinalysis ........................................................................... 38 
11.4 
Vital signs, physical findings, and other observations related to safety .......... 38 
11.4.1 
Vital signs .............................................................................................. 38 
11.4.2 
Electrocardiograms ................................................................................ 39 
REDACTED COPY
eedo
PY 
eedo
.....
CO
......
O
.
.
E
......
ED
.....
......
CT
......
eters
EDAC
eters
choo
RE
choo
support any marketing authorization application and any extensions or variations thereof. 
30
a
30
.....
or
.....30
r v
30
........
on
........
.......
en
.......
......
ex
........
x
..
.......
any
.......
.......
nd
.......
ys
o
ys.....
on 
.....
zure da
catio
zure da
m.......
pp
.......
.......
n
.......
.......
at
.......
........
hor
........
.......
au
.......
ol or wo
ting a
ol or wo
n subje
ketin
n subje
AND
mar
AND P
r
P
ROCE
ny 
ROCE
ES
ort
ES...
rt
...
exposu
uppo
exposu
This document cannot be used to 
e even
to su
e even
Def
ed t
Def
2.2
e u
2.2
Cli
be
Cli
11.
nno
11.


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 5 of 50 
 
11.4.3 
Physical examination ............................................................................. 39 
11.4.4 
Neurological examination ...................................................................... 39 
11.4.5 
Psychiatric and mental status ................................................................. 39 
11.4.6 
HADS ..................................................................................................... 39 
11.4.7 
Columbia-Suicide Severity Rating Scale ............................................... 40 
12 REFERENCES .......................................................................................................... 41 
13 APPENDICES ........................................................................................................... 42 
13.1 
QOLIE-31-P total and subscale score calculations .......................................... 42 
13.2 
Subject site transfers ........................................................................................ 44 
13.3 
PCST criteria .................................................................................................... 45 
13.3.1 
Hematology parameters ......................................................................... 45 
13.3.2 
Blood chemistry parameters .................................................................. 46 
13.3.3 
Urinalysis ............................................................................................... 48 
13.3.4 
Vital signs and body weight ................................................................... 48 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
42
a
42
.....
or
.....42
r v
42
........
on
........
.......
en
.......
........
ex
........
.......
any
.......
..
n
.......
nd
.....
....
on
........
n 
....


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 6 of 50 
 
LIST OF ABBREVIATIONS 
AE 
adverse event 
AED 
antiepileptic drug 
AMD 
antimyoclonic drug 
ALP 
Alkaline phosphatase 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
ATC 
Anatomic Therapeutic Class 
BMI 
body mass index 
bpm 
Beats per minute 
BRV 
brivaracetam 
BUN 
blood urea nitrogen 
CHMP 
Committee for Medicinal Products for Human Use 
CR CL 
creatinine clearance 
CRF 
case report form 
C-SSRS 
Columbia-Suicide Severity Rating Scale 
DBP 
diastolic blood pressure 
ECG 
electrocardiogram 
EDV 
Early Discontinuation Visit 
EQ-5D 
EuroQol 5 Dimensions 
ER 
emergency room 
EU 
European Union 
F 
Female 
FDA 
Food and Drug Administration 
FEV 
Full Evaluation Visit 
FV 
Final Visit 
GGT 
Gamma-glutamyl transpeptidase  
HADS 
Hospital Anxiety and Depression Scale 
HDL 
High-density lipoprotein  
HRQoL 
Health-Related Quality of Life 
ILAE 
International League Against Epilepsy 
LDL 
low-density lipoprotein 
MedDRA 
Medical Dictionary for Regulatory Activities 
M 
Male 
MEV 
Minimal Evaluation Visit 
N/A 
Not applicable 
PBO 
placebo 
PCST 
potentially clinically significant treatment-emergent 
PGS 
primary generalized seizures 
POS 
partial onset seizure 
PT 
preferred term  
QOLIE-31-P 
Patient Weighted Quality of Life in Epilepsy 
Questionnaire 
REDACTED COPY 
m
Y
m
nuatio
OPY
nuatio
Dimen
CO
Dimen
cy ro
TED 
cy ro
pean U
ACTE
pean U
male
DAC
male
Food 
RED
Food 
Fu
R
Fu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
r Hum
y ex
r Hum
Rating 
on a
Rating 
on Vis
app
on Vis
nsions
tion a
nsions
om
izat
om
Union
horiz
Union
d and D
ng a
d and D
ull Eva
eting
ull Eva
Final 
arke
Final 
Ga
ma
Ga
V
ot
V
N/A
nn
N/A
PBO
t can
PBO
PC
t 
PC


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 7 of 50 
 
RBC  
Red Blood Cell 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SBP 
systolic blood pressure 
SD 
standard deviation 
SEV 
Supplemental Entry Visit 
SGOT 
serum glutamic oxaloacetic transaminase 
SGPT 
serum glutamic pyruvic transaminase 
SOC 
system organ class 
TEAE 
treatment-emergent adverse event 
ULD 
Unverricht-Lundborg Disease 
ULN 
Upper Limit of Normal 
V  
Visit 
VAS 
visual analog scale 
WBC 
White Blood Cell 
WHO-DRL 
World Health Organization Drug Reference List 
YEV 
Yearly Evaluation Visit 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
rug Re
n and
rug Re


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 8 of 50 
 
1 
INTRODUCTION 
This statistical analysis plan (SAP) defines the scope of statistical analyses and provides a 
detailed description of statistical methodology for the statistical analyses to support the final 
clinical study report for N01125. 
2 
PROTOCOL SUMMARY 
2.1 
Study objectives 
2.1.1 
Primary objective 
To evaluate the long-term safety and tolerability of brivaracetam (BRV) at individualized 
doses with a maximum of 200mg/day in subjects suffering from epilepsy 
2.1.2 
Secondary objectives 
To evaluate the maintenance of efficacy over time of BRV (for subjects with partial onset 
seizures [POS] and subjects with primary generalized seizures [PGS]) 
No secondary efficacy objectives are defined for subjects with Unverricht-Lundborg Disease 
(ULD) or subjects entering the study from N01315. 
2.1.3 
Exploratory objectives 
Exploratory objectives for subjects with POS/PGS: 
 To explore direct medical resource use and indirect cost parameters for the first 2 years 
 To obtain a description of the subject’s self-reported health status for the first 2 years 
 To explore the effects of BRV on the subject’s Health-Related Quality of Life (HRQoL), 
anxiety, and depression for the first 2 years 
 To explore any change in the subject’s socio-professional status for the first 2 years 
No exploratory objectives are defined for ULD subjects or subjects entering the study from 
01315. 
2.2 
Study variables 
2.2.1 
Safety variables 
Note: Assessments specified as performed within the first 2 years of the Evaluation Period 
are not applicable to subjects entering the study from N01315. 
2.2.1.1 
Primary safety variables 
 Occurrence of a treatment-emergent adverse event (TEAE) 
 Withdrawal due to adverse event (AE) 
 Occurrence of a serious adverse event (SAE) 
REDACTED COPY 
PGS:
D CO
PGS:
e and 
CTED
e and 
ject’s 
DAC
ject’s 
on th
RE
on th
ny marketing authorization application and any extensions or variations thereof. 
idualiz
ons 
idualiz
cts with
any
cts with
GS])
nd
GS])
Unver
ion a
Unver
indirec
oriza
indirec
self
autho
self-
h
-f-f
h
f-f re
ho
re
he
in
he sub
ng 
sub
first 2 y
rketi
first 2 y
he subj
y ma
he subj
This document cannot be used to support a
are def
t any
are def
dy va
supp
dy va
Safety
ed to
Safety
ssment
e use
ssment
pplicab
t be
pplicab
1.1
nn
1.1

Oc
t c
Oc

m



UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 9 of 50 
 
2.2.1.2 
Other safety variables 
 Laboratory tests (hematology, blood chemistry, urinalysis) 
 Vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse rate) and 
body weight 
 Electrocardiogram (ECG) 
 Physical and neurological examinations 
 Change in Hospital Anxiety and Depression Scale (HADS) scores from the Baseline of 
the previous study to each assessment for the first 2 years and to the last Evaluation 
Period assessment during the first 2 years 
2.2.2 
Efficacy variables 
2.2.2.1 
Secondary efficacy variables 
For subjects with focal-onset epilepsy: 
• POS (type I) frequency per 28 days during the Evaluation Period 
 Percent reduction in POS (type I) frequency per 28 days from Baseline of the previous 
study to the Evaluation Period 
 Responder rate for POS (type I) frequency over the Evaluation Period. A responder is 
defined as a subject with a ≥50% reduction in seizure frequency from the Baseline Period 
of the previous study. 
No secondary efficacy variables are defined for subjects with generalized epilepsy or subjects 
with ULD or subjects entering the study from N01315. 
2.2.2.2 
Other efficacy variables 
For subjects with focal-onset epilepsy: 
 Percentage of subjects continuously seizure-free for all seizure types (I+II+III) for at least 
6 months and at least 12 months during the Evaluation Period 
For subjects with generalized epilepsy: 
 Generalized (type II) seizure days per 28 days during the Evaluation Period 
 Percent reduction in generalized (type II) seizure days per 28 days from Baseline of the 
previous study to the Evaluation Period 
 Responder rate for generalized (type II) seizure days over the Evaluation Period. A 
responder is defined as a subject with a ≥50% reduction in seizure days from the Baseline 
Period of the previous study. 
 Percentage of subjects continuously seizure-free for all seizure types (I+II+III) for at least 
6 months and at least 12 months during the Evaluation Period 
REDACTED COPY 
r 28
Y
r 28
cy ove
ED C
cy ove
uction
CTED
uction
e defi
RED
e defi
t
R
t
be used to support any marketing authorization application and any extensions or variations thereof. 
eline of
or v
eline of
uation 
ns o
uation 
n Perio
ation
n Perio
ays fro
pplic
ays fro
er the E
zatio
er the E
n in sei
oriza
n in sei
fined fo
ng a
fined fo
udy fro
keting
udy fro
variab
mark
variab
t epilep
any 
t epilep
cts con
port 
cts con
east 12
supp
east 12
h gener
d to s
h gener
zed (ty
use
zed (ty
This document cannot 
ent red
ot be
ent red
revious
nnot
revious
Res
t ca
Res
r
t
r


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 10 of 50 
 
The following will be evaluated separately for subjects with focal-onset epilepsy and subjects 
with generalized epilepsy: 
 Change in Patient Weighted Quality of Life in Epilepsy Questionnaire (QOLIE-31-P) 
scores from Baseline of the previous study to each assessment for the first 2 years and to 
the last Evaluation Period assessment during the first 2 years 
 EuroQol 5 Dimensions (EQ-5D) questionnaire response for each assessment for the first 
2 years for the Evaluation Period and for the last assessment during the first 2 years of the 
Evaluation Period 
2.2.3 
Pharmacoeconomic variables 
Due to the inconsistencies in data captured and collection forms across LTFU studies, the 
following variables will be provided in subject data listings only, but will not be evaluated or 
descriptive summarized: 
 Direct costs (healthcare provider consultations not foreseen by the protocol, concurrent 
medical procedures, concomitant medications, hospitalizations, and emergency room 
[ER] visits) during the first 2 years of the Evaluation Period 
 Indirect costs (work days or school days lost by the subject and days subject received help 
from a caregiver) during the first 2 years of the Evaluation Period 
 Socio-professional data for each assessment for the first 2 years and for the last 
assessment during the first 2 years of the Evaluation Period 
No pharmacoeconomic variables are defined for ULD subjects or subjects entering the study 
from N01315. 
2.3 
Study Design and Conduct 
This is an open-label, long-term follow-up, multicenter, noncomparative, single-arm study of 
BRV. The primary objective is to evaluate the long-term safety and tolerability of BRV at 
individualized doses up to a maximum of 200mg/day in subjects with epilepsy. The 
secondary objective is to evaluate the maintenance of efficacy of BRV. Exploratory 
objectives are to assess the effects of BRV on subjects’ HRQoL, obtain information on the 
direct and indirect costs, and explore changes in socio-professional status. 
N01125 enrolled subjects 16 years of age and older who had completed N01114, N01252 
(non-Indian subjects only), N01254 (non-Indian subjects only), N01187, or N01236. N01114 
and N01252 enrolled subjects with focal-onset seizures with or without secondary 
generalization (designated as “POS subjects”). N01254 enrolled subjects with focal-onset 
epilepsy and a smaller number of subjects with generalized epilepsy (designated as “PGS 
subjects”). N01187 and N01236 enrolled subjects with ULD. Subjects entering the study 
from long-term follow-up study (N01315) were 16 years of age and older with from POS. 
Subjects from double-blind, placebo-controlled studies N01114, N01187, and N01236 were 
to enter N01125 at a dose of 100mg/day after completion of a blinded Conversion Period. 
Subjects from double-blind, placebo-controlled N01252 were to enter N01125 at a dose of 
REDACTED COPY 
the
Y
the
he Ev
OPY
he Ev
ment fo
ED C
ment fo
the Ev
CTED
the Ev
define
EDAC
define
marketing authorization application and any extensions or variations thereof. 
st 
a
st 
of the 
aria
of the 
U studie
ensi
U studie
not be 
exte
not be 
the pro
nd a
the pro
ons, and
n an
ons, and
od
atio
od
ubject 
pplic
ubject 
valuatio
n app
valuatio
or the f
atio
or the f
valuati
oriza
valuati
ed for 
auth
ed for 
nd Co
rketi
nd Co
t be used to support any m
m follo
ma
m follo
e is to e
any 
e is to e
o a ma
ort a
o a ma
to eva
uppo
to eva
sess th
o sup
sess th
ct cost
d to 
ct cost
olled su
use
olled su
ian sub
t be u
ian sub
This document canno
01252 
not b
01252 
neraliza
cann
neraliza
epileps
nt ca
epileps
subj
men
subj
fr
m
fr


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 11 of 50 
 
50mg/day. The starting doses for subjects from double-blind, placebo-controlled, flexible-
dose study N01254 were based on the blinded dose levels achieved during the Maintenance 
Period of N01254 but were not to exceed 100mg/day; thus, starting doses for subjects from 
N01254 were 20mg/day, 50mg/day, or 100mg/day, with most subjects entering N01125 at a 
dose of 100mg/day. 
Subjects who enrolled in the study entered an Evaluation Period during which treatment with 
BRV was initiated. The dose of BRV can be adjusted based on the individual subject’s 
seizure control and tolerability. Dose increases can be made in increments of 50mg/day on a 
weekly basis up to a maximum of 200mg/day; dose decreases can be made in steps of 
50mg/day on a weekly basis. Subjects who discontinue treatment with BRV enter a Down-
Titration Period during which the dose of BRV is decreased in steps of 50mg/day with a last 
down-titration step at 20mg/day for 1 week. Subjects who have completed the Down-
Titration Period or subjects who discontinue during the Evaluation Period without entering 
the Down-Titration Period enter a Post-Treatment Period for a minimum of 2 weeks and a 
maximum of 4 weeks. 
The maximum allowable daily dose for this study was increased from 150mg/day to 
200mg/day based on integrated amendment 25 to the protocol. It is recommended that the 
daily dose be administered in 2 equal intakes. 
Dose adjustment to concomitant antiepileptic drugs (AEDs) may be made at any time during 
the study and subjects may start new AEDs. Concomitant AEDs may also be discontinued; 
however, special considerations apply if the discontinuation of such AEDs results in the 
subject receiving BRV monotherapy. Previously, in the event of excellent efficacy and 
tolerability of BRV, withdrawal of concomitant AEDs resulting in monotherapy of BRV may 
have been attempted by the Investigator for subjects with POS or PGS. With integrated 
amendment 25 to the protocol, conversion to monotherapy is no longer permitted; however, 
subjects already on BRV monotherapy are allowed to continue monotherapy treatment. No 
conversion to monotherapy is permitted for subjects with ULD. 
The visit schedule for this study depends on the previous study from which the subject was 
enrolled and the numbering of study visits differs depending on the previous study. Study 
visits at Months 6, 12, 18, 24, and so forth are either Full Evaluation Visits (FEVs) or Yearly 
Evaluation Visits (YEVs) at which a greater number of assessments are performed for all 
subjects from previous studies. For subjects coming from N01114, study visits at Months 1, 
3, 5, 15, 21 are Minimal Evaluation Visits (MEVs) at which few assessments are generally 
performed. Study visits at Months 2, 4, and 9 are FEVs. For subjects coming from N01252, 
N01254, N01187, and N01236, study visits at Months 1, 3, 9, 15, and 21 are MEVs. The 
study visit at Month 2 is an FEV. In addition, a phone call is scheduled at the end of the 
Down-Titration Period and a Drug-Free Final Visit (FV) is scheduled at the end of the Post-
Treatment Period. The study schedule, as just described, is shown in Table 2‒1 and Table 2‒
2. 
REDACTED COPY 
drugs (
COP
drugs (
Conc
ED C
Conc
the dis
CTED
the dis
Previo
DACT
Previo
conco
REDA
conco
gato
RE
gato
used to support any marketing authorization application and any extensions or variations thereof. 
i
y on a 
vari
y on a 
of 
o
of 
r a Dow
ons 
r a Dow
day wi
nsio
day wi
the Do
xten
the Do
od with
y ex
od with
um of 
any
um of 
ed from
tion a
ed from
col. It i
icatio
col. It i
(
o
(AEDs
on a
AEDs
comita
zatio
comita
scontin
oriza
scontin
ously, 
utho
ously, 
omitan
g au
omitan
tor for 
eting
tor for 
nversion
arket
nversion
therapy
mar
therapy
s perm
any m
s perm
is study
ort a
is study
bering 
uppo
bering 
12, 18
o sup
12, 18
ts (YEV
d to
ts (YEV
m previo
used
m previo
annot be
1 are M
be u
1 are M
med. St
ot b
med. St
254, N
anno
254, N
This document 
tudy vi
t ca
tudy vi
Dow
ent
Dow
Tr
m
Tr


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 12 of 50 
 
Table 2‒1: 
Study Schedule for Subjects from N01114, N01252, and 
N01254 
Subjects coming from Exploratory Studies 
(N01114) 
Subjects coming from Confirmatory Studies 
(N01252, N01254) 
Month 
Visit 
Type of Visit 
Month 
Visit 
Type of Visit 
1st year Follow-up 
1st year Follow-up 
MO 
V1 
Entry Visit 
MO 
V1 
Entry Visit 
M1 
V2 
MEV 
M1 
V2 
MEV 
M2 
V3 
FEV 
M2 
V3 
FEV
M3 
V4 
MEV 
M3 
V4 
MEV 
M4 
V5 
FEV 
M4 
 
 
M5 
V6 
MEV 
M5 
 
 
M6 
V7 
FEV 
M6 
V5 
FEV
M7 
 
 
M7 
 
 
M8 
 
 
M8 
 
 
M9 
V8 
FEV 
M9 
V6 
MEV 
M10 
 
 
M10 
 
 
M11 
 
 
M11 
 
 
2nd and subsequent years Follow-up 
2nd and subsequent years Follow-up 
M12 
V9 
YEV 
M12 
V7 
YEV 
M15 
V10 
MEV 
M15 
V8 
MEV 
M18 
V11 
FEV 
M18 
V9 
FEV
M21 
V12 
MEV 
M21 
V10 
MEV 
FEV=Full Evaluation Visit; MEV=Minimal Evaluation Visit; M=month; V=Visit; YEV=Yearly 
Evaluation Visit 
 
 
TED COPY
M
PY 
M
OPY
D C
D
REDACTED C
D C
D C
D C
CTE
DA
R
tion application and any extensions or variations thereof. 
ti
at
ati
ati
Visit
or v
Visit
va
MEV
ions
MEV
s o
F
sio
xte
y e
ny
nd
on
ca
ica
ca
ca
c
M8
on a
M8
ap
rizatio
M
t
M
pport any marketing authori
tio
ori
ho
ut
ow
ke
ow-
ket
-up
et
up
ing
YE
ma
YE
rk
y m
t a
o supp rt
V12
su
V12
pp
This document cannot be used to 
uation V
ed to
uation V
sit
se
sit
o


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 13 of 50 
 
Table 2‒2: 
Study Schedule for Subjects from N01187 and N01236 
Subjects coming from ULD Confirmatory Studies 
(N01187, N01236) 
Month 
Visit 
Type of Visit 
1st year Follow-up 
M0 
V1 
Entry Visit 
M1 
V2 
MEV 
M2 
V3 
FEV 
M3 
V4 
MEV 
M4 
 
 
M5 
 
 
M6 
V5 
FEV 
M7 
 
 
M8 
 
 
M9 
V6 
MEV 
M10 
 
 
M11 
 
 
2nd and subsequent years Follow-up 
M12 
V7 
YEV 
M15 
V8 
MEV 
M18 
V9 
FEV 
M21 
V10 
MEV 
... 
... 
... 
FEV=Full Evaluation Visit; MEV=Minimal Evaluation Visit; M=month; ULD=Unverricht-
Lundborg disease; V=Visit; YEV=Yearly Evaluation Visit 
All subjects should have a Visit 1 at the start of N01125. Visit 1 will typically correspond to 
the last visit from the previous study and should be the visit at which study drug is dispensed 
for N01125. However, some subjects had a delay in treatment with study drug after 
completion of the previous study. Such subjects may have had an additional Supplemental 
Entry Visit (SEV) at the time of entry into N01125. 
Subjects entering from N01315 will perform their Last Visit in N01315 and perform at the 
same time their First Visit in N01125. They will follow the schedule of 1 visit/3months: 1 
Full Evaluation Visit alternating with 1 Minimal Evaluation Visit. Yearly Evaluation Visit 
will be performed in replacement of the first Full Evaluation Visit of each year. 
REDACTED COPY 
PY
OP
D C
CT
nd su
RE
nd su
ED
R
rt any marketing authorization application and any extensions or variations thereof. 
va
va
va
v
s
si
xt
ny
F
nd
ion
lic
ap
tio
titio
tio
ti
or
ubseque
ng a
ubseque
au
V
t
V
ting
ar
y
to support an
rt
pp
be used to
valuatio
ed t
valuatio
g diseas
use
g diseas
t cannot 
to
ects sh
ot be
ects sh
ast visit
nnot
ast visit
r N011
can
r N011
This documen
compl
ent c
compl
En
me
En


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 14 of 50 
 
 
This study will run throughout the duration of the clinical development period of BRV, and 
will continue until a marketing authorization is granted by any Health Authority in an 
indication for the adjunctive treatment in adults with refractory POS, whether or not 
secondarily generalized, until the Sponsor decides to close the study, until a managed access 
program, named patient program, compassionate use program, or similar type of access 
program is established as allowed per country-specific requirement in addition to legal and 
regulatory guidelines, or until BRV development is stopped by the Sponsor. 
2.4 
Determination of Sample Size 
No sample size calculation was done. Sample size was dependent upon recruitment into and 
completion of preceding studies. At the time of development of this SAP amendment 1, the 
enrollment into this study has been completed; a total of 859 subjects were enrolled into 
N01125 including 6 subjects entering the study from N01315.  
3 
DATA ANALYSIS CONSIDERATIONS 
3.1 
General presentation of summaries and analyses 
Statistical analysis and generation of tables, figures, subject data listings, and statistical 
output will be carried out using SAS® Version 9.1 or higher. 
Descriptive statistics, such as the mean, standard deviation (SD), median, 25th percentile, 
75th percentile, minimum value, and maximum value for quantitative variables, and counts 
and percentages for categorical variables, will be provided. Denominators for percentages 
will generally be based on the set of subjects with at least 1 assessment at the time point or at 
least 1 assessment during the time interval being summarized. 
All summaries will be descriptive; no statistical hypothesis testing is planned. 
Unless otherwise noted, summaries will present BRV overall, which will include all subjects 
exposed to BRV during the study. 
Subject data listings will be provided and will present source data and key derived variables 
for statistical analyses. 
3.2 
Analysis time points 
3.2.1 
First and last dose of BRV 
Unless otherwise noted, all references to the first dose of BRV in this SAP refer to the first 
dose of BRV during N01125 (ie, not the first dose of BRV from the previous study in which 
subjects participated in prior to N01125). Unless otherwise noted, all references to the last 
known dose of BRV in this SAP refer to the last dose of BRV taken across any study periods 
(ie, the last dose of BRV across both the Evaluation and Down-Titration Periods). 
3.2.2 
Relative day 
Relative day will be calculated as the current date minus the date of first dose of study drug 
for days prior to the first dose of study drug, and the current date minus the date of first dose 
REDACTED COPY
, su
PY 
, su
9.1 or 
COPY
9.1 or 
ndard d
ED C
ndard d
ximum
CTED
ximum
les, w
DACT
les, w
f subj
REDA
f subj
inte
R
inte
keting authorization application and any extensions or variations thereof. 
d 
i
d 
tment i
nsio
tment i
mendm
xten
mendm
ere enro
y ex
ere enro
S
and a
ation
and a
ject dat
pplic
ject dat
higher
n app
higher
deviati
zatio
deviati
m value
oriza
m value
will be p
utho
will be p
jects w
g au
jects w
erval b
eting
erval b
t be used to support any ma
e; no st
marke
e; no st
maries 
ny m
maries 
e study
rt an
e study
will be p
uppo
will be p
ses.
o su
ses.
Analy
ed to
Analy
Fi
us
Fi
nt canno
otherw
not b
otherw
e of BR
ann
e of BR
subject
nt ca
subject
This documen
know
men
know
(i
m
(i


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 15 of 50 
 
of study drug plus 1 for days on or after the day first dose of study drug and prior to or on the 
day of last study drug dose (eg, the day of first dose will be Day 1 and the day prior to first 
dose will be Day -1), ie, Day 1 representing the day of first dose of BRV, the previous day is 
Day -1 and each day prior to that is Day -2, Day -3, etc; subsequent relative days to Day 1 
will be Day 2, Day 3, etc. For days after the last dose of BRV, relative day will be calculated 
as the current date minus the date of last dose of BRV and including a ‘+’ to denote post 
treatment days (eg, the day after the last dose of BRV will be Day +1). Relative day will not 
be calculated for partial or missing dates. 
3.2.3 
Summaries at Study Entry 
Study Entry denotes an analysis time point that will summarize assessments done at the last 
visit of the previous study for most subjects as described below, but may also include 
assessments that may have been performed at Supplemental Entry Visits (SEVs) for some 
subjects who did not immediately enter N01125. 
There are 4 groups of subjects to consider: 
1. Subjects who immediately entered N01125 after completing the Treatment Periods for 
N01252 and N01254 or the blinded Conversion Periods for N01114, N01187, and 
N01236 
2. Subjects who entered the Down-Titration Period of the previous study and entered 
N01125 during the Down-Titration Period 
3. Subjects who did not immediately enter N01125 and had a gap in treatment with 
study drug between the previous study and N01125Subjects  
4. Subjects entering the study from N01315 who entered after their N01315 study sites 
were closed 
Subjects in Categories 1 and 2 
Subjects in categories 1 and 2 will generally not have any interruption in study drug dosing 
during the transition to N01125. For such subjects, selected assessments from the following 
visits from the previous study will be summarized at Study Entry: 
 
 
 
Study  
 
 
 
Visit (Time Point) 
 
 
 
N01187/N01236  
Visit 9 (Week 16) 
 
 
 
N01114 
 
 
 
Visit 10 (Week 12) 
 
 
 
N01252 
 
 
 
Visit 7 (Week 12) 
 
 
 
N01254 
 
 
 
Visit 8 (Week 16) 
The following assessments were to be performed for all subjects at the above time points: 
laboratory parameters, vital signs, and ECGs; these assessments will be summarized at Study 
Entry. The following assessments were to be performed for all subjects from N01252 and 
N01254 at the above time points: QOLIE-31-P, HADS, EQ-5D and socio-professional data; 
however, these assessments will not be summarized at Study Entry. 
Subjects in Category 3 
Some subjects in category 3 have data available from an SEV at the time of entry into 
N01125. Laboratory parameters, vital signs, and ECGs collected at SEV will be summarized 
REDACTED COPY
Perio
PY 
Perio
od
CO
od
nter N0
ED C
nter N0
tudy a
CTED
tudy a
m N01
ACT
m N01
ny marketing authorization application and any extensions or variations thereof. 
ot 
at
ot 
ne at th
sions
ne at th
o includ
tensi
o includ
SEVs)
exte
SEVs)
ting th
n an
ting th
ds for N
ation
ds for N
d of the
appl
d of the
01125 
ation
01125 
and N0
oriza
and N0
1315
tho
1315 w
ill gene
mark
ill gene
25. For
ny m
25. For
t cannot be used to support a
udy wil
t any
udy wil
N0123
sup
N0123
14
d t
14
1252
sed 
1252
N0125
e us
N0125
llowing
not b
llowing
oratory
anno
oratory
nt 
Entry
nt ca
Entry. T
This documen
N012
ment
N012
ho
m
ho


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 16 of 50 
 
at Study Entry. If one or more of these assessments were not performed at SEV, or if a 
subject in category 3 does not have an SEV, then the subject will be excluded from 
summaries of Study Entry for the assessments that were not performed. 
Subjects in Category 4 
Subjects in category 4 will have their demographic data including date of birth, country, 
gender, race, and ongoing medication data transferred into N01125. Laboratory parameters, 
vital signs, and ECGs collected at SEV will be collected at Study Entry.  
3.2.4 
Study periods 
The study is divided into 3 periods: Evaluation Period, Down-Titration Period, and Post-
Treatment Period. A subject is classified as “discontinued” if the subject has a termination 
case report form (CRF) or has an early discontinuation visit (EDV). A subject is classified as 
“completed” if this subject completes the full extent of the study as defined in the protocol at 
database lock.   
A “discontinued” subject can be potentially slotted into the 3 periods of the study. The 
following algorithms will be used to slot the subject appropriately into the Evaluation Period, 
Down-Titration Period, and Post-Treatment Period. 
 For Evaluation Period, the start date is the date of first dose of BRV, and the 
following algorithm is used to determine the end date: 
 If the subject enters the Down-Titration Period, then the date of EDV is the 
end date; 
 If the subject does not enter the Down-Titration Period but meets 1 of the 
following criteria, the Evaluation Period ends on date of last dose of BRV, 
 Without an EDV but having a termination CRF, 
 With an EDV and having a termination CRF, 
 With an EDV and the date of EDV prior to the database lock date and 
having no termination CRF. 
 A subject is considered entering Down-Titration Period only if the subject has an 
EDV and at least 1 dose of study drug after the date of EDV, the start date of Down-
Titration Period is set as 1 day after the date of EDV, and the Down-Titration Period 
ends on date of last dose of BRV. A subject without an EDV but having a termination 
CRF or with an EDV but without any dosing of study drug after the EDV will not 
have the Down-Titration Period, and no artificial Down-Titration Period will be 
created for analysis. 
 A subject is considered entering the Post-Treatment Period if the subject has at least 1 
contact (scheduled visit, unscheduled visit, or telephone contact) after the date of last 
dose of BRV. The Post-Treatment Period starts 1 day after date of last dose of BRV 
irrespective of entering the Down-Titration Period, and there is no end date. 
REDACTED COPY 
e dat
OPY
e date
Y
e
ne the
CO
ne the
wn
TE
wn-
E
-T
ED
T
not ent
RED
not ent
e
R
e
used to support any marketing authorization application and any extensions or variations thereof. 
,
a
,
and
ion
and Pos
ns
Pos
a 
e
a termi
nsio
termi
ject is
exte
ject is 
ined in
ny e
ined in
riods o
n an
riods o
ately in
tion
ately in
of firs
app
of firs
e end d
ion 
e end d
Titratio
oriza
Titratio
nter 
ng
nter the
g au
the
Evalu
eting
Evalu
n EDV
mark
n EDV
an EDV
any 
an EDV
With an
port 
With an
havin
supp
havin
d
is
d t
is con
to 
con
and at l
sed 
and at l
This document cannot be 
ration P
be us
ration P
ends on
ot be
ends on
CRF
nnot
CRF
h
n
h


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 17 of 50 
 
A “completed” subject can potentially have Evaluation Period, Down-Titration Period, and 
Post-Treatment Period. At the time of study termination by the Sponsor, subjects will 
discontinue the study drug following the down titration process or will be converted without 
titration to commercial BRV where available; alternatively, subjects may be initiated without 
down-titration in a managed access program, named patient program, compassionate use 
program, or similar type of access program as allowed per country specific requirements in 
addition to legal and regulatory guidelines. 
3.2.5 
Monthly time intervals 
A month is defined as 30 days and time intervals based on monthly durations are defined as a 
multiple of 30 days (eg, 12 months is defined as 360 days). The following definitions of 
3-month and 6-month intervals are based on 30-day months where the date of first dose of 
BRV is Day 1: 
 
Interval 
 
 
Duration Definition 
 
Months 1-3 
 
Days 1-90 
 
Months 4-6 
 
Days 91-180 
 
Months 7-9 
 
Days 181-270 
 
Months 10-12  
Days 271-360 
 
Months 1-6 
 
Days 1-180 
 
Months 7-12  
Days 181-360 
 
Months 13-18  
Days 361-540 
 
Months 19-24  
Days 541-720 
Subsequent 3- and 6-month intervals are defined in a similar manner.  
Six-month intervals are defined for the evaluation of direct and indirect cost parameters. 
Statistical summaries for direct and indirect cost parameters will only present results through 
the first 2 years of treatment. Three-month intervals will be used for analysis of efficacy 
outcomes and AEs. 
For the analysis of efficacy outcomes, a subject is included in the analysis for a 3-month 
interval if the end date is on or after the last day of the 3-month interval and the subject diary 
was completed for at least 1 day during the 3-month interval. 
For the analysis of AEs, a subject is included in the analysis for a 3-month interval if the end 
date is on or after the first day of the 3-month interval. 
3.2.6 
Last Value on BRV Treatment 
Last Value for QOLIE-31-P, HADS, EQ-5D, and socio-professional data is the last 
assessment strictly after the date of first dose of BRV and up to and including the YEV at the 
end of the second year and any EDVs for subjects who did not complete through the YEV at 
the end of the second year. 
Last Value for clinical laboratory parameters, vital signs, and ECGs is the last available result 
obtained after the first dose of BRV and prior to or on the date of last dose of BRV. All 
REDACTED COPY 
s are d
EDA
s are d
th
R
th
support any marketing authorization application and any extensions or variations thereof. 
efined 
ns or
efined 
itions o
sions
itions o
f first d
tensi
f first d
define
aut
define
he eva
eting
he eval
g
l
nd indir
arke
nd indir
hree
y ma
hree-
m
-m
a
m
acy ou
port 
acy ou
e is on
upp
e is on
This document cannot be used to
r at lea
to su
r at lea
sis of A
sed 
sis of A
r after
e us
r after
st Valu
can
st Valu
assess
ent c
assess
end
me
end
t


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 18 of 50 
 
scheduled and unscheduled assessments within this time period will be considered. Last 
Value will be determined separately for each laboratory parameter.  
3.2.7 
Exposure duration and exposure duration cohorts 
At the final analysis, the overall duration of exposure (or On Treatment Period) will be 
calculated as the date of last dose of BRV minus the date of first dose of BRV plus 1 day. 
Each subject will be classified into one or more of the following exposure duration cohorts 
based on the duration of BRV exposure as calculated above:  
 
 
All subjects   
≥1 day 
 
 
≥3 months  
 
≥90 days 
 
 
≥6 months  
 
≥180 days 
 
 
≥12 months 
 
≥360 days 
This categorization will continue in 6-month increments past 12 months up to a time point 
that will be determined based on cumulative exposure at the time of the database lock. 
3.2.8 
Study visit cohorts 
Study visit cohorts are defined for summaries of QOLIE-31-P, HADS, and EQ-5D. Six-
month, 12-month, 18-month, and 24-month cohorts are defined. Subjects will be classified 
into a study visit cohort if they attend the scheduled visit at the time point defined by the 
cohort. For example, subjects will be included in the 18-month study visit cohort if they 
attend the scheduled visit at 18 months (ie, FEV at Month 18). Subjects may be classified in 
more than 1 cohort. Generally, subjects included in a cohort for a later visit will be included 
in all earlier study visit cohorts (eg, 6-month and 12-month study visit cohorts for subjects in 
the 18-month study visit cohort), although this may not be the case in the event of a missed 
visit or if an unscheduled visit is conducted in lieu of a scheduled visit.  
3.3 
Definition of Baseline Values 
Baseline for all study outcomes will be based on baseline from the previous studies. For 
assessments performed at scheduled and unscheduled visits, Baseline will generally be the 
last result obtained or prior to the randomization visit of the previous study. Baseline will be 
defined separately for each hematology, blood chemistry, and urinalysis parameter. 
Baseline for the evaluation of seizure frequency and seizure days will be calculated from the 
core study seizure diary based on the rules defined in Section 3.8.1 . 
3.4 
Protocol deviations 
The criteria for identifying important protocol deviations and the classification of important 
protocol deviations will be defined separately in the Specification of Protocol Deviations 
document. Whenever possible, criteria for identifying important protocol deviations will be 
implemented algorithmically to ensure consistency in the classification of important protocol 
deviations across all subjects. 
REDACTED COPY
OLI
PY 
OLI
orts ar
COPY
orts ar
eduled
D CO
eduled
ded in
TED 
ded in
(ie, FE
ACT
(ie, FE
cts inc
EDA
cts inc
, 6
RE
, 6-
RE
-m
E
m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
onths up
nd an
onths up
e of the
n and
e of the
31
ppli
31-
pl
-P, 
plic
P, 
re defin
n app
re defin
d visit 
tion
d visit 
n the 1
izat
n the 1
EV at 
thori
EV at 
cluded
auth
cluded
month a
ng a
month a
hough 
ketin
hough 
conduc
ark
conduc
of Bas
ny m
of Bas
tcomes
port a
tcomes
ed at sc
uppo
ed at sc
or prio
o sup
or prio
ely for 
ed to
ely for 
r the ev
e use
r the ev
dy seizu
t be 
dy seizu
The cri
nt c
The cri
prot
men
prot
d
m
d


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 19 of 50 
 
3.5 
Analysis Sets 
3.5.1 
Safety Analysis Set 
The Safety Analysis Set will consist of all subjects who took at least 1 dose of study drug but 
not including subjects entering the study from N01315. 
Summaries of demographics and baseline characteristics, medical history, AEDs, non-AEDs, 
HADS, study drug exposure, and safety outcomes will be provided for the Safety Analysis 
Set. 
A Modified Safety Analysis Set will also be defined to consist of all subjects who took at 
least 1 dose of study drug including subjects entering the study from N01315. Demographic, 
ongoing medication and safety assessment listings will be provided based on the Modified 
Safety Analysis Set. 
3.5.2 
Efficacy Analysis Sets 
Efficacy Analysis Sets will consist of all subjects who took at least 1 dose of study drug and 
have at least 1 seizure diary day during the Evaluation Period. Separate Efficacy Analysis 
Sets are defined for subjects with focal epilepsy from N01114, N01252, and N01254 and 
subjects with generalized epilepsy from N01254.  
A subject will be excluded from the Efficacy Analysis Set for POS or PGS if either they did 
not receive at least 1 dose of BRV, or the clinical database indicates that the daily seizure 
diary was not completed for any days on or after the first dose of BRV and on or prior to the 
end date of the Evaluation Period (see Section 8). 
Seizure outcomes will be summarized for either the Efficacy Analysis Set for POS or the 
Efficacy Analysis Set for PGS. Summaries of epilepsy history, QOLIE-31-P, and EQ-5D will 
be provided for the Efficacy Analysis Sets for both POS and PGS. No summaries of these 
outcomes will be provided for ULD subjects or subjects entering the study from N01315, but 
these data will only be provided in subject data listings. 
3.6 
Treatment Assignment and Treatment Groups 
This is an uncontrolled study in which all subjects receive BRV in doses that are optimally 
adjusted for each subject. Generally, statistical summaries will present all subjects combined 
as a single treatment arm unless otherwise indicated. 
3.7 
Coding dictionaries 
Medical history and AEs will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA). Medications will be coded using the World Health Organization Drug 
Reference List (WHO-DRL). Prior and concomitant medical procedures will not be coded. 
REDACTED COPY 
nalysis
COPY
nalysis
nical d
D CO
nical d
or afte
TED
or afte
Sectio
ACT
Sectio
zed fo
RED
zed fo
mm
R
mm
y marketing authorization application and any extensions or variations thereof. 
,
s 
ri
s 
took at
s or
took at
Demogr
ions
Demogr
the Mo
ensi
the Mo
st 1 dos
and 
st 1 dos
Separa
on a
Separa
14, N0
catio
14, N0
is Set 
n ap
is Set f
p
f
databas
ation
databas
er the f
rizat
er the f
on
th
on 8
ho
8).
or
).
or eithe
g au
or eithe
maries o
eting
maries o
ysis Set
arket
ysis Set
ULD su
ma
ULD su
nnot be used to support any
ded in 
any m
ded in 
ent As
port a
ent As
led stu
supp
led stu
subjec
d to s
subjec
atment 
sed 
atment 
C
u
C
cal hist
nnot 
cal hist
This document ca
tivities
cann
tivities
Refere
ent c
Refere


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 20 of 50 
 
3.8 
Definitions of study-specific derived variables 
3.8.1 
Calculation of seizure frequency/days 
3.8.1.1 
Initial seizure data processing 
Each seizure code in the clinical database will be mapped to exactly 1 of the following codes 
based on the 1981 International League Against Epilepsy (ILAE) classification: I, IA, IA1, 
IA2, IA3, IA4, IB, IB1, IB2, IC, II, IIA, IIB, IIC, IID, IIE, IIF, or III. 
With regard to cluster seizures, investigator sites are to report the number of cluster episodes 
rather than reporting the estimated number of individual seizures. Therefore, no imputation 
will be applied for the seizure counts corresponding to reports of cluster seizures. 
3.8.1.2 
Calculation of adjusted seizure frequency 
The following derivations apply only to subjects with Partial Onset Seizures. 
Baseline POS frequency for seizure types I, IA, IB, IC, and for all seizure types (I+II+III) 
will be obtained from the Baseline Period of the previous double-blind study. 
The total number of seizures for seizure types I, IA, IB, and IC, and the total number of 
seizures for all seizure types (I+II+III) will be calculated overall, by 3-month time intervals, 
and over the cohort interval for each exposure duration cohort. All seizure diary on or after 
the date of first dose of BRV and prior to or on the date of last dose of BRV will be 
considered for these calculations. 
Twenty-eight day adjusted seizure frequency for seizure types I, IA, IB, and IC, and for all 
seizure types (I+II+III) will be calculated overall, within each 3-month time interval, and 
over each exposure duration cohort interval by dividing the total number of seizures for each 
seizure type by the number of days for which the diary was completed overall, within each 
3-month interval, and within each exposure duration cohort interval, and multiplying the 
resulting value by 28. 
3.8.1.3 
Calculation of adjusted seizure days 
The following derivations apply only to subjects with Primary Generalized Seizures, based 
on the 1981 ILAE classification, Primary Generalized Seizures include the generalized 
seizure types and unclassified seizure types.  
Baseline seizure days for seizure types II, IIA through IIF, and for all seizure types (I+II+III) 
will be obtained from the Baseline Period of the previous study. 
The total number of seizure days for seizure types II, IIA through IIF, and the total number of 
seizure days for all seizure types (I+II+III) will be calculated overall, by 3-month time 
intervals, and over the cohort interval for each exposure duration cohort. The same seizure 
diary data defined in the Section 3.8.1.2 for POS frequency will be considered. 
Twenty-eight day adjusted seizure days for seizure types II, IIA through IIF, and for all 
seizure types (I+II+III) will be calculated overall, within each 3-month time interval, and 
over each exposure duration cohort interval by dividing the total number of seizure days for 
REDACTED COPY
at
Y
at
ration
OPY 
ration
n the d
COP
n the d
uency 
ACT
uency 
lated 
EDA
lated 
A
t inte
RE
t inte
nt cannot be used to support any marketing authorization application and any extensions or variations thereof. 
pisodes
r va
pisodes
putatio
s or
putatio
s.
i
s.
ures
y ex
ures.
eizure 
nd a
eizure 
blind 
and
blind 
IC, and
ation
IC, and
overall
plica
overall
n cohor
app
n cohor
date of
ion a
date of
y for se
thor
y for se
overal
auth
overal
erval
ing a
erval b
a
b
for wh
ketin
for wh
h expo
mark
h expo
on of 
rt an
on of 
ions ap
uppo
ions ap
classif
o sup
classif
d uncla
d to
d uncla
izure d
e use
izure d
btained
t be 
btained
otal nu
nno
otal nu
izure
t can
izure
This documen
d
n
d
interv
ment 
interv
dia
me
dia


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 21 of 50 
 
each seizure type by the number of days for which the diary was completed overall (ie, over 
the periods defined in the Section 3.8.1.2), within each 3-month interval, and within each 
exposure duration cohort interval, and multiplying the resulting value by 28. 
3.8.2 
QOLIE-31-P 
The QOLIE-31-P is an adaptation of the original QOLIE-31 (Cramer et al, 1998). The 
QOLIE-31-P includes 30 items grouped into 7 multi-item subscales (seizure worry [5 items], 
overall quality of life [2 items], emotional well-being [5 items], energy/fatigue [4 items], 
cognitive functioning [6 items], medication effects [3 items], and social function [5 items]) 
and a health status item. The QOLIE-31-P total score, subscale scores, and health status item 
score are calculated according to the scoring algorithm described below, with scores ranging 
from 0 to 100 and higher scores indicating better functioning. In addition to these 31 items, 
the QOLIE-31-P includes 7 items assessing the degree of “distress” associated with the topic 
of each subscale (ie, distress items) and 1 item asking about the relative importance of each 
subscale topic (ie, prioritization item). 
Subscale Scores 
As a first step to calculating the subscale scores, the individual responses for the 30 subscale 
items are rescaled to a 0 to 100 scale with higher scores reflecting better functioning; the 
rescaled values for each item are defined in Section 13.1. Each subscale score is then 
calculated by summing the rescaled responses for that subscale and dividing by the number of 
items without a missing response. A subscale score will be calculated only if at least 50% of 
the items within the subscale are present. 
Total Score 
Total score is calculated as a weighted sum of the subscale scores based on the weighting in 
Section 13.1. Total score will be missing if at least 1 subscale score is missing. Total score 
will range from 0 to 100 with a higher score reflecting better functioning. 
Health Status Item 
Responses for the health status item is a multiple of 10 ranging from 0 to 100 with a higher 
score corresponding to a better health status. The health status item response is analyzed 
without rescaling. 
Distress Items 
Each subscale includes 1 distress item. The response for each distress item is an integer 
ranging from 1 to 5. The response for each distress item will be converted to a 0 to 100 scale 
(ie, 0, 25, 50, 75, and 100) with a higher score corresponding to greater distress. 
Prioritization Item 
The response for each subscale for the prioritization item is an integer ranging from 1 to 7. 
The prioritization ranking is analyzed without rescaling. 
REDACTED COPY 
ore
Y
ore
on
OP
on 13
PY
13
 for th
D CO
 for th
ale sco
TED 
ale sco
t.
AC
t.
te
R
te
nt cannot be used to support any marketing authorization application and any extensions or variations thereof. 
],
ati
], 
,
ems])
r va
ems])
status i
s or
status i
cores ra
sions
cores ra
these 3
tensi
these 3
iated w
exte
iated w
e impo
ny e
e impo
ual res
catio
ual res
reflecti
pplic
reflecti
.1
a
.1. Ea
app
. Ea
hat sub
tion 
hat sub
ore wil
izati
ore wil
ed sum
keting
ed sum
missing
arke
missing
a highe
y ma
a highe
th statu
ppo
th statu
g to a b
sup
g to a b
g.
d
g.
s
u
s
scale i
t be
scale i
ng from
nnot 
ng from
, 0, 25
can
, 0, 25
This documen
Prior
ent
Prior
T
m
T


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 22 of 50 
 
3.8.3 
HADS 
The HADS assessment consists of 14 items that are each scored on a 4-point scale ranging 
from 0 to 3, with a higher score corresponding to worse anxiety or depression. The 
depression and anxiety scores will be calculated by summing the scores for the items 
corresponding to each subscale, as described in the Hospital Anxiety and Depression Scale 
Manual (Snaith and Zigmond, 1994): the depression score is calculated as the sum of all 
even-numbered items; the anxiety score is calculated as the sum of all odd-numbered items. 
Scores for each subscale range from 0 to 21, with higher scores corresponding to a greater 
level of anxiety or depression. 
Missing items will be replaced by the mean of non-missing items from the same subscale 
when calculating the above, provided at least 50% of the items (ie, at least 4 of 7 items) 
within the subscale are present. A subscale score will not be calculated if more than 50% of 
the items are missing within a subscale. This rule applies separately to the subscale scores for 
anxiety and depression; for example, it may be possible to calculate the depression score in 
cases where the anxiety score is not calculated due to non-response. 
3.9 
Subject site transfers 
Subjects may have transferred from one site to another through the course of participation in 
the study. Subjects that transferred from one site to another site, for whatever reason, have 
generally retained their subject number. However, in some cases, the subject number 
changed. When this is true, the most recently assigned subject number will be used for 
analyses and subject data listings. A record of any change in subject numbers will be 
presented in the Section 13.2. 
4 
STATISTICAL/ANALYTICAL ISSUES 
4.1 
Adjustments for covariates 
No statistical testing is planned; therefore, this section is not applicable. 
4.2 
Handling of dropouts or missing data 
Seizure frequency (subjects with POS) and seizure days (subjects with PGS) will be 
calculated over non missing diary days during each study period or time interval as described 
in Section 3.2.4 and Section 3.2.5; diary days for which seizure data were not obtained will 
not be considered in the calculation of seizure frequency or seizure days. Because the 
evaluation of efficacy is not the primary objective of this study, and because this is an 
uncontrolled study in a variable setting, which allows individualized optimization of dosing 
of BRV and concomitant AEDs, no summaries assessing the impact of missing seizure diary 
days are planned. 
For subjects who prematurely discontinue during the Evaluation Period, the calculation of 
POS frequency and PGS seizure days will be based on available seizure diary while the 
subject was receiving BRV. The presence of such dropouts may influence the evaluation of 
the long-term outcomes for subjects who either do not discontinue or do not discontinue early 
in the study. Therefore, as described below, selected summaries will be produced by exposure 
REDACTED COPY 
her
Y
her
to ano
OPY
to ano
ever, i
D CO
ever, i
tly ass
TED 
tly ass
ord of
ACTE
ord of
AN
RE
AN
nnot be used to support any marketing authorization application and any extensions or variations thereof. 
s.
ia
s.
ater 
va
ater 
e subsc
sions
e subsc
of 7 ite
tensi
of 7 ite
more th
exte
more th
the sub
ny e
the sub
the dep
d an
the dep
se.
a
se.
hrough
pplic
hrough
nother s
n app
nother s
in som
tion 
in som
signed
rizat
signed
f any c
thori
f any c
NALY
ting 
NALY
for co
marke
for co
ed; the
any m
ed; the
ng of d
port a
ng of d
subject
supp
subject
on mis
to s
on mis
4 and 
ed t
and S
idered 
e use
idered 
on of ef
t be 
on of ef
ntrolled
nnot 
ntrolled
This document ca
BRV a
cann
BRV a
days a
ent c
days a
Fo
me
Fo


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 23 of 50 
 
duration cohorts to allow an assessment of long-term outcomes without the potentially 
confounding influence of earlier discontinuations. 
4.3 
Interim analyses and data monitoring 
Interim summaries were produced to support regulatory submissions for marketing 
authorization while this study is ongoing. There are no statistical concerns with such interim 
assessments for this study design. 
4.4 
Multicenter studies 
Efficacy and safety outcomes will not be assessed for individual investigator sites due to the 
low expected number for enrollment within each investigator site. 
4.5 
Multiple comparisons/multiplicity 
No statistical testing is planned; therefore, this section is not applicable. 
4.6 
Use of an “Efficacy Subset” of subjects 
All subjects who receive at least 1 dose of study drug and have at least 1 seizure diary day 
during the Evaluation Period will be included in efficacy summaries. Separate Efficacy 
Analysis Sets are defined for subjects with focal epilepsy from N01114, N01252, and 
N01254 and subjects with generalized epilepsy from N01254. 
4.7 
Active-control studies intended to show equivalence 
This section is not applicable for this study. 
4.8 
Examination of subgroups 
Selected summaries will be provided for the following subgroups as specified within each of 
the following sections: 
 Two mappings of countries to regions are defined, 1 based on the classification requested 
by Food and Drug Administration (FDA), and 1 based on the regional classification for 
the CHMP (Committee for Medicinal Products for Human Use). 
Countries will be mapped to geographic regions as follows for the FDA: 
Geographic Region (FDA) Country 
North America 
Canada, United States, Puerto Rico 
Latin America 
Brazil, Mexico 
Western Europe 
Austria, Belgium, Finland, France, Germany, Ireland, 
Italy, Netherlands, Norway, Réunion, Spain, Sweden, 
United Kingdom, Switzerland 
Eastern Europe 
Bulgaria, Czech Republic, Estonia, Latvia, Hungary, 
Lithuania, Poland, Romania, Russia, Serbia and 
Montenegro, Turkey, Ukraine 
Asia/Pacific/Other 
Australia, Hong Kong, India, Israel, Japan, Singapore, 
South Africa, Republic of Korea, Taiwan, Tunisia 
REDACTED COPY 
ilep
Y
ilep
rom N
OPY
rom N
inten
ED C
inten
udy.
ACT
udy.
subg
REDA
subg
d
R
d
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
due to 
ns or
due to 
e at leas
ion a
e at leas
mmari
catio
mmari
y from 
pplic
y from 
N01254
n app
N01254
nded 
ation
nded 
group
g aut
group
d for the
keting
d for the
es to re
ny m
es to re
ministra
t any
ministra
ttee for
port
ttee for
be mapp
sup
be mapp
hic Re
ed to
hic Re
to
Ameri
use
Ameri
ed
n Ame
be u
n Ame
u
Wester
not b
Wester
t b
ca


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 24 of 50 
 
Countries will be mapped to geographic regions as follows for the CHMP: 
Geographic Region 
(CHMP) 
Country 
North America 
Canada, United States, Puerto Rico 
Latin America 
Brazil, Mexico 
Europe (European Union 
[EU] member states) *  
Austria, Belgium, Bulgaria, Czech Republic, Estonia, 
Finland, France, Germany, Hungary, Ireland, Italy, 
Latvia, Lithuania, Netherlands, Norway, Poland, 
Réunion, Romania, Spain, Sweden, United Kingdom 
Europe (non-EU member 
states) 
Russia, Serbia and Montenegro, Switzerland, Turkey, 
Ukraine 
Asia/Pacific/Other 
Australia, Hong Kong, India, Israel, Japan, Singapore, 
South Africa, Republic of Korea, Taiwan, Tunisia 
* EU member states plus Norway. 
 Indication (Partial Onset Seizures, Primary Generalized Seizures, ULD) 
 Randomized treatment in the previous study (placebo [PBO], BRV)  
5 
STUDY POPULATION CHARACTERISTICS 
5.1 
Subject disposition 
Due to differences in data format across studies, in order to facilitate summary of subject 
disposition, the reasons for discontinuation for individual studies will be collapsed as follows 
for summaries: 
LTFU Category 
CRF Reason 
ADVERSE EVENT 
ADVERSE EVENT 
LACK OF EFFICACY 
LACK OF EFFICACY 
LOSS OF EFFICACY 
LOST TO FOLLOW-UP 
LOST TO FOLLOW-UP 
SUBJECT CHOICE 
CONSENT WITHDRAWN 
WITHDRAWAL OF CONSENT FOR PERSONAL 
REASONS NOT RELATED TO AES 
WITHDRAWAL OF CONSENT FOR PERSONAL 
REASONS NOT RELATED TO AES OR LACK OF 
EFFICACY 
OTHER 
PROTOCOL VIOLATION 
OTHER REASON 
OTHER 
 
MISSING 
If subject discontinued the study and the termination CRF is 
not available 
Only 1 primary reason for discontinuation should have been reported. In the event that more 
than 1 reason is specified in the clinical database, both reasons will be summarized and a 
REDACTED COPY
A
PY
ARA
PY 
RA
udies,
TED
udies,
tion fo
ACT
tion fo
RF
R
RF
RE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
ingdom
s or v
ingdom
n
nd, Tur
ons 
nd, Tur
s o
Japan, 
xten
Japan, 
Taiwan
y ex
Taiwan
ns
y 
ures
an
ures, U
nd
, U
BO], B
ation
BO], B
CTER
pplic
CTER
, , in ord
rizat
in ord
for indi
thor
for indi
Reaso
ting
Reaso
g 
DVER
rke
DVER
et
LACK
ma
LACK
ar
LO
y 
LO
y m
an
UP
rt
UP
an
an
an
or
THER
nno
THER
ot
e


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 25 of 50 
 
footnote will be added to the summary table to indicate that at least 1 subject is counted for 
multiple reasons for discontinuation. 
An overall summary of disposition will be provided for all enrolled subjects (ie, all subjects 
who signed informed consent). The following will be summarized: 
 The number of subjects in the Safety Analysis Set 
 The number of subjects excluded from the Safety Analysis Set  
 The number of subjects completed the study 
 The number of subjects discontinued from the study, including the reason for 
discontinuation. If subject discontinued the study and the termination CRF is not 
available, the reason for discontinuation will be reported as “MISSING”. 
Additionally, an overall summary of disposition will present the following for subjects in the 
Safety Analysis Set: 
 The number of subjects completed the study  
 The overall number of subjects discontinued and the number of subjects discontinued by 
primary reason for discontinuation. If subject discontinued the study and the termination 
CRF is not available, the reason for discontinuation will be reported as “MISSING”. 
Overall subject disposition will also be summarized by geographic region and indication for 
the Safety Analysis Set. 
The number of subjects within each geographic region and the number of subjects with each 
indication will be summarized for the Safety Analysis Set. 
Kaplan-Meier estimates of the percentage of subjects completing 3, 6, 12, 24, 36, 48, and 
60 months of treatment with BRV will be provided. This analysis will be based on the 
duration of exposure to BRV as defined in Section 3.2.7. Subjects who have permanently 
discontinued will be analyzed as events on the last day of treatment with study drug; subjects 
who complete the study will be censored on the last day of treatment with study drug.  
The date of first subject in (date of earliest Visit 1), date of last subject out (date of last 
scheduled or unscheduled visit), number of enrolled subjects, and the number of subjects in 
each analysis set or indication will be summarized overall and by investigator site. Subjects 
who transferred sites will be summarized according to their original site. 
Overall summary of disposition will be provided for safety analysis set, in addition, a 
separate overall summary will also be provided for modified safety analysis set. 
5.2 
Protocol Deviations 
The number and percentage of subjects with at least 1 important protocol deviation will be 
summarized overall and by category of protocol deviation for the Safety Analysis Set.  
REDACTED COPY 
sco
Y
sco
nuation
OPY
nuation
marize
ED C
marize
geogra
DAC
geogra
the Sa
RED
the Sa
marketing authorization application and any extensions or variations thereof. 
is not 
nsio
is not 
.
t
.
ing for
ny e
ing for
mber o
catio
mber o
tinued t
pplic
tinued t
n will 
n app
n will 
ed by 
ation
ed by 
n
aphic r
auth
aphic r
afety 
ng a
afety A
entage 
rketi
entage 
V will 
mark
V will 
not be used to support any
as defi
ny m
as defi
zed as 
t any
zed as 
will b
port 
will b
bject in
sup
bject in
chedul
d to s
chedul
set or i
sed 
set or i
erred s
be us
erred s
l summ
not b
l summ
This document can
arate ov
anno
arate ov
5.2
ent c
5.2
Th
m
Th


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 26 of 50 
 
6 
DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS 
For subjects entering the study from N01315, their demographics data including date of birth, 
country, gender, race, and ongoing medication will be transferred into N01125. These data 
will be provided in subject data listing only, but will not be summarized.  
6.1 
Demographics 
Demographics summaries will be based on demographic data from follow-up studies for 
subjects who enrolled in a follow-up study that collected demographic data. Otherwise, 
demographics summaries will be based on demographic data collected in the previous 
double-blind study.  
Age, age category (<17, 17 to <65, and ≥65 years), gender, racial group and overall racial 
group (see below), body weight (kg), height (cm), body mass index (BMI) (kg/m2), and BMI 
category (<18.5, 18.5 to <25, 25 to <30, 30 to <40, ≥40) will be summarized for the Safety 
Analysis Set. Demographic data will be summarized overall and by subgroup for indication 
and geographic region. 
Racial group was not collected in a consistent manner across studies. For this reason, racial 
group will be collapsed as follows for statistical summaries: 
Category 
CRF Racial Group 
American Indian/Alaskan 
Native 
American Indian/Alaskan Native 
Asian 
Asian, Asian/Pacific Islander, Indian/Pakistani 
Black 
Black, African-American  
Native Hawaiian or Other 
Pacific Islander 
Native Hawaiian or Other Pacific Islander 
White 
White, Caucasian, Hispanic 
Other/Mixed 
Other, Other/Mixed, Mixed Race 
moreover, the overall racial group will be collapsed as follows for statistical summaries: 
Category  
Racial Group from Previous Study 
White  
 
White, Caucasian, Hispanic 
Black  
 
Black, African-American 
Asian  
Asian, Native Hawaiian or Other Pacific Islander, Asian/Pacific Islander, 
Indian/Pakistani 
Other  
 
American Indian/Alaskan Native, Other, Other/Mixed 
All subjects should be classified into one of the above categories. 
Racial group, ethnicity (Hispanic or Latino, Not Hispanic or Latino), and racial subgroup 
(Indian/Pakistani, Japanese, Other) were not collected in a consistent manner across all 
studies; these variables will be provided in subject data listings if available in the clinical data 
from the previous study but will not be summarized. 
ED COPY
er
Y
er
umm
OPY 
umm
acial G
D CO
acial G
REDACTE
ican I
TED
ican I
Asian
EDA
Asian
Bl
RE
Bl
ation application and any extensions or variations thereof. 
for 
r v
for 
wise,
s or
wise,
evious
ions
evious
and 
ex
and ove
exte
ove
MI
ny
MI)
ny
) (k
y
(k
mmar
d a
mmariz
a
iz
by sub
n an
by sub
ross stu
plica
ross stu
aries:
app
aries:
Group
ation
Group
nnot be used to support any marketing authoriz
Indian
rizat
Indian
n, Asia
aut
n, Asia
lack, A
ting a
lack, A
Nativ
ketin
Nativ
racial g
ppor
racial g
Racia
to su
Racia
Wh
d to
Wh
B
d
B
This document can
Other
anno
Other
All sub
ent c
All sub
Ra
me
Ra


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 27 of 50 
 
6.2 
Medical and procedure history 
6.2.1 
Medical history diseases 
The summary of medical history will be based on the medical history at the time of entry into 
the previous studies.  
The number and percentage of subjects with a medical history condition, including both 
resolved and ongoing conditions at the time of entry into the previous studies, will be 
summarized overall and by primary MedDRA system organ class (SOC) and preferred term 
(PT) for the Safety Analysis Set. 
6.2.2 
Procedure history and concomitant procedures 
Medical procedures are not coded and will only be provided in subject data listings. 
6.3 
History of epilepsy 
All of the following are summarized using data collected at the time of entry into the previous 
studies or from the Baseline Period of the previous studies. 
6.3.1 
Etiology of epilepsy 
The number and percentage of subjects with each type of etiology as specified on the CRF 
(genetic, congenital, etc) from the previous studies will be summarized for the Efficacy 
Analysis Sets for POS and PGS. A subject will be counted as having a particular etiology if 
that etiology was either confirmed or suspected based on the investigator's assessment. 
6.3.2 
Epileptic seizure profile 
The number and percentage of subjects experiencing each seizure type at any time prior to 
study entry will be summarized for the Efficacy Analysis Sets for POS and PGS. The 
following seizure types will be summarized: I, IA, IA1 through IA4, IB, IB1, IB2, IC, II, IIA 
through IIF, III. A subject with a history of a more specific seizure type will be counted in all 
higher levels of seizure types (eg, a subject with a history of IB1 seizures will be counted for 
seizure types I, IB, and IB1). 
6.3.3 
Classification of epileptic syndrome 
The number and percentage of subjects with each epileptic syndrome will be summarized for 
the Efficacy Analysis Sets for POS and PGS. This summary will include the number and 
percentage of subjects within the following categories: localization-related epilepsy; 
idiopathic, symptomatic, and cryptogenic localization-related epilepsy; generalized epilepsy; 
and idiopathic, symptomatic, and cryptogenic generalized epilepsy. 
6.3.4 
Focus localization 
The number and percentage of subjects with each category of focus localization (unknown, 
frontal, temporal, parietal, occipital) will be summarized for the Efficacy Analysis Set for 
POS. Subjects may be counted in more than 1 category of focus localization. A category for 
no available data will be included in the summary to account for subjects from N01114 since 
REDACTED COPY
ype 
PY 
ype 
ies wi
COPY
ies wi
ill be 
D CO
ill be 
ected 
TED
ected 
ofile
DAC
ofile
jects 
RED
jects 
h
R
h
port any marketing authorization application and any extensions or variations thereof. 
term
varia
term
listing
xtens
listing
e of en
nd a
e of en
of etiolo
pplic
of etiolo
ill be s
n ap
ill be s
counte
ation
counte
based 
rizat
based 
 exper
ing a
 exper
the Eff
ketin
the Eff
ummari
mark
ummari
h a hist
y m
h a hist
es (eg,
t any
es (eg,
not be used to suppo
B1).
port
B1).
sific
supp
sifica
pp
a
d percen
d to 
d percen
Analys
used
Analys
e of sub
be u
e of sub
hic, sym
ot be
hic, sym
This document can
idiopat
anno
idiopat
6.3.4
nt ca
6.3.4
Th
me
Th


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 28 of 50 
 
focus localization was not obtained for subjects from N01114. Percentages will still be out of 
the full POS Efficacy Analysis Set, including subjects from N01114. 
6.3.5 
History of epileptic seizures 
History of epileptic seizures, including the number and percentage of subjects with a history 
of status epilepticus and quantitative summaries of epilepsy duration, age at onset of first 
seizure, and percent of life with epilepsy, will be summarized for the Efficacy Analysis Sets 
for POS and PGS. 
6.3.6 
Seizure types experienced during baseline of the previous study 
The number and percentage of subjects experiencing each seizure type during the Baseline 
Period will be summarized for the Efficacy Analysis Sets for POS and PGS based on the 
Baseline seizure diary data from the previous studies. The following seizure types will be 
summarized: I, IA, IB, IC, II, and IIA through IIF. 
Subjects will be counted for all higher levels of seizure type categories corresponding to the 
seizure types or seizure sub-types reported on the CRF. 
6.4 
Medications 
Medications recorded on the Concomitant Medications CRF and the Concomitant 
Medications (AEDs only) CRF will be classified as either AEDs or non-AEDs based on the 
preferred drug name search criteria, which are documented outside of the SAP. 
 The medication is not an AED if it does not meet the search criteria based on preferred 
drug name, regardless of which CRF is used for reporting the medication. However, 
further review will be performed for medications that are recorded on the Concomitant 
Medications (AEDs only) CRF but are not included in the AEDs search criteria; 
 For non-benzodiazepine medications, if the medication meets the search criteria for an 
AED based on preferred drug name, then the medication will be classified as an AED 
regardless of indication and regardless of which CRF the medication is recorded on; 
 For benzodiazepines (identified using the search criteria), if the benzodiazepine is 
recorded on the Concomitant Medications (AEDs only) CRF, then the benzodiazepine 
will be classified as an AED; 
 For benzodiazepines (identified using the search criteria), if the benzodiazepine is 
recorded on the Concomitant Medications CRFs, then the benzodiazepine will not be 
classified as an AED.  
After medications are classified as AEDs or non-AEDs, the standard date imputation 
algorithms for start and stop date of the medication and first dose and last dose of BRV in the 
study will be applied. If an AED was taken at any time during dosing with BRV, then the 
AED is classified as a concomitant AED. 
REDACTED COPY
ions
PY 
ions
d as ei
COPY
d as ei
e docu
D CO
e docu
oes no
CTE
oes no
RF is 
DAC
RF is 
ed for 
RED
ed for 
bu
R
bu
rketing authorization application and any extensions or variations thereof. 
s 
a
s 
study
or v
study
e Base
ions
e Base
ased o
nsio
ased o
re type
exte
re type
ries co
nd a
ries co
CRF an
ppli
CRF an
either A
n ap
either A
cument
ation
cument
ot mee
horiz
ot mee
used f
autho
used f
r medic
ng au
r medic
ut are n
keting
ut are n
e used to support any ma
dication
mark
dication
drug
ny m
drug na
m
na
n and re
t any
n and re
es (ide
ppo
es (ide
Conco
sup
Conco
fied as
d to 
fied as
zodiaze
use
zodiaze
This document cannot b
ded on 
be u
ded on 
ssifie
not b
ssified
b
d
ter me
can
ter me
algori
ent c
algori
stu
me
stu


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 29 of 50 
 
6.4.1 
Non-AEDs taken at study entry 
The number and percentage of subjects taking non-AED medications at study entry for the 
previous double-blind study will be summarized by WHO-DRL primary therapeutic group 
(Anatomic Therapeutic Class [ATC] level 1), therapeutic subgroup (ATC level 2), and 
preferred drug name for the Safety Analysis Set. 
6.4.2 
Number of previous AEDs 
The number and percentage of subjects taking an AED prior to entry into the previous study 
will be summarized by WHO-DRL preferred drug name for the POS and PGS Efficacy 
Analysis Sets based on the following categorization: 0-1 AEDs, 2-4 AEDs, and ≥5 AEDs.
6.4.3 
History of previous AED use 
The number and percentage of subjects who had taken at least 1 AED prior to entry into the 
previous study will be summarized overall and by WHO-DRL preferred drug name for the 
POS and PGS Efficacy Analysis Sets. 
6.4.4 
AEDs taken at study entry 
The number and percentage of subjects taking AEDs at study entry for the previous double-
blind study will be summarized by WHO-DRL preferred drug name for the POS and PGS 
Efficacy Analysis Sets.  
6.4.5 
Concomitant AEDs 
A concomitant AED is an AED which was taken during administration of BRV, regardless of 
the start and stop date of the AED. The number and percentage of subjects taking 
concomitant AEDs will be summarized by WHO-DRL preferred drug name for the POS and 
PGS Efficacy Analysis Sets. 
7 
MEASUREMENTS OF TREATMENT COMPLIANCE 
Study drug compliance will not be assessed due to the complexities associated with the 
calculation and interpretation of study drug compliance for this study. Study drug dosing will 
be provided in subject data listings. 
8 
EFFICACY ANALYSES 
In general, all study outcomes based on seizure frequency will be summarized for the 
Efficacy Analysis Set for POS and all study outcomes based on seizure days will be 
summarized for the Efficacy Analysis Set for PGS. No efficacy summaries are provided for 
ULD subjects or subjects entering the study from N01315. 
The derivations of 28-day adjusted seizure frequency and 28-day adjusted seizure days are 
described in detail in Section 3.8.1.2 and Section 3.8.1.3, respectively. 
All summaries of efficacy data are descriptive; no statistical testing will be performed. 
8.1 
Statistical analyses of secondary efficacy variables 
The following variables are summarized for the Efficacy Analysis Set for POS. 
REDACTED COPY
ferre
PY 
ferre
was tak
ACTE
was tak
he num
EDAC
he num
rized 
RED
rized 
t any marketing authorization application and any extensions or variations thereof. 
stu
va
study 
varia
dy 
acy 
or
acy 
5 AED
ns o
5 AED
or to e
ext
or to e
ed drug
any 
ed drug
dy entr
icati
dy entr
d drug 
pplic
d drug 
aken du
thori
aken du
umber a
auth
umber a
d by W
ing a
d by W
ENTS
mar
ENTS
l not be
t any
l not be
This document cannot be used to suppo
ation o
port 
ation o
t data l
uppo
t data l
FFICA
to s
FFICA
ll study
used
ll study
Analys
be u
Analys
arized f
not b
arized f
D subje
anno
D subje
The de
nt c
The de
des
men
des


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 30 of 50 
 
8.1.1 
Partial onset seizure frequency 
Twenty-eight day adjusted POS frequency will be summarized with quantitative descriptive 
statistics for all subjects for the Baseline Period, the On Treatment Period, and by 3-month 
time intervals over the On Treatment Period. The summary over the On Treatment Period 
will include all subjects in the POS Efficacy Analysis Set. Similar summaries will be 
provided for the full cohort interval and by 3-month time intervals for each exposure duration 
cohort.  
8.1.2 
Percent reduction in POS frequency 
Percent reduction in POS frequency from Baseline to the On Treatment Period will be 
calculated as follows, where On Treatment Period Frequency is the 28-day adjusted POS 
frequency during On Treatment Period and Baseline Period Frequency is the 28-day adjusted 
POS frequency during the Baseline Period of the previous study.  
 
Frequency
 
Period
 
Baseline
Frequency
 
Period
Treatment 
On 
Frequency
 
Period
 
Baseline
100
Reduction
 
%



 
A similar calculation applies to each 3-month time interval over the On Treatment Period and 
for the cohort interval for each exposure duration cohort. 
Percent reduction from Baseline for POS frequency will be summarized with quantitative 
descriptive statistics for the On Treatment Period, and by 3-month time intervals over the On 
Treatment Period. The summary over the On Treatment Period will include all subjects in the 
POS Efficacy Analysis Set. Similar summaries will be provided for the full cohort interval 
and by 3-month time intervals for each exposure duration cohort. Percent reduction from 
Baseline for POS frequency will be summarized in the same manner by geographic region. 
8.1.3 
Responder outcome for POS frequency 
Responders over the On Treatment Period are defined as subjects with a 50% or greater 
reduction in 28-day adjusted POS frequency from Baseline to the On Treatment Period. 
A similar calculation applies to each 3-month time interval over the On Treatment Period and 
for the cohort interval for each exposure duration cohort. 
The number and percentage of responders for POS frequency will be summarized for the On 
Treatment Period, and by 3-month time intervals over the On Treatment Period. The 
summary over the On Treatment Period will include all subjects in the POS Efficacy Analysis 
Set. Similar summaries will be provided over the full cohort interval and by 3-month time 
intervals for each exposure duration cohort. Responder rates for POS frequency will be 
summarized in the same manner by geographic region. 
8.2 
Analysis of other efficacy variables  
8.2.1 
Subjects with partial onset seizures 
All of the following variables are summarized for the Efficacy Analysis Set for POS.
REDACTED COPY 
ho
Y
ho
ncy w
COPY
ncy w
riod, a
D CO
riod, a
On Tr
TED
On Tr
mmari
ACT
mmari
ach exp
EDA
ach exp
e sum
RE
e sum
be used to support any marketing authorization application and any extensions or variations thereof. 
n
i
n
ll be
ns o
ll be 
usted P
nsion
usted P
e 28
xten
e 28-
n
-da
ns
da
d
ency
and
ency
Period
d any
Period
ver the
atio
ver the
will be 
n ap
will be 
and by
ation
and by
reatme
rizat
reatme
ies wil
thor
ies wil
xposure
aut
xposure
mmariz
ting a
mmariz
ome
rke
ome fo
t
fo
ment 
y m
ment P
d POS
t any
d POS
pli
po
plies to
ort 
es to
l for ea
uppo
l for ea
percent
d to s
percent
iod, an
sed t
iod, an
ver the
e use
ver the
This document cannot b
lar sum
t be 
lar sum
vals for
nnot 
vals for
mmariz
cann
mmariz
8.2
ent
8.2
8
m
8


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 31 of 50 
 
8.2.1.1 
Specified Month seizure freedom 
The numbers and percentages of subjects who are seizure free for all seizure types for any 
continuous 6-month interval, 12-month interval, 18-month interval, and so forth will be 
summarized overall for the period of time that subjects are being treated with BRV and by 
Exposure Duration Cohort. The overall summary will present the number and percentage of 
subjects who reported no seizures for the specified duration of seizure freedom and the 
seizure diary was completed for at least 90% of days within the seizure-free interval. Subjects 
whose duration of BRV treatment was less than the specified duration of seizure freedom will 
be considered failures for seizure-freedom. Summaries by exposure duration cohort will 
present the number and percentage of subjects who reported no seizures for the specified 
duration of seizure freedom at any time during the cohort interval (eg, through the end of 
Month 6 for the 6-month cohort) and the seizure diary was completed for at least 90% of days 
within the seizure-free interval. Percentages are relative to the number of subjects within each 
Exposure Duration Cohort.  
A subject is seizure free for a 6-month interval if the subject did not report any seizures in the 
6-month interval and the seizure diary was completed for at least 90% of days within the 
seizure-free interval. The percentage of days for which seizure diary was completed within a 
given 6-month interval will be calculated as follows based on a 30-day month: 
% of days diary was done = 100 × [180 −number of days diary was not done in the interval
180
]  
A similar calculation applies for 12-month seizure freedom based on 360 days, 18-month 
seizure freedom based on 540 days, and so forth. 
8.2.2 
Subjects with Primary Generalized Seizures 
The following variables are summarized for the Efficacy Analysis Set for PGS. 
8.2.2.1 
All type seizure days 
Twenty-eight day adjusted all other type seizure days will be summarized with quantitative 
descriptive statistics in the same manner as 28-day adjusted POS frequency. 
8.2.2.2 
Percent reduction in all type seizure days 
Percent reduction in all other type seizure days from Baseline will be calculated in the same 
manner as percent reduction in POS frequency as described in Section 8.1.2. This variable 
will be summarized in the same manner as percent reduction in POS frequency. 
8.2.2.3 
Responder outcome for all type seizure days 
Responder outcome for all other type seizure days will be derived in a manner similar to the 
responder outcome for POS frequency as described in Section 8.1.3. This variable will be 
summarized in the same manner as 50% responder outcome for POS frequency. 
8.2.2.4 
Specified month seizure freedom 
Specified month seizure freedom for subjects in the PGS Efficacy Analysis Set will be 
derived in a manner similar to specified month seizure freedom for the POS Efficacy 
REDACTED COPY 
s ba
Y
s ba
ber of 
COP
ber of 
CO
th seiz
CTE
th seiz
nd so f
DAC
nd so f
imar
RED
imar
nt cannot be used to support any marketing authorization application and any extensions or variations thereof. 
ects
riatio
ects 
m wil
vari
m wil
will
or v
will
pecifie
ons 
pecifie
h the en
nsio
h the en
t least 
xten
t least 
f subje
y ex
f subje
not rep
and
not rep
ast 90%
tion a
ast 90%
ure dia
icatio
ure dia
ed on a
pplic
ed on a
days di
n ap
days di
on
zure fr
horiza
zure fr
forth.
utho
forth.
ry Gen
ing a
ry Gen
arized f
rket
arized f
re 
y m
re day
ma
day
all oth
rt any
all oth
the sam
port
the sam
cent re
sup
cent re
on in
d to
on in a
o
a
ercent r
use
ercent r
ummari
be u
ummari
.3
n
.3
Respond
t ca
Respond
This documen
respo
ment
respo
su
m
su


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 32 of 50 
 
Analysis Set as described in Section 8.2.1.1. This variable will be summarized in the same 
manner as specified month seizure freedom for subjects in the POS Efficacy Analysis Set. 
8.2.3 
QOLIE-31-P 
The scoring algorithm for QOLIE-31-P is described in Section 13.1. QOLIE-31-P will be 
summarized for the POS and PGS Efficacy Analysis Sets. No summaries of QOLIE-31-P will 
be provided for subjects with ULD. QOLIE-31-P was to be assessed at Months 2, 6, 12, 18, 
and 24 during the first 2 years of the Evaluation Period for subjects from N01252 and 
N01254, and assessments at Months 3, 6, 12, 18, and 24 during the first 2 years of the 
Evaluation Period for subjects from N01114. Additionally, QOLIE-31-P was to be assessed 
at EDVs. The limited number of assessments obtained at Month 3 for N01114 will not be 
summarized but will be provided in subject data listings. Prior to Protocol Amendment 25, 
QOLIE-31-P may have been assessed for more than 2 years after study entry for some 
subjects. These additional assessments will not be summarized but will be provided in subject 
data listings. 
Observed values for QOLIE-31-P total score and subscale scores for Seizure Worry, Daily 
Activities/Social Function, Energy/Fatigue, Emotional Well-Being, Cognitive Function, 
Medication Effects, Overall Quality of Life, and Health Status will be summarized for 
Months 2, 6, 12, 18, and 24 and Last Value for the Efficacy Analysis Sets for POS and PGS. 
For each time point, summary statistics will be presented for the baseline scores for subjects 
with a change from baseline at the time point in addition to summaries of the observed values 
and changes from baseline at each time point. Only subjects with a non-missing change from 
baseline will be summarized at each time point. 
The above scores will be also summarized for the 6-Month, 12-Month, 18-Month, and 
24-Month Study Visit Cohorts, including summaries of the baseline scores for all subjects 
within each study visit cohort and summaries of observed values and changes from baseline 
for each time point for each study visit cohort. 
Similar summaries will be provided for QOLIE-31-P distress items Seizure Worry, Daily 
Activities/Social Function, Energy/Fatigue, Emotional Well-Being, Cognitive Function, 
Medication Effects, Overall Quality of Life. Only subjects with a non-missing change from 
baseline will be summarized at that time point. 
The rankings of prioritization items (Seizure Worry, Daily Activities/Social Function, 
Energy/Fatigue, Emotional Well-Being, Cognitive Function, Medication Effects, and Overall 
Quality of Life) will be summarized at the same time points as above and for all subjects and 
by study visit cohort as defined above. Changes from baseline will not be summarized, and 
only the numbers of subjects and sample means will be presented. 
8.2.4 
EQ-5D 
EQ-5D (EuroQol Group, 2000) will be summarized for the POS and PGS Efficacy Analysis 
Sets. No summaries of EQ-5D will be provided for subjects with ULD. EQ-5D was to be 
assessed at Months 2, 6, 12, 18, and 24 during the first 2 years of the Evaluation Period for 
subjects from N01252 and N01254. Additionally, QOLIE-31-P was to be assessed at EDVs. 
REDACTED COPY
e Effi
OPY 
e Effi
prese
COP
prese
nt in ad
ED C
nt in ad
oint. O
CTED
oint. O
me po
DACT
me po
mariz
RED
mariz
R
not be used to support any marketing authorization application and any extensions or variations thereof. 
o
assess
s or
assess
will not
ions
will not
mendm
ensi
mendm
ntry for
exte
ntry for
 be pro
ny e
 be pro
s f
n a
s for S
n an
or S
fo
f
n a
fo
f
Being,
ation
Being,
tatus w
plicat
tatus w
cacy 
appl
cacy A
pl
A
ented fo
on ap
ented fo
addition
zatio
addition
Only s
oriza
Only s
oint.
utho
oint.
z
n
zed for
ng a
ed for
uding s
keting
uding s
d summ
marke
d summ
udy vis
y ma
udy vis
provid
rt any
provid
ion, En
port
ion, En
Overal
supp
Overal
ummar
to s
ummar
of prio
used
of prio
tigue, E
be us
tigue, E
of Life
ot be
of Life
This document can
udy vi
nno
udy vi
nly the 
t can
nly the 
8.2.
men
8.2.


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 33 of 50 
 
EQ-5D was not routinely assessed for subjects from N01114. Prior to Protocol Amendment 
25, EQ-5D may have been assessed for more than 2 years after study entry for some subjects. 
These additional assessments will not be summarized but will be provided in subject data 
listings. 
EQ-5D dimensions will be summarized for Months 2, 6, 12, 18, and 24 and Last Value for 
the Efficacy Analysis Sets for POS and PGS. The number and percentage of subjects with 
each response will be summarized for each dimension and time point. Percentages will be 
relative to the number of subjects with a response to the dimension at that time point. 
Additionally, for each dimension and time point, the number and percentage of subjects with 
each response will be summarized for baseline for subjects with an observed response at that 
time point. Additionally, each dimension will be summarized for the 6-Month, 12-Month, 18-
Month, and 24-Month Study Visit Cohorts, including summaries for baseline for all subjects 
within each cohort and summaries of observed responses for all time points for each cohort.
Observed values for the EQ-5D visual analog scale (VAS) score will be summarized for 
Months 2, 6, 12, 18, and 24 and Last Value for the Efficacy Analysis Sets for POS and PGS. 
For each time point, summary statistics will be presented for the baseline VAS score for 
subjects with a change from baseline at the time point in addition to summaries of the 
observed values and changes from baseline at each time point. Only subjects with a non-
missing change from baseline will be summarized at each time point. 
EQ-5D VAS score will also summarized for the 6-Month, 12-Month, 18-Month, and 
24-Month Study Visit Cohorts, including summaries of the baseline scores for all subjects 
within each study visit cohort and summaries of observed values and changes from baseline 
for each time point for each study visit cohort. 
8.2.5 
Direct cost parameters 
Direct costs data are collected based on concurrent medical procedures, healthcare provider 
consultations not foreseen by protocol, hospital stays, and ER visits. All direct cost 
parameters will be not summarized but will be provided in subject data listings.  
8.2.6 
Indirect cost parameters 
8.2.7 
The number of school or working days lost will not be 
summarized but will be provided in subject data listings. Socio-
professional data 
Socio-professional data is collected at Month 12 and Month 24 and at EDVs. Prior to 
Protocol Amendment 25, socio-professional data may have been collected for more than 
2 years after study entry for some subjects. These additional assessments will not be 
summarized but will be provided in subject data listings. Socio-professional data are not 
collected for subjects from N01114 and subjects with ULD. 
9 
PHARMACOKINETICS AND PHARMACODYNAMICS 
Plasma samples for BRV and concomitant AEDs and antimyoclonic drugs (AMDs) will no 
longer be obtained, as directed by the integrated protocol amendment 25. No summaries of 
REDACTED COPY
tim
PY 
tim
ed at e
COPY
ed at e
the 6
ED C
the 6
summ
CTED
summ
mmarie
DACT
mmarie
visit co
REDA
visit co
R
annot be used to support any marketing authorization application and any extensions or variations thereof. 
ects wi
or v
ects wi
ponse a
ons 
ponse a
, 12
nsio
, 12-
si
-M
o
M
ne for a
xten
ne for a
ints for
y ex
ints for
ll be su
d an
ll be su
ysis Se
and
ysis Se
he base
tion a
he base
ddition 
icatio
ddition 
point. 
pplic
point. 
each tim
n app
each tim
-
a
-Mont
atio
Mont
maries 
oriza
maries 
es of o
utho
es of o
ohort.
g au
ohort.
eters
keting
eters
ased on
mar
ased on
protoc
ny m
protoc
mmariz
t any
mmariz
ct cos
ppo
ct cos
e num
to su
e num
summ
ed to
summ
pro
use
pro
rofessio
ot be
rofessio
col
nno
col A
ot
Am
t
m
This document c
years a
can
years a
summ
ent c
summ
col
me
col


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 34 of 50 
 
BRV or concomitant AED/AMD plasma levels will be provided; plasma levels will only be 
provided in subject data listings. 
10 
IMMUNOLOGICAL PROCEDURES 
This section is not applicable for this study. 
11 
SAFETY ANALYSES 
Safety is assessed with AEs, laboratory tests (blood chemistry, hematology, urinalysis, and 
pregnancy test), vital signs, body weight, ECGs, physical examination, neurological 
examination, mental status, and psychiatric status. Summary tables will be provided for AEs; 
blood chemistry, hematology, and urinalysis; vital signs; body weight; and ECGs. No 
summary tables will be provided for pregnancy testing, physical examination, neurological 
examination, mental status, or psychiatric status. 
All safety summaries will be based on the Safety Analysis Set. 
For subjects entering from N01315, their ongoing AEs will be transferred into N01125, and 
their safety assessments will be provided in subject data listings only, no summaries will be 
presented. 
 
11.1 
Extent of exposure 
A daily dose will be calculated for each study day from the day of first dose of BRV to the 
day of last dose of BRV for the purposes of calculating modal dose. Daily dose will be 
calculated as the sum of the AM and PM dose for each day. 
Modal daily doses will be calculated across all study days on or after the day of first dose of 
BRV and up to and including the day of last dose of BRV. Modal daily dose is the most 
frequently taken daily dose during this period. In the event of a tie, the modal dose will be set 
to the lower of the tied doses. Modal daily dose will be categorized as follows: 
 
 
Category  
 
Definition 
5 mg/day  
 
<20mg/day 
20mg/day         
≥20mg/day to <50mg/day  
50mg/day  
 
≥50mg/day to <100mg/day 
100mg/day 
 
≥100mg/day to <150mg/day 
150mg/day 
 
≥150mg/day to <200mg/day 
200mg/day 
 
≥200mg/day 
Subject years of exposure will be calculated by summing the exposure duration in days for all 
subjects being summarized, and dividing the resulting value by 365.25. 
Subject years of exposure will be presented overall and by modal dose for the Safety 
Analysis Set. The subject years of exposure presented by modal dose will be the total subject 
years of exposure of subjects with that modal dose. 
REDACTED COPY 
tudy d
CTED
tudy d
es of 
DACT
es of 
d PM 
REDA
d PM 
d
R
d
y marketing authorization application and any extensions or variations thereof. 
and 
ari
and 
ed for A
ns o
ed for A
Gs. No
sion
Gs. No
n, neur
tens
n, neur
ansferre
and
ansferre
gs only
tion a
gs only
day fro
oriza
day fro
calcul
utho
calcul
dose f
g au
dose f
across
keting
across
day of 
arke
day of 
ring thi
y ma
ring thi
cannot be used to support any
s. Mod
any 
. Mod
Def
port
Def
y       
d to 
y       
/day
sed
/day
0mg/da
be us
0mg/da
150mg
ot be
150mg
200m
nnot
200m
This document
Subject
nt ca
Subject
subj
men
subj


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 35 of 50 
 
The number and percentage of subjects exposed to BRV will be summarized overall and by 
modal dose category. The number and percentage of subjects in each Exposure Duration 
Cohort (≥3 months, ≥6 months, ≥12 months, and so forth) will be summarized. 
The number and percentage of subjects within each modal dose category will be summarized 
for each Exposure Duration Cohorts; percentages will be relative to the total number of 
subjects in each Exposure Duration Cohort. 
In addition to the overall summaries of the above, the above will also be summarized by 
subgroup for region (North America, Europe [EU member states], Europe [non-EU member 
states], Asia/Pacific/Other), and by indication (Partial Onset Seizures, Primary Generalized 
Seizures, ULD). 
11.2 
Adverse events 
11.2.1 
Definition of treatment-emergent AE 
AEs will be classified as either pre-study or treatment-emergent. Pre-study AEs are defined 
as AEs which had onset prior to the date of the first dose of BRV. TEAEs are defined as AEs 
that had onset on or after the day of first BRV dose. AEs with an incomplete onset date will 
be classified as TEAEs if the month and year of onset (when only the month and year are 
specified) is the same as the month and year of the first BRV dose or the year of onset (when 
only year is specified) is the same as the year of first BRV dose. 
11.2.2 
General summaries of TEAEs 
Pre-treatment AEs will be provided in a subject data listing; no summaries of pre-treatment 
AEs are planned. 
An overall summary of AEs will provide the overall number of TEAEs and the numbers and 
percentages of subjects with at least 1 TEAE, with a TEAE that led to permanent 
discontinuation of study drug, with a drug-related TEAE, with a severe TEAE, with a 
treatment-emergent SAE, and with a drug-related treatment-emergent SAE. The number and 
percentage of subjects who died will also be summarized. This summary will be provided for 
all subjects in the Safety Analysis Set and also by subgroup for geographic region and 
indication. 
The following summaries of TEAEs will be provided by MedDRA SOC and PT. All 
summaries are for the combined Evaluation, Down-Titration, and Post-Treatment Periods 
unless otherwise indicated. 
Overall Incidence Summaries 
 Incidence of TEAEs 
 Incidence of TEAEs by 3-month time interval 
 Incidence of TEAEs by study period (Evaluation, Down-Titration, Post-Treatment) 
 Incidence of TEAEs for TEAEs occurring in at least 5% of subjects 
REDACTED COPY
e first
PY 
e first
f first 
COP
f first 
EAEs
ED C
EAEs
a subj
ACT
a subj
rov
R
rov
used to support any marketing authorization application and any extensions or variations thereof. 
ember
r va
ember
neralize
s or
neralize
re
n
re-
d
-stud
nd a
stud
V. TEA
n an
V. TEA
h an inc
ation
h an inc
en only
licat
en only
BRV d
appl
BRV d
t BRV 
on ap
t BRV 
s
z
s
ject da
thor
ject da
vide th
eting
vide th
st 1
ark
st 1 TE
ke
TE
with a
ma
with a d
nd wit
any 
nd with
y
h
ho died
ort a
ho died
ty 
p
ty Ana
ppo
Ana
summa
ed to
summa
re for t
use
re for t
This document cannot be
erwise
be u
erwise
all Inci
not
all Inci
Inci
t ca
Inci

me



UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 36 of 50 
 
 Incidence of TEAEs by 3-month time intervals for TEAEs occurring in at least 5% of 
subjects overall 
 Incidence of non-serious TEAEs occurring in at least 5% of subjects 
The incidence of TEAEs occurring in at least 5% of subjects will be summarized overall as 
noted above and also by subgroup for geographic region, indication, and randomized 
treatment from the previous double-blind study. 
A subject is included in a 3-month interval if the subject was receiving BRV at any time 
during that interval based on their duration of exposure to BRV (eg, a subject with exposure 
for 91 days is included in the time interval for Months 1-3 and Months 4-6). Summaries of 
AEs by 3-month intervals will include all subjects who are classified into each time interval 
as defined above. TEAEs which had onset prior to or on the date of the last dose of BRV are 
included in summaries by 3-month time intervals. 
Maximum Intensity and Causality 
 Incidence of TEAEs by maximum intensity 
 Incidence of drug-related TEAEs 
Serious Adverse Events 
 Incidence of treatment-emergent SAEs 
Discontinuations due to TEAE 
 Incidence of TEAEs leading to permanent discontinuation of study drug 
TEAEs of interest 
AEs of interest will be identified based on MedDRA search criteria, which are documented 
outside of the SAP.  The following summaries will be provided for AEs of interest: 
 Incidence of TEAEs of interest 
 Incidence of TEAEs of interest by 3-month time interval 
For the summary by maximum intensity, each subject will be counted at most once per SOC 
or PT according to the maximum intensity of all AEs within that SOC or PT. Severe intensity 
will be assumed for AEs for which intensity is not specified. 
Drug-related AEs are AEs for which the relationship to study drug is specified as Related or 
AEs for which relationship is not specified. 
11.3 
Clinical laboratory evaluations 
Clinical laboratory parameters (blood chemistry, hematology, urinalysis) are assessed at all 
FEVs, YEVs, EDVs, and at FV, and may also be assessed at Unscheduled Visits. 
For subjects entering the study from N01315, the clinical laboratory assessments will be 
provided in subject data listings only. The baseline assessment of these subjects will not be 
carried over from the previous studies. 
REDACTED COPY 
ermane
DAC
ermane
be used to support any marketing authorization application and any extensions or variations thereof. 
me
v
me
xposur
or v
xposur
mmaries
ons 
mmaries
h time i
nsio
h time i
dose o
xten
dose o
nent dis
auth
nent dis
ased o
arke
ased o
wing su
ma
wing su
inte
t an
intere
ny
re
s
p
s of in
ppor
of in
by max
to su
by max
g to the
ed to
g to the
This document cannot b
med
use
med for
ed
for
ated A
t be 
ated A
for whi
nnot 
for whi
1.3
t ca
1.3
Clin
men
Clin
F
m
F


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 37 of 50 
 
11.3.1 
Hematology and blood chemistry parameters 
Observed values for each planned hematology and blood chemistry parameter will be 
summarized for Baseline, Study Entry, and each scheduled visit during the Evaluation Period 
for which laboratory parameters were assessed, Last Value, EDV, and FV. Change from 
Baseline will be summarized for all post-Baseline time points including EV. Only laboratory 
parameters planned per protocol will be summarized; results for laboratory parameters not 
planned per the protocol will only be provided in subject data listings. 
The number and percentage of subjects with an on-treatment potentially clinically significant 
treatment-emergent (PCST) value, PCST low value, and PCST high value will be 
summarized. This summary will consider all assessments after the first dose of BRV and 
prior to or on the date of the last dose of BRV.  
Additionally, the number and percentage of subjects with a PCST value, PCST low value, 
and PCST high value will be summarized for Baseline, Study Entry, each visit during the 
Evaluation Period for which laboratory parameters were scheduled to be assessed, EDV, Last 
Value, and FV. Percentages for each parameter and time point will be relative to the number 
of subjects with a value at that time point. 
PCST criteria (Sections 13.3.1 and 13.3.2)  are based on FDA Division of 
Neuropharmacologic Drug Products guidelines with some UCB-defined additions. 
Creatinine clearance, when available from the central laboratory, will be provided in subject 
data listings only and will not be summarized. 
11.3.2 
Macroscopic urinalysis 
Quantitative urinalysis parameters will be summarized in the same manner as hematology 
and blood chemistry parameters. Response categories are negative, 1+, 2+, and 3+ for the 
qualitative urinalysis parameters occult blood, leukocytes, glucose, protein, and ketones and 
negative and positive for nitrates. Outcome values for these parameters are mapped to the 
levels Negative, 1+, 2+, and 3+ as follows for purposes of summary tables and the 
determination of PCST: 
Category 
Definition 
Negative 
“Negative”, “NEGATIVE”, or other outcomes that clearly reflect a negative 
finding 
1+ 
“1+”, “+” , “Trace”, “TRACE”, or other outcomes that clearly reflect trace 
amount 
2+ 
“2+” or “++” 
3+ 
“3+”, “+++”, or other outcomes that clearly reflect the data above 3+ (eg, 
“4+”, “5+” etc) or more than 4 plus signs (eg, “++++”, “+++++”etc) 
For qualitative urinalysis parameters (occult blood, leukocytes, glucose, protein, ketones, and 
nitrates), the number and percentage of subjects with each response category will be 
summarized for Baseline, Study Entry, each scheduled visit during the Evaluation Period for 
REDACTED COPY 
d o
Y
d o
with so
OPY
with so
e cent
D C
e cent
ized.
CTED
ized.
lysis
DAC
lysis
will 
RE
will 
marketing authorization application and any extensions or variations thereof. 
nifican
or va
nifican
BRV a
sions
BRV a
PCST 
y ext
PCST 
each vi
any 
each vi
to be a
nd a
to be a
will be 
n an
will be 
FDA D
plic
FDA D
ome U
n app
ome U
ntral lab
ation
ntral lab
l be sum
ting a
l be sum
esponse
ketin
esponse
occult
mark
occult
This document cannot be used to support any
tes. Ou
ny m
tes. Ou
d 3
t a
d 3+ as
any
+ as
nition
supp
nition
“Negat
ed to
“Negat
find
used
find
2+
t ca
2+
3+
n
3+


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 38 of 50 
 
which urinalysis parameters were scheduled to be assessed, Last Value, EDV, and FV. 
Percentages for each parameter will be relative to the number of subjects with a result at each 
time point. 
For occult blood, leukocytes, glucose, protein, ketones, and nitrates, the number and 
percentage of subjects with an on-treatment PCST value, PCST low value, and PCST high 
value will be summarized. This summary will consider all assessments after the first dose of 
BRV and prior to or on the date of the last dose of BRV.  
Additionally, for occult blood, leukocytes, glucose, protein, ketones, and nitrates, the number 
and percentage of subjects with a PCST value, PCST low value, and PCST high value will be 
summarized for Baseline, Study Entry, each visit during the Evaluation Period for which 
laboratory parameters were scheduled to be assessed, EDV, Last Value, and FV. Percentages 
for each parameter and time point will be relative to the number of subjects with a value at 
that time point. 
11.3.3 
Microscopic urinalysis 
In microscopic urinalysis, a small sample of urine is centrifuged to remove the liquid. The 
sediment is then examined under a microscope. In the urinalysis laboratory test group, other 
than urinalysis parameters such as Bilirubin, Blood, Glucose, Ketone, Nitrite, pH, Protein, 
Specific Gravity, Total protein, Hemoglobin, Beta-HCG, Occult Blood, and Leukocytes, a 
listing of microscopic analysis parameters will be provided; no summaries of microscopic 
analysis findings are planned.   
11.4 
Vital signs, physical findings, and other observations related 
to safety 
For subjects entering the study from N01315, the vital signs, physical findings, and other 
observations related to safety assessments will be provided in subject data listings only. The 
baseline assessment from the previous studies of these subjects will not be presented. 
11.4.1 
Vital signs 
Vital signs are assessed at all FEVs, MEVs, YEVs, EDVs, and at FV, and may also be 
assessed at Unscheduled Visits. Body weight is assessed at all FEVs, YEVs, EDVs, and at 
FV, and may also be assessed at Unscheduled Visits. 
Observed values for SBP, DBP, pulse rate, and body weight will be summarized for Baseline, 
Study Entry, each visit during the Evaluation Period for which vital signs or body weight 
were assessed, EDV, Last Value, and FV. Changes from Baseline for SBP, DBP, pulse rate, 
and body weight will be summarized for all post-Baseline time points. 
The number and percentage of subjects with an on-treatment PCST value, PCST low value, 
and PCST high value will be summarized for SBP, DBP, pulse rate, and body weight. This 
summary will consider all assessments after the first dose of BRV and prior to or on the date 
of the last dose of BRV.  
Additionally, the number and percentage of subjects with a PCST value, PCST low value, 
and PCST high value will be summarized for the above parameters for Study Entry, each visit 
REDACTED COPY 
 Gl
Y
 Gl
ta
O
ta-
OP
-HC
OPY
HC
l be p
D CO
l be p
al
DAC
al fin
ACT
fin
R
t be used to support any marketing authorization application and any extensions or variations thereof. 
numbe
r va
numbe
alue wi
ns or
alue wi
for whi
sions
for whi
FV. Pe
tensi
FV. Pe
ts with
exte
ts with
ed to re
ion a
ed to re
lysis la
catio
lysis la
cose, K
pplic
cose, K
CG, Oc
n app
CG, Oc
provide
tion 
provide
nding
uthor
nding
N0131
keting
N0131
essmen
marke
essmen
previou
y ma
previou
s
rt
s
d at all
ppo
d at all
duled V
o sup
duled V
o be as
d to 
o be as
alues fo
use
alues fo
try
be
try, eac
be u
, eac
This document canno
ssessed
not b
ssessed
d body w
cann
d body w
The n
ent c
The n
and
me
and


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 39 of 50 
 
during the Evaluation Period for which vital signs or body weight were scheduled to be 
assessed, Last Value, EDV, and FV. Percentages will be relative to the number of subjects 
with a value at each time point. 
PCST criteria (Section 13.3.4) are based on FDA Division of Neuropharmacologic Drug 
Products guidelines with some UCB-defined additions. 
11.4.2 
Electrocardiograms 
ECGs are assessed at all YEVs, EDVs, and at FV, and may also be assessed at Unscheduled 
Visits. 
The number and percentage of subjects with no abnormality, an abnormal but not clinically 
significant finding, and a clinically significant finding will be summarized overall. This 
summary will consider all assessments after the first dose of BRV and prior to or on the date 
of the last dose of BRV. 
Additionally, the number and percentage of subjects with no abnormality, an abnormal but 
not clinically significant finding, and a clinically significant finding will be summarized for 
Baseline, Study Entry, each visit during the Evaluation Period for which an ECG is scheduled 
to be performed, Last Value, EDV, and FV. Percentages will be relative to the number of 
subjects with an ECG assessment at each time point. Subjects are counted at most once at 
each time point based on the worst observed outcome across all abnormalities reported at that 
time point. 
A subject number listing will be provided that identifies subjects with a clinically significant 
finding after the first dose of BRV for each type of ECG abnormality. 
11.4.3 
Physical examination 
A listing of abnormal physical examination findings will be provided; no summaries of 
physical examination findings are planned. 
11.4.4 
Neurological examination 
A listing of neurological examination findings will be provided; no summaries of 
neurological examination findings are planned. 
11.4.5 
Psychiatric and mental status 
A listing of abnormal Psychiatric and Mental Status findings will be provided; no summaries 
of Psychiatric and Mental Status findings are planned. 
11.4.6 
HADS 
The scoring algorithm for HADS is described in 3.8.3. 
During the first 2 years, HADS was assessed at Month 2, Month 6, Month 12, Month 18, and 
Month 24 and at EDV for subjects who discontinued the study prior to the YEV at the end of 
the second year for all subjects, and was also assessed at Month 4 and Month 9 for some 
subjects from N01114. HADS was not assessed for subjects from N01187 and N01236. Prior 
to integrated protocol amendment 25, HADS was being assessed for time points beyond the 
REDACTED COPY
nt.
PY
nt. Su
Y 
Su
tcome
COP
tcome
d that
ACTE
d that
r each
DAC
r each
R
atio
RE
atio
keting authorization application and any extensions or variations thereof. 
duled 
varia
duled 
ot clini
ions
ot clini
verall. T
ensio
verall. T
or to or
exte
or to or
mality,
nd a
mality,
ding wi
n an
ding wi
d for w
tion
d for w
will be r
licat
will be r
ubjects 
appli
ubjects 
e acros
on ap
e acros
t identi
horiz
t identi
h type o
autho
h type o
e used to support any mar
on
tin
on
aminati
arke
aminati
are plan
ma
are plan
cal ex
t any
cal ex
al exam
ppor
al exam
nation f
supp
nation f
Psych
d to
Psych
abnorm
use
abnorm
This document cannot b
iatric a
t be 
iatric a
6
n
6
The sco
nt ca
The sco
Du
me
Du


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 40 of 50 
 
YEV at the end of the second year. These additional assessments will not be summarized but 
will be provided in subject data listings. 
Observed values for HADS depression and anxiety scores will be summarized for Baseline 
and Last Value for the Safety Analysis Set. Additionally, observed values will be 
summarized for Baseline and by visit for each study visit cohort. Summaries for each study 
visit cohort will only include scheduled visits up to the time of cutoff for the study visit 
cohort. Change from Baseline will be summarized at each visit during the Evaluation Period. 
For summaries of observed values at each time point, only subjects with a change from 
Baseline value at that time point will be summarized. Additionally, the mean and SD for each 
Baseline score will be provided at each post-Baseline time point for subjects included in the 
summary of change from Baseline. 
11.4.7 
Columbia-Suicide Severity Rating Scale 
With global amendment 25 to the protocol, the Columbia-Suicide Severity Rating Scale 
(C-SSRS) was added as an assessment at all study visits. Specific rules are provided to the 
study sites with regard to the identification of AEs or SAEs based on the outcome of this 
assessment. Because clinical events of interest will be recorded as AEs or SAEs, no study 
variable is defined for this assessment and no analyses are planned for the C-SSRS within the 
context of this study. However, subject data listings of the data for the C-SSRS will be 
provided. Additional listings will be provided for the subset of subjects with suicidal ideation 
and the subset of subject with actual suicide attempts. 
Suicide ideation includes a “yes” answer to any 1 of the 5 suicidal ideation questions: 





Suicide attempt includes response of a “yes” answer to any 1 of the 3 suicide attempt 
questions: 



ACTED COPY 
ses
Y
ses
ngs of
OPY
ngs of
for th
D CO
for th
e attem
TED 
e attem
er to a
ACT
er to a
This document 

t

d to s
clude
to s
clude
ication and any extensions or variations thereof. 
iod.
riat
iod.
m
or
m
SD for 
ns or
SD for 
cluded 
sions
cluded 
everity 
d any
everity 
rules a
and
rules a
sed on 
ion a
sed on 
ded as 
catio
ded as 
thorization app
re plann
pplic
re plann
f the da
n app
f the da
he subs
tion 
he subs
mpts.
izati
mpts.
any 1 o
tho
any 1 o


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 41 of 50 
 
12 
REFERENCES 
Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. 
Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. 
Epilepsia 1998, 39(1): 81-88. 
EuroQol Group. EQ-5D. A measure of health-related quality of life developed by the 
EuroQol group. User guide. 8th issue. April 2000. 
Snaith RP, Zigmond AS. The hospital anxiety and depression scale manual. London: 
nferNelson Publishing Company Ltd. 1994. 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 42 of 50 
 
13 
APPENDICES 
13.1 
QOLIE-31-P total and subscale score calculations 
The following outlines the calculation of the subscale scores for the QOLIE-31-P. The 
rescaled responses are provided for each item. The subscale scores are calculated by 
summing the rescaled responses for that subscale and dividing by the number of items with a 
non-missing response. Note that the divisors shown assume that all items for each subscale 
have a response; the divisor will differ if there are missing responses. A subscale score will 
be calculated only if at least 50% of the items within the subscale are present. 
 
Response 
Final Score 
Scale/Item Numbers 
1 
2 
3 
4 
5 
6 
Subtotal 
0-100 point scale  
 
Seizure Worry 
 
30. 
0 
20 
40 
60 
80 
100 
_____ 
 
31. 
0 
33.3 
66.7 
100 
–– 
–– 
_____ 
 
32. 
0 
50 
100 
 
–– 
–– 
_____ 
 
33. 
0 
33.3 
66.7 
100 
–– 
–– 
_____ 
 
34. 
100 
75 
50 
25 
0 
–– 
_____ 
 
 
 
 
 
 
 
 
TOTAL :   
_____ 
÷ 5 =  _____ 
Overall Quality of Life 
 
1. 
Multiply each response by 10 
 
 
_____ 
 
36. 
100 
75 
50 
25 
0 
–– 
_____ 
 
 
 
 
 
 
 
 
TOTAL : 
_____ 
÷ 2 =  _____ 
Emotional Well-Being 
 
7. 
0 
20 
40 
60 
80 
100 
_____ 
 
8. 
0 
20 
40 
60 
80 
100 
_____ 
 
9. 
100 
80 
60 
40 
20 
0 
_____ 
 
10. 
0 
20 
40 
60 
80 
100 
_____ 
 
11. 
100 
80 
60 
40 
20 
0 
_____ 
 
 
 
 
 
 
 
 
TOTAL : 
_____ 
÷ 5 =  _____ 
Energy/Fatigue 
 
2. 
100 
80 
60 
40 
20 
0 
_____ 
 
3. 
100 
80 
60 
40 
20 
0 
_____ 
 
4. 
0 
20 
40 
60 
80 
100 
_____ 
 
5. 
0 
20 
40 
60 
80 
100 
_____ 
 
 
 
 
 
 
 
 
TOTAL : 
_____ 
÷ 4 = _____  
Cognitive Functioning 
 
19. 
0 
20 
40 
60 
80 
100 
_____ 
 
20. 
0 
33.3 
66.7 
100 
–– 
–– 
_____ 
 
21. 
0 
20 
40 
60 
80 
100 
_____ 
 
22. 
0 
20 
40 
60 
80 
100 
_____ 
 
23. 
0 
20 
40 
60 
80 
100 
_____ 
 
24. 
100 
75 
50 
25 
0 
–– 
_____ 
 
 
 
 
 
 
 
 
TOTAL : 
_____ 
÷ 6 = _____ 
REDACTED COPY 
25
D
25
40
RED
40
4
R
4
t be used to support any marketing authorization application and any extensions or variations thereof. 
w
va
will
ari
ill
l Score
ons 
l Score
s o
100 po
nsio
100 po
ns
__
n
__
____
d a
____
____
n
____
_
OTAL 
plic
OTAL 
0
tio
0
60
au
60
0
ti
0
60
ket
60
40
rk
40
0
y
0
100
upp
100
100
su
100
This document canno
tive Fu
not b
tive Fu
19.
n
19.
20.
ca
20.
2


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 43 of 50 
 
Medication Effects 
 
28. 
0 
33.3 
66.7 
100 
–– 
–– 
_____ 
 
26. 
100 
75 
50 
25 
0 
–– 
_____ 
 
27. 
100 
75 
50 
25 
0 
–– 
_____ 
 
                                                                                      
 
TOTAL : 
_____ 
÷ 3 =  _____ 
Daily Activities/Social Functioning 
 
13. 
0 
20 
40 
60 
80 
100 
_____ 
 
14. 
0 
25 
50 
75 
100 
–– 
_____ 
 
15. 
0 
25 
50 
75 
100 
–– 
_____ 
 
16. 
100 
75 
50 
25 
0 
–– 
_____ 
 
17. 
100 
75 
50 
25 
0 
–– 
_____ 
 
 
 
 
 
 
 
 
TOTAL : 
_____ 
÷ 5 =  _____ 
 
Total score is calculated as a weighted sum of the subscale scores based on the weighting 
shown below. Total score will be missing if at least 1 subscale score is missing. Total score 
will range from 0 to 100 with a higher score reflecting better functioning. 
 
QOLIE-31-P Scale 
 
Final Scale 
Score 
 
 
Weight 
 
 
Subtotal 
 
 
 
 
 
 
 
Seizure worry 
(a) 
____ 
 
0.08 
= 
____ 
Overall quality of life 
(b) 
____ 
 
0.14 
= 
____ 
Emotional well-being 
(c) 
____ 
 
0.15 
= 
____ 
Energy/fatigue 
(d) 
____ 
 
0.12 
= 
____ 
Cognitive functioning 
(e) 
____ 
 
0.27 
= 
____ 
Medication effects 
(f) 
____ 
 
0.03 
= 
____ 
Daily activities/Social functioning 
(g) 
____ 
 
0.21 
= 
____ 
 
 
 
 
 
 
 
TOTAL SCORE: Sum subtotals (a) through (g) 
____ 
 
REDACTED COPY 
Y
_
C
_
(c)
CT
(c)
(d)
DAC
(d)
ny marketing authorization application and any extensions or variations thereof. 
5 = 
nsi
5 = 
d on th
ny e
d on th
e is mis
d an
e is mis
ctionin
and
ctionin
on
on
on
plplpl
__
io
__
___
za
___
_
)
(e)
ng
(e)
(f)
ting
(f)
ng
ma
ng
This document cannot be used to support a
ubtota
t any
ubtota


UCB                                                                                                                                              11 February 2019 
Statistical Analysis Plan                                          Brivaracetam                                                                N01125 
 
Page 44 of 50 
 
13.2 
Subject site transfers 
 
RED
This document cannot be used to support any marketing au
nd any extensions or variations thereof. 


UCB 
 
19 May 2016 
Statistical Analysis Plan 
Brivaracetam 
N01125 
 
Confidential 
Page 45 of 50 
 
13.3 
PCST criteria 
13.3.1 
Hematology parameters 
Parameter 
UCB Conventional Units 
SI Units 
CF 
Hematocrit 
For 1 m to < 6 m:    25% 
For 1 m to < 6 m:    0.25 
0.01 
For 6 m to < 2 y:    27% 
For 6 m to < 2 y:    0.27 
For 2 y to < 4 y:    29% 
For 2 y to < 4 y:    0.29 
For 4 y to < 12 y:    32% (Female[F]);  35% (Male [M]) 
For 4 y to < 12 y:    0.32 (F);  0.35 (M) 
For  12 y:   
 32% (F);  37% (M) 
For  12 y:   
 0.32 (F);  0.37 (M) 
Hemoglobin 
For  6 m:   
 9.7 g/dL 
For  6 m:   
 97 g/L 
10 
For 6 m to < 12 y:    10.0 g/dL 
For 6 m to < 12 y:    100 g/L 
For  12 y:   
 9.5 g/dL (F);  11.5 g/dL (M) 
For  12 y:   
 95 g/L (F);  115 g/L (M) 
Platelets 
 75 x 109/L or  700 x 109/L 
 75 x 109/L or  700 x 109/L 
Not applicable (N/A) 
White Blood 
Cell (WBC) 
For  17 y:   
< 3.0 x 109/L or > 20 x 109/L;  
For  17 y:   
< 3.0 x 109/L or > 20 x 109/L;  
N/A 
For  17 y:   
< 2.8 x 109/L or > 16 x 109/L; 
For  17 y:   
< 2.8 x 109/L or > 16 x 109/L; 
Red Blood 
Cell (RBC) 
For  17 y:  < 2.5 x 106/mm3 
For  17 y:   
< 2.5 x 1012/L 
1 
For  17 y:  < 2.0 x 106/mm3 (F); < 2.5 x 106/mm3 (M) 
For  17 y:   
< 2.0 x 1012/L (F); < 2.5 x 1012/L (M) 
Eosinophils 
 10% or  0.7 x 109/L 
 0.10 or  0.7 x 109/L 
0.01 or N/A 
Neutrophils 
 15% or  1.0 x 109/L 
 0.15 or  1.0 x 109/L 
0.01 or N/A 
Basophils 
 5% or  0.4 x 109/L 
 0.05 or  0.4 x 109/L 
0.01 or N/A 
Monocytes 
 20% or  1.5 x 109/L 
 0.20 or  1.5 x 109/L 
0.01 or N/A 
Lymphocytes 
For 1 m to < 6 m:    22% or  80% 
For 1 m to < 6 m:    0.22 or  0.80  
0.01 
 
 2.1 x 109/L or  8.5 x 109/L 
 
 2.1 x 109/L or  8.5 x 109/L 
N/A 
For 6 m to < 2 y:    15% or  80%  
For 6 m to < 2 y:    0.15 or  0.80  
0.01 
 
 1.5 x 109/L or 7.5 x 109/L 
 
 1.5 x 109/L or 7.5 x 109/L 
N/A 
For 2 y to < 12 y:    12% or  80%  
For 2 y to < 12 y:    0.12 or  0.80  
0.01 
 
 1.0 x 109/L or  7.5 x 109/L 
 
 1.0 x 109/L or  7.5 x 109/L 
N/A 
For 12 y to  17 y:   10% or  80%  
For 12 y to  17 y:    0.10 or  0.80  
0.01 
 
 0.5 x 109/L or  5.5 x 109/L 
 
 0.5 x 109/L or  5.5 x 109/L 
N/A 
For  17 y:   
 10% or  80%  
For  17 y:   
 0.10 or  0.80  
0.01 
 
 0.5 x 109/L or  4.5 x 109/L 
 
 0.5 x 109/L or  4.5 x 109/L 
N/A 
EDACTED COPY 
For
Y
For
For 
OPY
For 
OP

O

OP
OP
OP
C
CT
/mm
EDA
/mm3
DA
3
RED
R
authorization application and any extensions or variations thereof. 
nits
ten
nits
ns
xte
.27
ny
.27

d
0.29
d a
0.29
y: 
a
y: 
and
0.
d
0.

io
m to < 1
plic
m to < 1

a
12 y:
app
12 y:
75 x 1
on a
75 x 1
ap
For 
atio
For 
ion
za
F
a
F
za
za
or
(M)
au
(M)
annot be used to support any marketing a
ting
ke
ma
%
a
%
y
L or 
rt a
L or 
a
8
r 
p
r 
pp
80%
ppo
80%
x 10
sup
x 109
upp
9/L
p
/L
12% or
to s
12% or

ed
1.0 x
ed t
1.0 x
7 y: 
us
7 y: 
se
1
e
1
This document can
y:  
not
y:  
an


UCB 
 
19 May 2016 
Statistical Analysis Plan 
Brivaracetam 
N01125 
 
Confidential 
Page 46 of 50 
 
13.3.2 
Blood chemistry parameters 
Parameter 
UCB Conventional Units 
SI Units 
CF 
AST (SGOT) 
> 3 times of  ULN 
> 3 times of  ULN 
N/A 
ALT (SGPT) 
> 3 times of  ULN 
> 3 times of  ULN 
N/A 
ALP 
For  17 y:   
> 2 times of  ULN, if normal range 
 
adjusted to the age range;  
For  17 y:   
> 2 times of  ULN, if normal range 
 
adjusted to the age range;  
N/A 
For  17 y:   
> 3 times of  ULN 
For  17 y: 
> 3 times of  ULN 
GGT 
> 3 times of  ULN, if baseline value < 3 times of  ULN 
> 3 times of  ULN, if baseline value < 3 times of  ULN 
N/A 
BUN 
> 30 mg/dL 
> 10.71 mmol/L 
0.357 
Urea 
> 60 mg/dL 
> 10.02 mmol/L 
0.167 
Creatinine 
For  17 y:  
> 1.5 mg/dL;  
For  17 y:   
> 132.6 umol/L;  
88.4 
For  17 y:   
 > 2.0 mg/dL 
For  17 y:   
> 176.8 umol/L 
Creatinine 
clearance 
(calc) 
For  12 y:   
 70 ml/min (Schwartz)(a) 
For  12 y:   
 70 ml/min (Schwartz)(a) 
N/A 
For  12 y:   
 70 ml/min (Cockroft)(b) 
For  12 y:   
 70 ml/min (Cockroft)(b) 
Total 
bilirubin 
> 2.0 mg/dL 
> 34.2 umol/L 
17.1 
Glucose 
 50 mg/dL or  180 mg/dL 
 2.775 mmol/L or  9.99 mmol/L 
0.0555 
Total Protein 
For  1 m to  6 m:    3.6 g/dL or  7.8 g/dL 
For  1 m to  6 m:    36 g/L or  78 g/L 
10 
For  6 m to  17 y:    4.7 g/dL or  9.5 g/dL 
For  6 m to  17 y:    47 g/L or  95 g/L 
For  17 y:  
 4.5 g/dL or  9.0 g/dL 
For  17 y:  
 45 g/L or  90 g/L 
Albumin 
For  17 y:   
 2.4 g/dL or  6.5 g/dL 
For  17 y:   
 24 g/L or  65 g/L 
10 
For  17 y:  
 2.5 g/dL or  6.5 g/dL 
For  17 y:  
 25 g/L or  65 g/L 
Globulin 
For  17 y:  
 1.2 g/dL or  5.0 g/dL 
For  17 y: 
 12 g/L or  50 g/L 
10 
For  17 y:  
 1.5 g/dL or  5.0 g/dL 
For  17 y:  
 15 g/L or  50 g/L 
Sodium 
For  17 y:   
 120 mEq/L or  155 mEq/L 
For  17 y:   
 120 mmol/L or  155 mmol/L 
1 
For  17 y:  
 115 mEq/L or  155 mEq/L 
For  17 y:  
 115 mmol/L or  155 mmol/L 
Potassium 
For  17 y:   
 3.0 mEq/L or  6.5 mEq/L 
For  17 y:   
 3.0 mmol/L or  6.5 mmol/L 
1 
For  17 y:  
 3.0 mEq/L or  5.8 mEq/L 
For  17 y:  
 3.0 mmol/L or  5.8 mmol/L 
Calcium 
For  17 y:   
 7 mg/dL or  11.5 mg/dL 
For  17 y:   
 1.75 mmol/L or  2.875 mmol/L 
0.25 
For  17 y:   
 7 mg/dL or  15.5 mg/dL 
For  17 y:   
 1.75 mmol/L or  3.875 mmol/L 
REDACTED COPY 
F
Y
F
Y
CO
CT
RE
R
annot be used to support any marketing authorization application and any extensions or variations thereof. 
Units
sion
Units
on
si
te
> 2
ny
2 time
y e
time
n
adjus
any
adjus
ex
>
 
>
 ULN, 
n an
ULN, 
an
mmol/L
tion
mmol/L
n 
02 mmo
icat
02 mmo
ati
r 
p
r 
pp
17 y
pli
17 y
lic
For 
ap
For 
p

For
on
For
n
tio
tio
tio
ho
a
g/dL
keti
g/dL
ting
9.5 g/dL
mark
9.5 g/dL
9.0 g/dL
y ma
9.0 g/dL

an
6.5 g
any
6.5 g
y
L or 
ort
L or 
t a
6
a
6
g/dL or 
ppo
g/dL or 
or
.5 g/dL
sup
.5 g/dL

t
120 m
to s
120 m
s

ed
11
t
11

e

se
y: 
y: 
7 y: 
not b
7 y: 
b

a
17 y:
ann
17 y:
This document can
an


UCB 
 
19 May 2016 
Statistical Analysis Plan 
Brivaracetam 
N01125 
 
Confidential 
Page 47 of 50 
 
Uric Acid 
 
For < 12 y:   
 8 mg/dL 
For < 12 y:   
 475.84 umol/L 
59.48 
For  12 y:   
 8 mg/dL (F);  9.5 mg/dL (M) 
For  12 y:   
 475.84 umol/L (F);  565.06 umol/L 
(M) 
Cholesterol 
 300 mg/dL 
 7.77 mmol/L 
0.0259 
HDL 
 25 mg/dL 
 0.65 mmol/L 
0.0259 
LDL 
 200 mg/dL 
 5.18 mmol/L 
0.0259 
Triglycerides 
 300 mg/dL 
 3.42 mmol/L 
0.0114 
(a)  Schwartz equation (patients <12):  
Cr Cl ml/min = [Height (cm) * 0.55] / serum creatinine  
(b)  Cockroft equation (patients >12): 
Male: Cr Cl ml/min = [(140-age) x body weight (kg)] / (72 x serum creatinine), 
 
 
 
 
 
 
                      Female: Cr Cl ml/min = [(140-age) x body weight (kg)] / (72 x serum creatinine)] x 0.85 
ALT=alanine aminotransferase; ALP=Alkaline phosphatase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; CR CL=creatinine clearance; 
GGT=Gamma-glutamyl transpeptidase; HDL=High-density lipoprotein; LDL=low-density lipoprotein; SGOT=serum glutamic oxaloacetic transaminase; 
SGPT=serum glutamic pyruvic transaminase; ULN=Upper Limit of Normal.  
COPY
mi
Y
mi
DL=low
OPY 
DL=low
mal
CO
mal. 
O
. 
REDACTED CO
CO
nd any extensions or variations thereof. 
/L
s
/L
or
mol/L (
ions
mol/L (
n
on application and
ne 
n a
ne 
kg)] / (7
tion 
kg)] / (7
ght (kg)
catio
ght (kg)
ansfera
plica
ansfera
w
a
w-densit
app
densit
This document cannot be used to support any marketing authorization
nd
on


UCB 
 
19 May 2016 
Statistical Analysis Plan 
Brivaracetam 
N01125 
 
Confidential 
Page 48 of 50 
 
13.3.3 
Urinalysis 
Qualitative urine parameters are generally reported by a descriptive score, which differs 
among laboratories. For data analysis purpose, a four-point scale is used. Five-point, six-
point, or seven-point scales will be collapsed into a four-point scale first. A value is 
considered possibly clinically significant treatment emergent abnormal if an upward shift of 
at least 2 degrees from the baseline occurs under investigational treatment.  To collapse the 
results in a five-point scale into a four-point scale, the lowest two positive results will be 
combined (see example below). For results reported with a scale of more than five-point, 
please consult your study physician for how to collapse into four-point scale. 
Original Five-point Scale 
Four-point Scale 
 
 
Negative/None 
Negative/None 
Trace/Rare/Mild/A Few 
Trace/1+/Rare/Mild/A Few 
1+ 
 
2+/Mod 
2+/Mod 
3+/Sev 
3+/Sev 
13.3.4 
Vital signs and body weight 
Pulse rate 
For 1 m to  12 m:  <110 bpm and a decrease of > 20 bpm from 
baseline or > 180 bpm and an increase of > 20 bpm from 
baseline 
For 12 m to  3 y:  < 90 bpm and a decrease of > 20 bpm from 
baseline or > 150 bpm and an increase of > 20 bpm from 
baseline 
For 3 y to  12 y:  < 65 bpm and a decrease of > 20 bpm from 
baseline or > 130 bpm and an increase of > 20 bpm from 
baseline 
For 12 y to  17 y:  < 60 bpm and a decrease of > 20 bpm from 
baseline or > 120 bpm and an increase of > 20 bpm from 
baseline 
For  17 y:  < 50 bpm and a decrease of > 30 bpm from 
baseline or > 120 bpm and an increase of > 30 bpm from 
baseline 
bpm=Beats per minute. 
 
 
REDACTED COPY 
m
CO
m: 
COP
: <
OP
<1
P
1
180 b
D CO
180 b
m to
DAC
m to
eline 
RED
eline 
elin
R
elin
PY
pplication and any extensions or variations thereof. 
int,
r v
int, 
any marketing authorization app
110 bp
on ap
110 bp
bpm an
ation
bpm an

ut
3 y
uth
3 y
or 
g
or >
g a
> 1
u
1
g
ne
eti
ne
or 3 y 
mark
or 3 y 
basel
y m
basel
ba
ny
ba
This document cannot be used to support an
app
nn
an
m=Bea
can
m=Bea


UCB 
 
19 May 2016 
Statistical Analysis Plan 
Brivaracetam 
N01125 
 
Confidential 
Page 49 of 50 
 
Systolic blood pressure 
For 1 m to  12 m:  < 60 mmHg and a decrease of > 20 mmHg 
from baseline or > 110 mmHg and an increase of  
> 30 mmHg from baseline 
For 12 m to  6 y:  < 70 mmHg and a decrease of > 20 mmHg 
from baseline or > 120 mmHg and an increase of  
> 30 mmHg from baseline 
For 6 y to  13 y:  < 70 mmHg and a decrease of > 20 mmHg 
from baseline or > 130 mmHg and an increase of  
> 30 mmHg from baseline 
For 13 y and  17 y:  < 90 mmHg and a decrease of > 20 
mmHg from baseline or > 140 mmHg and an increase of  
> 30 mmHg from baseline 
For  17 y:  < 90 mmHg and a decrease of > 30 mmHg from 
baseline or > 180 mmHg and an increase of > 40 mmHg from 
baseline 
Diastolic blood pressure 
For 1 m to  12 m:  < 40 mmHg and a decrease of > 15 mmHg 
from baseline or > 60 mmHg and an increase of  
> 20 mmHg from baseline 
For 12 m to  6 y:  < 45 mmHg and a decrease of > 15 mmHg 
from baseline or > 80 mmHg and an increase of  
> 20 mmHg from baseline 
For 6 y to  13 y:  < 50 mmHg and a decrease of > 15 mmHg 
from baseline or > 85 mmHg and an increase of  
> 20 mmHg from baseline 
For 13 y to  17 y:  < 55 mmHg and a decrease of > 20 mmHg 
from baseline or > 90 mmHg and an increase of  
> 30 mmHg from baseline 
For  17 y:  < 50 mmHg and a decrease of > 20 mmHg from 
baseline or > 105 mmHg and an increase of > 30 mmHg from 
baseline 
Weight 
For  17 y:  < 3% or  97% of the normal body weight growth 
curve ranges for the age at date of weight assessment (a) and 
gender; 
For  17 y:  change of  7% of baseline weight 
(a) Once the subject reaches 17 years of age use the body curve criteria of a 17-year old 
regardless of their age in the study.  
 
REDACTED COPY
60 m
OPY 
60 m
m bas
COP
m bas

TE
6 y
ED 
6 y
seline 
ACT
seline 
mm
EDA
mmHg
DAC
Hg
6 y
R
6 y
ation and any extensions or variations thereof. 
mHg 
aria
mHg 
ase of >
nsio
ase of >
an incre
xten
an incre
ase of 
d an
ase of 
ncrease
and
ncrease
ns
any marketing authorization applicat
mmHg 
plica
mmHg 
mmHg a
app
mmHg a
seline
on a
seline
y:  < 4
rizat
y:  < 4
e or > 8
thori
e or > 8
Hg from
auth
Hg from
y to
eting
y to 
ng

m base
rket
m base
> 20 m
mar
> 20 m
Fo
ny
Fo
This document cannot be used to support an
at
an
ght
ot
ght
be
e


UCB 
 
19 May 2016 
Statistical Analysis Plan 
Brivaracetam 
N01125 
 
Confidential 
Page 50 of 50 
 
14 
AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN 
Rational for the amendment 
The primary purpose for the amendment is (1) include subjects entering the study from study 
N01315 into this statistical analysis plan; (2) remove rules and definitions based on data 
cutoffs for interim analyses; (3) remove the summary analysis for direct cost parameter and 
indirect cost parameters, and as well as Socio-professional data. 
Change #1 (global) 
Removed all rules and definitions based on data cutoffs for interim analyses throughout SAP. 
Change #2 (global)  
Added analysis plan for subjects entering the study from study N01315 throughout SAP. 
Change #3 (global) 
Section 8.2.5 Direct cost parameters, Section 8.2.6 Indirect cost parameters, Section 8.2.7 
Socio-professional data 
Removed all direct/indirect cost parameters and socio-professional data summary analysis. 
Change #4 
Section 2.4 Determination of Sample Size 
Changed the sample size to include subjects entering from N01315. 
Change #5 
Section 3.5.1 Safety Analysis Set 
Modified Safety Analysis Set and added a modified Safety Analysis Set. 
Change #6 
Section 13.2 Subject site transfers 
Removed subjects 
 
Change #7 
Removed signature page. Using e-signature approval process through Source Submission. 
 
 
REDACTED COPY 
cts en
CTED
cts en
keting authorization application and any extensions or variations thereof. 
ghout S
ns or
ghout S
rougho
exte
rougho
aramet
and 
aramet
fessiona
licati
fessiona
ntering
oriza
ntering
This document cannot be used to 
rt any ma
added
arke
added
transfe
rt a
transfe
gnature
used
gnature


Approval Signatures
Name:
N01125-SAP-Amendment-1
Version:
1. 0
Document Number:
CLIN-000130975
Title:
N01125-SAP-Amendment-1
Approved Date:
25 Feb 2019
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 11-Feb-2019 14:05:58 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 25-Feb-2019 20:26:08 GMT+0000
OPY
App
OPY 
App
DACTED CO
CO
REDA
DA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
p
proval
app
proval
uthorization 
n a
ori
Name:
atio
Name:
Cap
za
Cap
D
marketing aut
ut
ma